Status: Approved , Date: 31 May 2016 1Janssen Research & Development*
Clinical Protocol
A Randomized, Double -blind, Multicenter, Active -controlled Study to Evaluate the 
Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral 
Antidepressant in Adult Subjects with Treatment- resistant Depression
Trial of R apid-a cting Intra nasal Esketamine for Treatment -resistant Major Depressive Disorder 
(TRANSFORM -1)
Protocol ESKETINTRD3001; Phase 3
AMENDMENT 2
JNJ-54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc .; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entities; the sponsor is identified on the Contact Informa tion page that accompanies the 
protocol.
This compound is being investigated in Phase 3 clinical studie s.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 2014 -00458 4-20
Status: Approved
Date: 31 May 2016
Prepared by: Janssen Research & Development, LLC
EDMS number and version :EDMS- ERI-93094731, 3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 2TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 5
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 29
TIME AND EVENTS SCHE DULE (Screening/Prospective Observational Phase and Double -
blind Induction Phase) .............................................................................................................................. 41
TIME AND EVENTS SCHE DULE (F ollow -up Phase ).............................................................................. 48
ABBREVIA TIONS ...................................................................................................................................... 51
1. INTRODUCTION ................................................................................................................................ 53
1.1. Background .................................................................................................................................... 54
1.1.1. Summary  of Nonclinical Findings ............................................................................................... 54
1.1.2. Clinical Studies ........................................................................................................................... 57
1.1.2.1. Pharmacokinetics and Product Metabolism ............................................................................ 57
1.1.2.2. Pharmacodynamics and Efficacy ............................................................................................ 59
1.1.2.3. Safety and Tolerability ............................................................................................................. 61
1.1.3. Marketing Experience ................................................................................................................. 65
1.2. Active Comparators in Double -blind Induction Phase ................................................................... 65
1.2.1. Selective Serotonin Reuptake Inhibitors ..................................................................................... 65
1.2.1.1. Escitalopram ............................................................................................................................ 65
1.2.1.2. Sertraline ................................................................................................................................ .66
1.2.2. Serotonin and Norepinephrine Reuptak e Inhibitors ................................................................... 67
1.2.2.1. Duloxetine ................................................................................................................................ 67
1.2.2.2. Venlafaxine Extended -release ................................................................................................ .67
1.3. Overall Rationale for the Study ...................................................................................................... 68
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 68
2.1. Objectives ...................................................................................................................................... 68
2.2. Hypothesis ..................................................................................................................................... 70
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .70
3.1. Overview of Study Design .............................................................................................................. 70
3.2. Study Design Rationale .................................................................................................................. 73
3.2.1. Study Population ......................................................................................................................... 73
3.2.2. Study Phases .............................................................................................................................. 74
3.2.3. Blinding and Randomization ....................................................................................................... 75
3.2.4. Treatment Groups and Dose Selection ...................................................................................... 75
3.2.5. Efficacy  Measures ...................................................................................................................... 77
3.2.6. Safety Evaluations ...................................................................................................................... 78
3.2.7. Medical Resource Utilization ...................................................................................................... 79
3.2.8. Other Assessments .................................................................................................................... 79
3.2.9. Pharmacokinetic Assessments ................................................................................................... 79
3.2.10. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations .............................. 80
4. STUDY POPUL ATION...................................................................................................................... 80
4.1. Inclusion Criteria ............................................................................................................................ 80
4.2. Exclusion Criteria ........................................................................................................................... 84
4.3. Prohibitions and Restrictions ......................................................................................................... 89
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 35. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 89
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 91
6.1. Screening/Prospective Observational Phase ................................................................................ 91
6.2. Double -Blind Induction Phase ........................................................................................................ 92
6.2.1. Guidance on Blood Pressure Monitoring on Intranasal Treatment Session Day s..................... 94
6.3. Follow -up Phase ............................................................................................................................ 95
7. TREA TMENT COMPLIA NCE ............................................................................................................ 95
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 95
9. STUDY EVA LUATIONS .................................................................................................................... 97
9.1. Study Procedures ........................................................................................................................... 97
9.1.1. Overview ..................................................................................................................................... 97
9.1.2. Screening/Prospective Observational Phase ............................................................................. 98
9.1.3. Double -Blind Induction Phase .................................................................................................. 100
9.1.4. Follow -up Phase ....................................................................................................................... 101
9.2. Efficacy ......................................................................................................................................... 102
9.2.1. Evaluations ............................................................................................................................... 102
9.2.1.1. Primary Efficacy  Evaluation ................................................................................................... 102
9.2.1.2. Key Secondary Efficacy  Evaluation (Clinician -completed) .................................................... 102
9.2.1.3. Key Secondary Effica cy Evaluation (Patient- reported Outcome) .......................................... 103
9.2.1.3.1. SDS .................................................................................................................................... 103
9.2.1 .3.2. PHQ -9................................................................................................................................ 103
9.2.1.4. Other Secondary Efficacy  Evaluations (Clinician- completed) ............................................... 103
9.2.1.4.1. CGI-S................................................................................................................................ .103
9.2.1.5. Other Secondary Efficacy  Evaluations (Patient- reported Outcomes) ................................... 103
9.2.1.5.1. GAD-7 ................................................................................................................................ 103
9.2.1.5.2. EQ-5D-5L........................................................................................................................... 104
9.2.2. Endpoints .................................................................................................................................. 104
9.2.2.1. Primary Endpoint ................................................................................................................... 104
9.2.2.2. Secondary Endpoints ............................................................................................................ 104
9.3. Pharmacokinetics ......................................................................................................................... 105
9.3.1. Evaluations ............................................................................................................................... 105
9.3.2. Analytical Procedures ............................................................................................................... 105
9.3.3. Pharmacokinetic Parameters ................................................................................................... 105
9.4. Pharmacokinetic/Pharmacodynamic Evaluations ........................................................................ 105
9.5. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations ................................ 106
9.6. Medical Resource Utilization ........................................................................................................ 106
9.7. Safety Evaluations ....................................................................................................................... 107
9.8. Other Evaluations ......................................................................................................................... 114
9.9. Sample Collection and Handling .................................................................................................. 116
10. SUBJECT COMPLETION/W ITHDRA WAL..................................................................................... 116
10.1. Completion ................................................................................................................................... 116
10.2. Withdrawal from the Study ........................................................................................................... 116
10.3. Withdrawal from the Use of Samples in Future Research ........................................................... 118
11. STATISTICA L METHODS ............................................................................................................... 118
11.1. Subject Information ...................................................................................................................... 118
11.2. Sample Size Determination ......................................................................................................... 118
11.3. Interim Analysis for Sa mple Size Re -estimation or Stopping for Futility ...................................... 119
11.4. Efficacy  Analyses ......................................................................................................................... 119
11.5. Pharmacokinetic Analy ses........................................................................................................... 121
11.6. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ 122
11.7. Biom arker and Pharmacogenomic Analyses ............................................................................... 122
11.8. Medical Resource Utilization Analyses ........................................................................................ 122
11.9. Safety Analys es........................................................................................................................... 122
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 411.10. Independent Data Monitoring Committee .................................................................................... 124
12. ADVERSE EVENT REPORT ING.................................................................................................... 124
12.1. Definitions .................................................................................................................................... 125
12.1.1. Adverse Event Definitions and Classifications ......................................................................... 125
12.1.2. Attribution Definitions ................................................................................................................ 126
12.1.3. Severity Criteria ........................................................................................................................ 127
12.2. Special Reporting Situations ........................................................................................................ 127
12.3. Procedures ................................................................................................................................... 127
12.3.1. All Adverse Events .................................................................................................................... 127
12.3.2. Serious Adverse Events ........................................................................................................... 129
12.3.3. Pregnancy ................................................................................................................................ .130
12.4. Contacting Sponsor Regarding Safety ......................................................................................... 131
13. PRODUCT QUA LITY COMP LAINT HA NDLING ............................................................................ 131
13.1. Procedures ................................................................................................................................... 131
13.2. Contacting Sponsor Regarding Product Quality .......................................................................... 131
14. STUDY DRUG INFORM ATION....................................................................................................... 131
14.1. Physical Description of Study Drug(s) ......................................................................................... 131
14.2. Packaging .................................................................................................................................... 132
14.3. Labeling ........................................................................................................................................ 133
14.4. Preparation, Handling, and Storage ............................................................................................. 133
14.5. Drug Accountability ...................................................................................................................... 133
15. STUDY -SPECIFIC M ATERIA LS..................................................................................................... 134
16. ETHICA L ASPECTS ....................................................................................................................... 135
16.1. Study-specific Design Considerations ......................................................................................... 135
16.2. Regulatory Ethics Compliance ..................................................................................................... 137
16.2.1. Investigator Responsibilities ..................................................................................................... 137
16.2.2. Independent Ethics Committee or Institutional Review Board (IEC/IRB) ................................ .137
16.2.3. Informed Consent ..................................................................................................................... 139
16.2.4. Privacy of Personal Data .......................................................................................................... 139
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 140
16.2.6. Countr y Selection ..................................................................................................................... 140
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 140
17.1. Protocol Amendments .................................................................................................................. 140
17.2. Regulatory Documentation .......................................................................................................... 141
17.2.1. Regulatory Approval/Notification .............................................................................................. 141
17.2.2. Required Prestudy Documentation ........................................................................................... 141
17.3. Subject Identification, Enrollment, and Screening Logs .............................................................. 142
17.4. Source Documentation ................................................................................................................. 142
17.5. Case Report Form Completion .................................................................................................... 143
17.6. Data Quality Assurance/Qual ity Control ...................................................................................... 143
17.7. Record Retention ......................................................................................................................... 144
17.8. Monitoring .................................................................................................................................... 144
17.9. Study Com pletion/Termination ..................................................................................................... 145
17.9.1. Study Com pletion ..................................................................................................................... 145
17.9.2. Study Termination ..................................................................................................................... 145
17.10. On-site Audits ............................................................................................................................... 145
17.11. Use of Information and Publication .............................................................................................. 146
REFERENCES .......................................................................................................................................... 148
INVESTIGA TOR A GREEME NT............................................................................................................... 160
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 5LIST OF A TTACHMENTS
Attachment 1: Prohibited Concomitant Medications with Intranasal Study Medication 
(Esketamine or Placebo) .......................................................................................... 153
Attachment 2: New York Heart Association Classification of Cardiac Disease ............................... 156
Attachment 3: Oral Antidepressant Titration Schedule for Double -Blind Induction Phase .............. 157
Attachment 4: Anticipated Events .................................................................................................... 158
LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in 
the Product Information of Anesthetic Ketamine and Esketamine ........................................... 61
Table 2: Intranasal Treatment Administration during t he Double -blind Induction Phase ....................... 92
Table 3: Volume of Blood to Be Collected From Each Subject .............................................................. 98
FIGURES
Figure 1: Study Design for ESKETINTRD3001 ...................................................................................... 72
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 6PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 10 March 2015
Amendment 1 07January 2016
Amendment 2 31May 2016
Amendments below are listed beginning with the most recent amendment.
Amendment 2 (31May 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
The overall reason for the amendment: Based on feedback received from Investigators involved in the study, the 
subject entry criteria are being revised to i mprove recruitment.
Applicable Section(s) Description of Change(s)
Rationale: To im prove recruitment, the antidepressant treatment requirements at study entry (ie, time of signing the 
ICF) in inclusion criterion no. 3 .1were changed. In addition, the definition of nonresponse at the end of the 
screening/prospective observational phase was revised.
4.1. Inclus ion Criteria Inclusion criterion no. 3 .1was revised as follows (bold text added):
At the start of the screening/prospective observational phase, subject must have had non-
response (≤25% improvement) to ≥ 12but ≤5 (if current episode is > 2 years, upper limit is
applicable to only the last 2 years) oral antidepressant treatments in the current episode of 
depression, assessed using the MGH- ATRQ and confirmed by documented records (eg, 
medical/pharmacy/prescription records /or a letter from a treating physician, etc .,). In 
addition, the sSubject must be istaking one of the a different oral antidepressant 
treatment (s) with nonresponse that is documented (on the MGH -ATRQ) for at least the 
previous 2 weeks (ie, this oral antidepressant treatment must have been taken for at least 
6 weeks at or above the minimal therapeutic dose with a lack of clinically meaningful 
improvement) at the start of the screening/prospective observational phase .
-For specific tricyclic antidepressants which are ongoing and being taken at a 
dose below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within the therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressant treatment.
-Subjects must have been beadherent to the cont inued oral antidepressant 
treatment medication(s) (w ithout adjustment in dosage) through the 
screening/prospective observational phase, as documented on the PAQ. Missing 
≥4 days of antidepressant medication in the prior 2 -week period w ill be 
considered as inadequate adherence.
-Subjects who are non -responders to their current oral antidepressant 
medication(s) from the screening/prospective observational phase (as assessed by 
independent, remote raters) may be eligible for randomization if all other entry 
criteria are met. Non -response at the end of the screening/prospective 
observational phase is defined as ≤25% improvement in the MADRS total score 
for 2 consecutive visits from  Week 1 to Week 4 and a MADRS total score of 
≥28 for 2 consecutive visits on Week 2 and Week 4 .  
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 7Applicable Section(s) Description of Change(s)
Synopsis, Overview of 
Study Design; 
Synopsis, Study 
Population; Synopsis, 
Dosage and 
Administration; 3.1. 
Overvie w of Study 
Design; 3.2.1. Study 
Population; 6.1. 
Screening/Prospective 
Observational Phase ; 
9.1.2. 
Screening/Prospective 
Observ ational PhaseText regarding antidepressant treatment during the screening/prospective observational 
phase was revised as follows (bold text added):
“…the subject must have had documented non -response to at least 1 antidepressant 
treatm ent (based on MGH-ATRQ criteria) in the current episode of depression ,and
the subject isbetaking one of the adifferent oral antidepressant treatment (s)with 
nonresponse ( ≤25% improvement) that will be documented (on the MGH ATRQ) for at 
least the previous 2 weeks (ie, this oral antidepressant treatment must have been taken
for at least 6 w eeks at or above the mini mum therapeutic dose with a lack of clinically 
meaningful improvement) . This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/augmentation therapies), 
will continue unchanged, at the same dosage, from the start of Week 1 through the end of 
Week 4 of the screening/prospective observational phase. Dose adjustment is permitted 
per clinical judgm ent, but the oral antidepressant treatment is to remain at or above 
the minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4. ”
Synopsis, Study 
Population; 3.2.1. 
Study Population; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for the minimum number of oral antidepressant treatments in the current episode 
of depression with non -response at the start of the screening/pro spective observational 
phase was revised from ≥2 to ≥1.
Synopsis, Overview of 
Study Design; 
Synopsis, Study 
Population; 3.1. 
Overvie w of Study 
Design; 3.2.1. Study 
Population; 6.1. 
Screening/Prospective 
Observational Phase ; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for non -response at the end of the screening/prospective observational phase was 
revised as follows (bold text added):
Non-response at the end of the screening/prospective observational phase is defined as 
≤25% improvement in the MADRS total score for 2 consecutive visits from  Week 1 to 
Week 4 and a MADRS total score of ≥ 28 for2 consecutive visits on Week 2 and Week 4 .
3.1. Overview  of 
Study DesignFigure 1 w as revised to correspond w ith the changes in the text regarding the subject 
selection criteria for the screening/ prospective observational phase.
16.1. Study -specific 
Design ConsiderationsText w as revised as follows (bold text added):
For eligibility, subjects must have had non -response to at least 1 prior antidepressant 
treatm ent and TRD and be currently taking non-responders to their current an
antidepressant treatm ent with non -response being observed with at the start of the 
screening/prospective observational phase that will be continued as prospective 
treatment in the screening/prospective observational phase. Only subjects w ith non -
response to their current antid epressant treatment after 4 weeks of prospectively observed 
treatment (for a total duration of antidepressant treatment of at least 106weeks by the end 
of the screening/prospective observational phase), will be eligible to proceed to the 
double- blind ind uction phase, when reall subject swill receive a new  oral antidepressant in 
addition to intranasal esketamine or placebo.
Rationale: The list of key secondary objectives, evaluations, and endpoints has been reordered to correspond to the 
revised order of the planned analysis.
Synopsis, Objectives 
and Hypothesis; 2.1. 
ObjectivesKey secondary objectives reorder ed to show  “Depressive symptoms (subject -reported)” as 
the third key secondary objective.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 8Applicable Section(s) Description of Change(s)
Synopsis, Efficacy 
Evaluations/EndpointsUnder the “Key Secondary Evaluations and Endpoints” heading, text describing the onset 
of clinical response was moved to the first key secondary evaluation, text describing the 
SDS was moved to second, and text describing PHQ -9 was moved to third. Numbering 
described in the text was revised accordingly.
Synopsis, Statistical 
Methods; 9.2.2.2. 
Secondary Endpoints; 
11.4. Efficacy 
AnalysesText revised to indicate that analysis of key secondary efficacy endpoints will be analyzed 
in the following order: first, onset of clin ical response results; second, SDS results, and 
third, PHQ- 9 results.
The detailed description of the efficacy analyses in Section 11.4 has been revised to reflect 
changes in the order of analysis and adjustments to the testing procedure.
9.2.1.3. Key 
Secondary Efficacy 
Evaluation (Patient -
reported Outcome)Order of key secondary patient -reported outcome efficacy evaluations was revised to 
show description of SDS before that of PHQ -9.
Rationale: Analysis of onset of clinical response revised to indicate that subjects are allowed one excursion .
Synopsis, Efficacy 
Evaluations/Endpoints; 
Synopsis, Statistical 
Methods; 3.2.5. 
Efficacy Measures; 
9.2.1.2. Key 
Secondary Efficacy 
Evaluation (Clinician -
completed); 9.2.2.2. 
Secondary Endpoints; 
11.4. Efficacy 
AnalysesThe description of the onset of clinical response was revised as follows (bold text added) :
Clinical response is defined as ≥50% improvement in MADRS total score by Day 2 (ie, 
the day after t aking the first dose of double- blind intranasal medication) that continues 
through the end of the double -blind phase with one excursion allowed . 
Rationale: Inclusion criterion no. 11 .1 was revised to specify the same requirements for contraception for female 
partners of male subjects as specified for female subjects and to remove numbering that was added in error.
4.1. Inclusion Criteria The text of inclusion criterion no. 11 .1has been changed as follow s (bold text added):
During the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately 
90 days) after receiving the last dose of intranasal study medication, in addition to the u ser 
independent highly effective method of contraception, a man who is sexually active with 
a wom an of childbearing potential
-must be practicing a highly effective method of contraception with his 
female partner from  those listed above (see examples of hig hly effective 
methods of contraception provided for fem ale subjects). who is sexually 
active with a w oman of childbearing potential must agree to use a double -barrier 
method of contraception (eg, diaphragm or cervical/vault caps plus condom with 
spermicida l foam/gel/film/cream/suppository) .
-who is sexually active with a woman who is pregnant must use a condom if his 
partner is pregnant .
-must agree not to donate sperm.
12.Alternatively female partners of childbearing potential may be practicing a highly 
effective method of birth control, eg, established use of oral, injected, or implanted 
horm onal methods of contraception; placement of an intrauterine device (IUD) or 
intrauterine system (IUS); or male partner sterilization. Note: If the childbearing potential 
changes after start of the study, a female partner of a male study subject, must begin a 
highly effective method of birth control, as described above.
4.1. Inclusion Criteria The numbering of the last 2 inclusion criteria has been corrected.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 9Applicable Section(s) Description of Change(s)
Rationale: Exclusion criterion no. 11 .1was revised to delete the exclusion for first degree atrioventricular (AV) 
block as the analyses of PR intervals from subjects in Phase 1 and Phase 2 esketamine studies show ed no impact of 
esketamine on PR interval.
4.2. Exclusion Criteria Exclusion criterion no. 11 .1was revised as follows (bold text added):
Subject has clinically significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the double -blind induction 
phase prior to randomization, defined as:
-During screening, a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec; if the QTcF is prolonged on the initial ECG, the average 
QTcF of three ECG ’s, recorded 4 minutes apart, must not be ≥450 msec.
-On Day 1 (predose), a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec based on the site -evaluated ECG; if the QTcF is prolonged 
on the initial ECG, the average QTcF of three ECG ’s, recorded 4 minutes apart, 
must not be ≥450 msec.
-Evidence of 2nd and 3rd degree AV block, or 1st degree AV block w ith PR 
interval >200 msec (may repeat ECG once, and use average of both readings, if 
the initial PR interval is <240 msec), com plete left bundle branch block (LBBB), 
or complete right bundle branch block (RBBB). 
-Features of new ischemia.
-Arrhythmia (except premature atrial contractions [PACs] and premature 
ventricular contractions [PVCs]).
Rationale: Exclusion criterion no. 14 .1was revised to allow prescription use of psychostimulan ts with dosing 
restrictions on intranasal treatment session days to allow  subjects to safely use at other permitted times during study 
participation.
4.2. Exclusion Criteria Text in exclusion criterion no. 14 .1was revised as follows (bold text added):
Subject has positive test result(s) for drugs of abuse (including barbiturates, methadone, 
opiates, cocaine, phencyclidine, and amphetamine/methamphetamine) at the start of the 
screening/prospective observational phase or Day 1 of the double -blind inductio n phase 
prior to randomization.
-Subjects who have a positive test result at screening due to prescribed 
psychostimulants (eg, am phetam ine, methylphenidate, etc.) taken for an 
indication other than MDD are perm itted to continue to take this medication 
durin g the study in accordance with Attachm ent 1 .
-Otherwise, Subjects subjects who have a positive test result at screening due to 
prescribed/over -the-counter opiates ,or barbiturates , or amphetamines may be 
permitted to continue in the screening/prospective ob servational phase if the 
medication is discontinued at least 1 w eek or 5 half -lives, whichever is longer, 
before Day 1 of the double -blind induction phase (prior to randomization) in 
accordance w ith Attachment 1 restrictions. The result of the Day 1 (prior to 
randomization) test for drugs of abuse must be negative for the subject to be 
randomized.
oRetesting is not permitted for positive test result(s), except for reasons stated 
above.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 10Applicable Section(s) Description of Change(s)
Rationale: Clarifications made regarding the usage of antidepressant treatments for indications other than 
depression during the screening/prospective observational phase, and the use of corticosteroids, psychostimulants, 
and ADHD medications.
8. Prestudy and 
Concomitant TherapyThe follow ing text was added:
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for an indication other than depression (eg , 
insomnia) should be continued during the screening/prospective observational phase but 
must be discontinued before the start of the double -blind induction phase.
Attachment 1 For antidepressants, changed 3rdbullet to read “Even if used for other indications (eg, 
trazodone primarily for sleep ), trazodone the use of any m edication listed on th e ATRQ
is not permitted during the treatment phase” 
For corticosteroids, changed “oral” to “systemic”; allowed episodic use (previously 
prohibited); added that intermittent IM/IV corticosteroids are permitted (chronic use 
prohibited). 
For pseudoephedri ne, clarified that is an orally administered agent (not intranasal).
For psychostimulants, allowed continuous use (previously prohibited); added that 
prescribed psychostimulants taken for indications other than MDD can be continued but 
must not be taken w ithin 12 hours prior to the intranasal treatment session or for 2 hours 
after the intranasal treatment session. 
For ADHD medications, allowed continuous use (previously prohibited) ; added that these 
medications can be continued but must not be taken within 12 hours prior to the intranasal 
treatment session or for 2 hours after the intranasal treatment session .
Rationale: In Amendment 1, inclusion of subjects who have thyroid -stimulating hormone (TSH) outside the normal 
ranges was permitted; however, the text indicating that a subject must have a normal TSH at screening was not 
removed from Amendment 1. This has been corrected in Amendment 2.
4.1 Inclusion Criteria The bullet sin inclusion criterion no. 7 .1were revised as follow s:
-Subjects with a pre- existing history of thyroid disease/disorder w ho are treated 
with thyroid hormones must be on a stable dosage for 3 months prior to the start 
of the screening/prospective observational phase and must have thyroid -
stimulating hormone (TS H) within normal range in the screening/prospective 
observational phase.
-For any subject (regardless of thyroid history), if the thyroid -stimulating 
horm one ( TSH )value is out of range, a free thyroxine (FT4) w ill be conducted. 
If the FT4 is normal, the su bject can be enrolled. If the FT4 value is abnormal 
and considered to be clinically significant (after discussion with the m edical 
monitor) out of range , the subject is not eligible.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 11Applicable Section(s) Description of Change(s)
Rationale: Add MADRS assessment at Visit 3.2 during the follow -up phase and provide clarification in the 
footnotes regarding antidepressant treatment in the screening /prospective observational phase and guidance on 
repetition of the MADRS assessment .
Time and Events 
Schedule, Screening 
and Induction PhaseFootnote “a”revised to state (bold text added) : Subjects who do not require a taper and 
are thus eligible to immediately proceed to the double- blind induction phase canwillhave 
Visit 1.3 and Visit 2.1 occur ringon the same day or within 1 week of each other (if not 
occurring the sam e day, the antidepressant treatment regim en should be continued 
and discontinued prior to Visit 2.1 ).
Deleted “only” from footnote “d”.
Footnote “p” revised to state (bold text added): The MADRS should be administered no 
more than 2 days prior to the subject’s scheduled targeted (not actual) clinic visit date 
(except Visit 2.10, which is within 1 day prior) . If performed on the day of the 
scheduled clinic visit for an intranasal treatment session, the MADRS must be performed 
prior to the intranasal treatment session.
Time and Events 
Schedule, Follow -up 
PhaseAMADRS assessment was added to Visit 3.2.
Rationale: Revise the visit window  for Day 28 of the double -blind  induction phase to allow  more flexibility for 
conducting the visit.
Time and Events 
Schedule, Screening 
and Induction PhaseFor Visit 2.10 during the induction phase, the visit window  was revised to ±1 day (rather 
than -1 day ). 
Rationale: To obtain AE and concomitant therapy data in between clinic visits.
Time and Events 
Schedule, Follow -up 
PhaseThe follow ing statement was added as footnote “f” to each remote assessment during the 
follow -up phase:
At each “Remote Assessment ” visit, site staff will contact the subject by telephone to 
obtain information regarding a dverse events and concomitant therapies
Rationale: To add information about 54135419TRD3008 , an open -label safety extension study ,which may be 
available for eligible subjects participating in ESKETINTRD3001.
Synopsis, Overview of 
Study Design; 3.1. 
Overvie w of Study 
Design; 9.1.4. Follow -
up PhaseThe follow ing text was added:
An open -label safety extension study, 54135419TRD3008 , may be available (pending 
country and site approval) for eligible subjects participating in the ESKETINTRD3001 
study. Please refer to the 54135419TRD3008 protocol for full details when available.
Rationale: Removal of requirement to report arterial oxygen saturation <93% and any treatment -emergent change 
in the nasal examination as adverse events because adverse event reporting in these instances should be at the 
discretion of the PI.
9.7. Safety Evaluations Any arterial oxygen saturation (SpO 2) <93% should be and lasting for more than 
2minutes, and confirmed by an additional measurement on anoth er part of the body , will 
be reported as an adverse event .
The follow ing statement was deleted from the description of nasal examinations: Any 
treatment -emergent change or worsening from the baseline examination will be recorded 
as an adverse event.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 12Applicable Section(s) Description of Change(s)
Rationale: The maximum sertraline dose was changed from 150 mg/day to 200 mg/day as the maximum dose 
allow ed by  product labelling is 200 mg/day.    
1.2.1.2. Sertraline; 
Attachment 3 Maximum dose of sertraline changed from 150 mg/day to 200 mg/day. Titration schedule 
adjusted accordingly. 
Rationale: Revise text regarding uptitration of duloxetine dose, which referred to an incorrect phase of the study.
1.2.2 .1. Duloxetine Text revised to state that certain subjects may be started on a 30 mg dose of duloxetine 
and up -titrated to the therapeutic range of 60 mg by the start of Week 2 of the double-
blind induction phase (not the screening/prospective observational phase).
Rationale: Removal of LSD and MDMA from urine drug screen results that will lead to discontinuation as LSD is 
not measured in the current urine drug screen and prescribed p sychostimulants are now  permitted.
4.3. Prohibitions and 
RestrictionsLysergic acid diethylamide (LSD) and MDMA weredeleted from the list of drugs that 
will lead to discontinuation if detected in the urine drug screen during the study .
Rationale: Clarification of procedure to follow  if subjects wish to withdraw from the study.
10.2 Withdraw al from 
the StudyUnder “Withdraw al of Consent”, the following text was revised to state (bold text added): 
Subjects who wish to withdraw from the study should be asked if they are agreeable to 
continue to an early withdrawal visit (if withdrawin g from the double -blind 
induction phase) and the follow up phase, or to be contacted t o collect follow -up 
information.
Rationale: Added definition of treatment -resistant depression (TRD) to the synopsis .
Synopsis, Study 
PopulationDefinition of TRD from Section 3.2.1 also added to the synopsis under Study Population.
Rationale: Clarification of adverse event reporting procedures in the instance of pregnancy .In addition, 
clarification that all SAEs must be reported using the SAE form.
12.3.1. All Adverse 
EventsText revised as follows (bold text added) :
All adverse events and special reporting situations, whether serious or non -serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's 
last study -related procedure (which may include contact for follow -up of safety), with the 
exception of pregnancy which will be reported up to 6 weeks after the last dose of 
study medication (fem ales) or 90 days after the last dose of study m edication 
(partners of m ale participants) .  Serious adverse events, including those spontaneously 
reported to the investigator, within 30 days after the last dose of study drug, must be 
reported using the Serious Adverse Event Form. The sponsor w ill evaluate any safety 
information that is spontaneously reported by an investigator beyond the time frame 
specified in the protocol.
Rationale: Minor changes were made throughout the protocol for compliance with updated protocol template text
and to correct errors.
Cover page Updated Sponsor Statement to remove Janssen Infectious Diseases BVBA. 
Time and Events 
Schedule, Screening 
and Induction PhaseFootnote “p” was added to the MADRS assessment (7 -day recall) at Visit 1.2.
4.1. Inclusion Criteria The follow ing text was added toinclusion criterion no. 9. 1:
Contraceptive use by men or women should be consistent with local regulations regarding 
the use of contraceptive methods for subject sparticipating in clinical studies.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 13Applicable Section(s) Description of Change(s)
9.3. Pharmacokinetics To correct an error, the text was revised as follows (bold text added): Plasm aSerum
collected for PK may additionally be used to evaluate safety or efficacy aspects that 
address concerns arising during or after the study period.
17.5 Case Report Form 
Com pletionDeleted text stating “All data relating to the study must be recorded in CRF.”
References Removed edition number and date from reference 42. 
Deleted references to Wiens BL (2003) as w ell as Wiens BL and Dmitrienko A (2005) as 
these are not r eferenced in the document due to text revisions.
Investigator 
Agreement PageRemoved the “LAST PAGE” designation.
Amendment 1 (07January 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union 
The overall reason for the amendment: The overall reason for th is amendment is to update and/or clarify protocol 
content based onongoing feedback received during study initiation activities .
Applicable Section(s) Description of Change(s)
Rationale: Clarify that “at least 7 treatments with unilateral ECT” encompasses bilateral ECT treatments as well. 
Synopsis, Study Population;
4.2. Exclusion CriteriaExclusion criteria no.1 now states “unilateral/bilateral” rather than only 
“unilateral.” 
Rationale: Indication that subjects who received vagal nerve stimulation in the current depressive episode are 
excluded.
4.2. Exclusion Criteria The current exclusion criteria no. 2 has now been changed, to exclude a subject 
who has received vagal nerve stimulation (VNS) in the current depressive 
episode.
It previously stated subjects with vagal nerve stimulation (VNS) implant were 
excluded .
Rationale: Exclusion criteria expanded to include additional DSM -5 diagnostic codes (317, 318.0, 318.1, 318.2, 
315.8, and 319) for intellectual disability, and autism spectrum disorder.
Synopsis, Study Population;
4.2. Exclusion CriteriaExclusion criteria no. 3 expanded to include additional intellectual disability 
DSM -5 diagnostic codes (317, 318.0, 318.1, 318.2, 315.8, and 319), and autism 
spectrum disorder.
Rational e: Clarification of the de scription ofMDD and obsessive compulsive disorder, under criteria for subject 
exclusion. 
Synopsis, Study Population;
4.2. Exclusion CriteriaThe text of the current exclusion criteria no.3. was modified : 
-“MDD with psychosis” was revised to “MDD with psychotic features ” 
-“Only ”subjects w ith “current” o bsessive compulsive disorder will be 
excluded.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 14Applicable Section(s) Description of Change(s)
Rationale: Clarification of the conditions for exclusion of subjects with coronary artery disease.
4.2. Exclusion Criteria The text of exclusion criteria no.8. w as modified such that the following 
cardiovascular conditions will now  be excluded :
Coronary artery disease with myocardial infarction, unstable angina, “or”
revascularization procedure (eg, coronary angioplasty or bypass graft 
surgery) within 12 months before the st art of the screening/prospective 
observational phase. Subjects who have had a revascularization performed > 
12 months prior to screening and are clinically stable and symptom -free, “per 
investigator’s clinical judgment ”, can be included.
Rationale: Clarification of the w ording used for describing a subject’s antihypertensive medication.
4.2. Exclusion Criteria The text of the current exclusion criteria no. 9. will now state:
antihypertensive “medication(s)” rather than “regimen”.
Rationale: Clarification of definition of clinically significant ECG abnormalities as defined by QT interval 
corrected according to Fridericia’s formula (QTcF) .
4.2. Exclusion Criteria The text of the current exclusion criteria no.11 w as modified as follows:
The first subbullet, was separated into 2 separate bullets, and the following 
bold text w as added:
-During screening ,a QT interval corrected according to Fridericia’s 
formula (QTcF): ≥450 msec; if the QTc Fis prolonged on the initial 
ECG, the average QTcF of three ECG’s ,recorded 4 minutes apart, 
must not be ≥450 msec .
--On Day 1 (predose) , a QT interval corrected according to Fridericia’s 
formula (QTcF): ≥450 msec based on the site -evaluated ECG; if the 
QTcF is prolonged on the initial ECG, the average QTcF of three 
ECG’s, recorded 4 minutes apart, m ust not be ≥450 m sec.
In the second subbullet, the follow ing bold text w as added:
-Evidence of 2ndor 3rddegree AV block, or 1stdegree AV block with PR 
interval ˃200 msec “[may repeat the ECG once, and use average of both 
readings, if the initial PR interval is <240 msec ]”
-“complete ” was added to LBBB and RBBB.
Rationale: The use of concomitant medications that prolong the QT interval/corrected QT (QTc) are no longer 
excluded ,as there is no known increase in QTc signal associated with esketamine ; extensive ECG monitoring is in 
place ,and precautions in c ase of increase in QTc added .”
4.2. Exclusion Criteria The current exclusion criteria no. 12 has been modified:
The follow ing text has been deleted, as:
The “use of concomitant medication that prolong the QT interval/corrected QT (QTc) 
interval” no longer excludes a subject from study enrollment.  
Rationale: Inclusion of a repeat screening test for abnormal ALT and AST values during the screening/prospective 
observational phase.
4.2. Exclusion criteria The current exclusion criteria no. 13 has been modified:
Where the subject has a history of, or symptoms and signs suggestive for liver 
cirrhosis/alanine aminotransferase (ALT)/aspartate aminotransferase (AST) 
values ≥2x the upper limit (normal) , the following is applicable:
“Repeat of screening test for abnor mal ALT and AST is permitted once  
during the screening period provided per investigator discretion and provided 
that there is an alternative explanation for the out of range value .”
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 15Applicable Section(s) Description of Change(s)
Rationale: Clarification that a positive test for cannabinoids on Day 1is exclusionary, but not at screening. 
4.2. Exclusion Criteria The text of the current exclusion criteria no. 14 w as modified :
Clarification that “a positive test for cannabinoids at the start of the 
screening/prospective phase is not exclusionary, however a positive test result for 
cannabinoids on Day 1 (predose) of the double- blind -treatm ent phase is 
exclusionary ”.
Rationale: The term “secondary diabete s” was removed from theexclusion criterion because, as stated in the 
criterion, any uncontrolled diabetes mellitus is exclusionary.
4.2. Exclusion Criteria The text of the current exclusion criteria no. 15 was modified to delete the terms 
“secondary diabetes ”.
Rationale: Provide clarification that investigator’s clinical judgment based on the assessment will be used to 
exclude subjects on the basis of any anatomical or medical condition that may impede delivery or absorption of 
intranasal study drug .
4.2. Exclusion Criteria The text of exclusion criteria no. 17 was modified to indicate that the 
‘investigator’s clinical judgment based on the assessment ’will be used to 
determine eligibility .
Text that is redundant (ie, examples of structural or functional abnorm alities) has 
been deleted.
Rationale: Exclusion criteria no. 18 is no longer required as it is covered as part of exclusion criteria no. 17.
4.2. Exclusion Criteria The te xt of exclusion criteria no. 18 has been deleted.
Rationale: Clari fication that a subject is excluded if currently enrolled in an investigational study , which is 
interventional , and clarification that the limit for participation in 2 or more MDD or other psychiatric condition 
clinical interventional studies in the previous 1 year is based on studies with different investigational medications. .
4.2. Exclusion Criteria The text of exclusion criteria no . 24 has been modified to include:
-Subject who has participated in 2 or more MDD or other psychiatric 
condition clinical interventional studies “(with different investigational 
medication)” in the previous 1 year.
-Subject is currently enrolled in an i nvestigation al “interventional” st udy.
Rationale: Subjects w ith severe renal impairment (creatinine clearance < 30 ml/min) are being excluded (exclusion 
criterion no. 30), as a safety precaution, since the effect of impaired renal clearance on the PK of intranasal 
esketamine is not fully known and subjects may be more vulnerable to blood pressure increases.
4.2. Exclusion Criteria Added exclusion criteria no. 30 for all subjects: Severe renal impairment 
(creatinine clearance < 30 ml/min)
Rationale: Clarification to inclusion criterion regarding nonresponse to oral antidepressant treatments in current 
episode of depression was added . 
Synopsis, Study Population;
3.1. Overview  of Study Design;
3.2.1. Study Population;
4.1. Inclusion Criteria ;
6.1 Screening/Prospective 
Observational Phase;
9.1.2 Screening/Prospective 
Observational PhaseThe text of the current inclusion criteria no. 3 w asmodified :
At the start of the screening/prospective observational phase, subject must 
have had non-response (≤ 25% improvement) to ≥2 but ≤5 (if current episode 
is ˃2years, upper limit applicable to only the last 2 years) oral antidepressant 
treatments in current episode of depression, assessed using the MGH -ATRQ
and confirmed by documented records (eg, medical/ph armacy/prescription 
records or a letter from a treating physician e.t.c.). 
Subject must be taking one of the oral antidepressant treatment(s) with 
nonresponse that is documented on the MGH -ATRQ (ie, this oral 
antidepressant treatment must be taken for at least 6 weeks at the minimal 
therapeutic dose with a lack of clinically meaningful improvem ent) at the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 16Applicable Section(s) Description of Change(s)
start of the screening/prospective observational phase.
-For specific tricyclic antidepressants which are being taken at a dose 
below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within the therapeutic (antidepressant) range, is acceptable to establish 
the adequacy of the antidepressant treatment. 
Non-response at the end of the screening/prospective observational phase is 
defined as ≤ 25% improvement in the MADRS total score for 2 consecutive 
visits and a MADRS total score of ≥ 28 for 2 consecutive visits.
Rationale: Indicate that the severity of a subject’s depressive symptoms in their current major depressive episode is 
also being confirmed using a Site Independent Qualification Assessment.
Synopsis, Study Population;
3.2.1. Study Population;
4.1. Inclusion Criteria;
9.1.2.Screening/Prospective 
Observational PhaseThe text of the current inclusion criteria no. 5 w as modified:
The subject’s current major depressive episode, “depression symptom severity 
(Week 1 MADRS total score ≥ 28 required)”, and antidepressant treatment 
response in the current depressive episode, must be confirmed using a Site 
Independent Qualification Assess ment. 
Rationale: Inclusion of an additional lab test which measures levels of free thyroxine (FT4) , in the event that TSH 
values are out of range.
4.1. Inclusion Criteria The text of the inclusion criteria no. 7 was modified to include an additional lab
testfor assessing levels of free thyroxine:
-For any subject (regardless of thyroid history), if the TSH value is out of 
range, a free thyroxine (FT4) will be conducted. If the FT4 is norm al, the 
subject can beenrolled. If the FT4 value is out of range, the subject is not 
eligible.
Rationale: Clarification of the criteria for assessing pregnancy in women of childbearing potential.
4.1. Inclusion Criteria The text of the current inclusion criteria no.10 now  states that:
• A woman of childbearing potential must have a negative “highly sensitive”
serum (β -human chorionic gonadotropin [β -hCG]) at the start of the 
screening/prospective observational phase .
•A negative urine pregnancy test “ must be obtained before the first dos e of 
study drug ” on Day 1 of the double- blind induction phase prior to 
randomization.
Rationale: Inclusion criteria for methods of birth control were updated per new  Sponsor protected template 
requirements .
4.1. Inclusion Criteria The text of the current inclusion criteria no. 11 w as modified:
During the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as 
approximately 90 days) after receiving the last dose of intrana sal study 
medication, in addition to the user independent highly effective method of 
contraception, a man
who is sexually active with a woman of childbearing potential must agree to 
use a double -barrier method of contraception (eg, diaphragm or cervical/va ult 
caps plus condom with spermicidal foam/gel/film/cream/suppository).
who is sexually active with a woman who is pregnant must use a condom
must agree not to donate sperm
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 17Applicable Section(s) Description of Change(s)
4.1. Inclusion Criteria The text of the current inclusion criteria no. 9 w asalso modified :
A woman must be either:
a. Not of childbearing potential defined as:
opostmenopausal
A postmenopausal state is defined as no menses for 12 months without 
an alternative medical cause. A high follicle stimulating hormone (FSH) 
level ( ˃40 IU/L or mIU/ml in the postmenopausal range) willbe used to 
confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy, however in the 
absence of 12months of amenorrhea, a single FSH measurement is 
insufficient.
operma nently sterile 
Perm anent sterilization methods include hysterectomy, bilateral 
salpingectomy, bilateral tubal occlusion/ligation procedures, and 
bilateral oophorectomy.
b. Of childbearing potential and
opracticing a highly effective method of contraception (failure rate of 
<1% per year when used consistently and correctly).
Examples of highly effective contraceptives include 
-user-independent methods:
implantable progestogen -only horm one contraception associated 
with inhibition of ovulation; intrauterine device (IUD); 
intrauterine horm one-releasing system (IUS); vasectomized 
partner; sexual abstinence (sexual abstinence is considered a 
highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk 
associated with the study drug. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifesty le of the subject.)
-user-dependent methods:
combined (estrogen -and progestogen -containing) hormonal 
contraception associated with inhibition of ovulation: oral, 
intravaginal, and transdermal; progestogen -only horm one 
contraception associated with inhibit ion of ovulation: oral and 
injectable
Typical use failure rates may differ from those when used consistently 
and correctly. Use should be consistent with local regulations regarding 
the use of contraceptive methods for subjects participating in clinical 
studies.
Hormonal contraception may be susceptible to interaction with the 
study drug, which may reduce the efficacy of the contraceptive method.
oagrees to use a highly effective method throughout the study and for at 
least 6 weeks after the last dose of stu dy drug .
1. Note: If the childbearing potential changes after start of the study or the risk 
of pregnancy changes (eg, a woman who is not heterosexually active 
becomes active) ,a woman must begin a highly effective method of 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 18Applicable Section(s) Description of Change(s)
contraception, as described throug hout the inclusion criteria.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 19Applicable Section(s) Description of Change(s)
Rationale: Allow option for subjects who have in the past shown increased sensitivity towards SSRI/SNRIs to start 
at a 30 mg dose of duloxetine in the oral antidepressant titration schedule.
1.2.2.1. Duloxetine ;
Attachment 3 ,
Legend ‘a’Deletion of textin Section 1.2.2.1 .stating : ‘Although not in the US prescribing 
information , an initial starting dose of 30 mg/day has also been evaluated’ .
The follow ing text has been added , as the US prescribing information does 
indicate that:
“For some patients, it may be desirable to start at 30 mg once daily for 1 w eek, to 
allow  patients to adjust to the medication before increasing to 60 mg once daily .”
“In the current study, subjects should be initiated with 60mg/day . Subjects that
have in the past shown increased sensitivity towards SSRI/SNRIs can,at the 
discretion of the treating physician, be started on 30mg dose and up-titrated into 
the therapeutic range of 60mg by the start of Week 2 of the 
screening/prospective observational phase ”.
Rationale: Update to align with ne w protocol template text regarding data being collected for medical resource 
utilization
9.6. Medical Resource 
UtilizationDeleted text that specified “including surgeries and other selected procedures; 
“number and character of diagnostic and therapeutic tests and procedures”, 
and “outpatient medical encounters and treatments (including physician or 
emergency room visits, tests and procedures, and medications)”.
Rationale: Total bilirubin was om itted in error from the serum chemistry panel in the prior protocol .
9.7. Safety Evaluations Total bilirubin was added to the serum chemistry panel.
Rationale: Clarify that in the event that an intranasal treatment session is postponed/delayed (within a visit window)
due to a predose vital sign assessment (e.g., blood pressure), on the actual day of theintranasal treatment session, 
specific assessments (including predose) must be performed/repeated, as specified in the T&E Schedule.
9.7. Safety Evaluations;
Time & Ev ents ScheduleWhere a decision has been made to postpone/delay the intranasal treatment 
session within the visit window , alltime points (including predose) of the 
following assessments listed in the Time & Events Schedule, must be repeated on 
the actual intranasal treatment session day: vital signs (ie, blood pressure, pulse, 
respiratory rate, and temperature), 12-lead ECG, C-SSRS (since last visit), 
MOAA/S, pulse oximetry, BPRS+, and CADSS .
A footnote ‘q’ was added to the following assessments in the double- blind 
induction phase to indicate what needs to be performed/repeated for a postponed 
(within the visit window ) intranasal dosing visit:
Vital signs, 12-lead ECG, C-SSRS, MOAA/S, pulse oximetry, BPRS+, and 
CADSS .
Rationale: Add recommendation for rescheduling smell test assessments ifasubject has significant nasal 
congestion on the day of a scheduled smell test(s).
Time & Events Schedule;
9.7. Safety EvaluationsA footnote ‘o’ was added to UPSIT and Smell Threshold Test to note that the 
smell test assessment (s)should be rescheduled for the next clinic visit if the 
subject has nasal congestion .
Rationale: Update to include new template text for reporting abnormal pregnancy outcomes
12.3.3. Pregnancy Instructions for the reporting of abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) were 
added.
Rationale: Clarification that menstrual cycle tracking will be documented for w omen with a menstrual cycle only.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 20Applicable Section(s) Description of Change(s)
Time & Events Schedule ;
9.8. Other EvaluationsA footnote ‘n’ was added to menstrual cycle tracking in the double -blind 
induction phase of the Time & Events Schedule to indicate it is only applicable to 
women with a menstrual cycle .
Rationale: Footnote corrected to specify at which clinic visit a predose and /orpostdose 12 -lead ECG w ill be 
performed. 
Time & Events Schedule The footnote ‘f’ was corrected to indicate that:
Twelve-lead ECG will be performed at t = 1 h postdose “only (ie, no predose 
ECG required)” at Visits 2.4, 2.6, and 2.9. 
Rationale: T he Time and Events Schedule row  that provided the assessment windows for MADRS was removed 
due to misunderstandings it was creating relative to the clinic visit windows.
Time & Events Schedule The row for MADRS assessment windows was deleted and afootnote ‘p’ was 
added , with the same guidance as previously stated in the row, to indicate thatthe 
MADRS should be administered no more than 2 days prior to the subject’s 
scheduled clinic visit, and that if perform ed on the day of the scheduled clinic 
visit for an intranasal treatment session ,the MADRS must be performed prior to 
the intranasal treatment session.
Rationale: Clarify arterial oxygen saturation level that requires further monitoring .
9.7. Safety Evaluations The symbol “<” was added to this sentence to clarify that additional assessments 
are required when the level is < 93%: 
“If oxygen saturation levels are < 93% at any time during the 1.5 hour postdose 
interval, pulse oximetry will be recorded every 5 minutes until levels return to ≥ 
93%.”
Rationale: Add an additional Sheehan Disability Scale (SDS) assessment between Day 1 and Day 28.
Time & Events Schedule An SDS assessment was added on Day 15 (Week 2) of the Double -blind 
Induction Phase , as indicated.
Rationale: The PWC -20 assessment is to be performed for all subjects on Day 25 of the Double- blind Induction 
Phase (last planned intranasal treatment session) because sites will not know at that time whether or not a subject 
will be continuing into ESKETINTRD3003 .
Time & Events Schedule Footnote “j” w as rem oved from the D ay 25PWC -20 assessment .
Rationale: Thescoring of the PAQ assessment was revised.
9.8. Other Evaluations Text describing scoring of the PAQ was revised to indicate :
The total score is based on the response selected for Question 1 ( previously 
stated it was calculated by adding response choices for questions 1c through 
1f), and
A score of 0-1 = adherent (previously stated 0 = adherent) and 2 or more is 
nonadherent (previously stated 1 or more = nonadherent) .
Rationale: Clarification of the description for the HVLT -R recall test.
9.7. Safety Evaluations Changes added to the description of the HVLT -R recall test:
Administration includes a delayed recall (20 minute) trial and a 24 -word 
recognition list.
The test administrator reads instructions and w ord lists aloud ,and records 
words recalled/recognized by the subjects .
Scores include learning, delayed recall, and recognition.
Additional text added stating that “All subjects will complete a practice 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 21Applicable Section(s) Description of Change(s)
session for the computerized cognitive battery during the 
screening/prospective observational phase. There is no practice session for 
the HVLT -R.”
Rationale: Alert site staff to ECG readings that w ould raise safety concerns and necessitate subject withdraw al and 
study discontinuation
9.7. Safety Evaluations;
10.2. Withdraw al from the 
StudyThe follow ing text was added:
-The subject must be discontinued at any time point after baseline (Day 1, 
predose), if:
QTcF change from baseline is ≥ 60 msec andQTcF > 480 msec, or 
QTCF > 500 msec.
Rationale: Indicate biomarkers will be protein and RNA and provide the rationale for recommendation of subject 
adherence to a low  fat diet on the day of sample collection.
3.2.10. Biomarker, 
Pharm acogenomic (DNA), and 
Expression (RNA) Evaluations ;
SynopsisAdded text to indicate that biomarkers will be assessed at both the protein and 
RNA level.
Addition of sentence stating that ‘On the day of biomarker sample collection, it is 
preferred that subjects adhere to a low fat diet (as an alternative to fasting) to 
reduce the level of postprandial lipemia in blood samples, since moderately or 
grossly lipemic specimens may interfere with assay results.
Rationale: Blood volume table update dto include tricyclic antidepressant and free thyroxine (FT4) blood level 
testing , if required , as w ell as changes in blood volumes for biomarker (protein/DNA) assessment.
9.1.1. Overview , 
Table 3 legend e)and f)Table 3. 
Screening/Prospective Observational Phase :
-Row added to blood volume table to include :
-asingle 6 mL sample per subject for analysis of blood levels of tricyclic 
antidepressant , if required . 
-a single 3.5 m Lsample per subject for analysis of blood levels of FT4, if 
required.
- Addition of footnote ‘e)’”for specific tricyclic antidepressants which are being 
taken at a dose below  the MGH -ATRQ minimum therapeutic dose, a blood level 
that is within the therapeutic (antidepressant) range ,is acceptable to establish the 
adequacy of antidepressant treatment ”.
-Addition of footnote ‘f)’ “for any subject (regardless of thyroid history), if the 
TSH value is out of range, a free thyroxine (FT4) will be conducted”
Double -blind Induction Phase :
- Merge the two row s for ‘Biomarker: protein visits’ to a single row , that will 
now state: “Biomarker: protei n (at Visits 2.1, 2.4, and 2.9). The volume of 
sample collected at each visit is 10 mL. The number of samples per subject is 
now 3.
All study phases:
-Volume of blood sample for Biomarker: protein is now 10 mL
-Volume of blood sample for Biomarker: DNA i s now 6 mL
-Delete footnote ‘d)’ Blood volume listed under protein biomarkers 
represents the combined volume of several different collection tubes.
Total Volume of Blood to be collected per subject is now  116 mL. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 22Applicable Section(s) Description of Change(s)
Rationale: Provide further clarification on how the current oral antidepressant treatment regimen should remain 
unchanged for the duration of the screening/prospective observational phase, and provide the criterion for non-
response at the end of the screening/prosp ective observational phase (ie, site inve stigators are no longer blinded ).
Synopsis, Overview of Study 
Design;
Dosage and Administration;
Study Population;
3.1. Overview Study Design;
3.2.1. Study Population;
6.1.Screening/Prospective 
Observational Phase;
9.1.2. Screening/Prospective 
Observational PhaseSubject’s current oral antidepressant treatment regimen should remain unchanged 
and at the same dosage for the 4 -week screening/prospective observational phase.
At the start of the screening/prospective observational phase. the subjec t must 
be taking one of the oral antidepressant treatment(s) with nonresponse (≤ 
25% im provement) that will be docum ented on the MGH -ATRQ (ie, this oral 
antidepressant treatment must have been taken for at least 6weeks at the 
minimum therapeutic dose with a lack of clinically meaningful 
improvement). This antidepressant treatment, as well as any other ongoing 
medications being taken for depression at screening (including adjunctive/ 
augmentation therapies), will continue unchanged, at the same dosage, from
the start of Week 1 through the end of Week 4 of the screening/prospective 
observational phase.
After 4 weeks, subjects who are non -responders to the current oral antidepressant 
treatment may be eligible to proceed to the double- blind induction phase. 
Nonresponse at the end of the screening/prospective observational phase is 
defined as ≤ 25% improvement in the MADRS total score for 2 consecutive 
visits and a MADRS total score of ≥ 28 for 2 consecutive visits.
Eligible subjects who are entering the double- blind induction phase will 
discontinue all of their current medication(s), being used for depression 
treatment, including adjunctive/augmentation therapies. 
-Subjects taking benzodiazepines (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non -benzodiazepine 
sleep medications (eg, zolpidem, zaleplon) during the screening/prospective 
observational phase can continue these medications.
-No dose increases beyond the equivalent of 6 mg/day lorazepam, or new 
benzodiazepines are permitted during the screening/prospective observational 
phase.
Eligible subjects who do not require a tapered discontinuation of their 
antidepressant treatment(s) can proceed immediately into the double- blind 
induction phase.
Rationale: Clarification on the mandatory use of oral antidepressant dosing titration schedule.
Synopsis, Dosage and 
Administration;
3.2.4. Treatment Groups and 
Dose Selection;
6.2. Double -Blind Induction 
Phase, 
Oral Antidepressant 
Medication;
9.1.3 Double- Blind Induction 
Phase-Use of the titration schedule provided in Attachment 3 is mandatory.
-Text regarding the use of local prescribing information and “maximum 
tolerated dose” has been deleted.
-“Doses are not to exceed the maximum dose defined in the titration s chedule” 
has been added.
Rationale: Clarifi cation of guidance on blood p ressure monitoring on intranasal treatment session days.
6.2.1. Guidance on Blood 
Pressure Monitoring on 
Intranasal Treatment Session 
DaysClarification ofguidance on blood pressure monitoring ;
predose blood pressure monitoring :
If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 23Applicable Section(s) Description of Change(s)
“(ie,applicable to all other intranasal treatment session days after Day 1)”, 
a subject’s pre-dose systol ic blood pressure “(SBP) is ˃140 mmHg and/or 
diastolic blood pressure (DBP) is ˃90mmHg ”,itis recommended to repeat the 
blood pressure measurement after subject rests in sitting or recumbent position.
-“If after rest and repeated measurements, pre -dose SBP is ˃140mmHg and/or 
DBP is ˃90mmH g”, then dosing should be postponed and the subject 
scheduled to return on the follow ing day or within the given visit window.
-If the blood pressure elevation still per sists on the next visit, the subject w ill 
be scheduled for a consultation by cardiologist, “other specialist ”or primary 
care physician , prior to further dosing ”
postdose blood pressure monitoring :
If at any postdose time point on the dosing day, the SBP is ≥180 mmHg but 
<200 mmHg and/or the DBP is ≥110 mmHg but <120 mmHg, further intranasal 
dosing should be interrupted and the subject should be referred to a cardiologist, 
“other specialist ”, or primary care physician for a follow -up assessment.”
-After the assessment by a cardiologist, “other specialist ”or prim ary care 
physician , “if recommended by the referring doct or and considered  
appropriate according to the clinical judgment ”for the subject to continue in 
the study, the subject may continue with intranasal dosing, if the predose 
blood pressure, at the next scheduled visit is within the acceptable range (see 
bullet point above).
If at any postdose time poin t on the dosing day the SBP is ≥200mmHg and/or 
the DBP is ≥120 mmHg, the subject “must” discontinue from further dosing and 
the subject should be referred to a cardiologist, “other specialist ”, or primary care 
physician for a follow -up assessment .
Addition of the following criteria for discharge based on post-dose blood 
pressure assessments during the double -blind induction phase:
During the double- blind induction phase, at 1.5 hours postdose, if the SBP is 
≥160 mmH g and/or the DBP ≥100 mmH g, asses sments should continue every 
30minutes unt il:
the blood pressure is <160 mmHg SBP and <100 mmHg DBP, or 
“in the investigator’s clinical judgment, the subject is clinically stable  and 
can be discharged from the study site ”, or
the subject is referred for appropriate medical care, if clinically in dicated.
“If the blood pressure remains ≥ 180 mmHg SBP and/or / ≥110 mmHg DBP , 
2hours after dosing, the subject should be referred for immediate medical 
treatment ”.
Rationale: Clarification of the language regarding subjects meeting blood pressure criteria on intranasal treatment 
session days for discontinuation from further dosing, to indicate that the discontinuation of such subjects is 
mandatory.
6.2.1. Guidance for Blood 
pressure Monitoring on 
Intranasal Treatment Session 
DaysUpdated the text in the section “Guidance for Blood Pressure Monitoring on 
Intranasal Treatment Session Days” to indicate that :
If at any postdose time point on the dosing day the SBP is ≥200 mmHg 
and/or the DBP is ≥120 mmHg, the subject “must ”discontinue from further 
dosing (rather than ‘should ’discontinue) , and the subject should be referred 
to a cardiologist, “other specialist”, or primary care physician for a follow -up 
assessment. .
Rationale: Clarification s for the use of prestudy and concomitant therap ies.
8. Prestudy and Concomitant 
Therapy ;Clarification of the following:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 24Applicable Section(s) Description of Change(s)
4.3. Prohibitions and 
RestrictionsConcom itant Therapy
Antidepressant treatments whichare not listed on the MGH -ATRQ, but were 
used, or are currently being used as antidepressant treatments in the current 
depressive episode must be recorded in ‘Concomitant T herapy ’eCRF .
Concomitant therapies must be recorded from signing of the inform ed consent 
and continuing up the last visit.
If a subject has routinely take nhis/her oral antihypertensive medications in the 
morning on dosing days ,the m orning dose should be taken prior to intranasal 
dosing.
Subjects receiving psychotherapy (including cognitive behavioral therapy, CBT) 
can continue receiving psychotherapy ; how ever, CBT must have been ongoing 
for the last 3 months prior to the start of the screening/prospective observational 
phase .
With the exception of new CBT, which is prohibited, new  psychotherapy is 
allow ed during the study . Anychange in existing therapy or new therapy must be 
documented on the concomitant therapies form.
Rescue Medications
Clarification of text: “Unless clinically indicated ”it is recommended that 
transient increases in blood pressure not be treated, as the blood pressure 
“typically ”returns to predose values in 2hours.
Rationale: Clarification of the language regarding subjects who develop treatme nt emergent ulcerative cystitis to 
indicate the discontinuation of such subjects is mandatory.
3.2.6. Safety Evaluations;
9.7. Safety EvaluationsUpdated/ added the text in these sections describing the BPIC -SS and 
instructions for discontinuing due to ulcerative cystitis, to read as follows,: “If a 
subject is determined to have a diagnosis of ulcerative c ystitis the subject must be 
discontinued from the study and followed up with appropriate medical care.”
Rationale: Provide further clarification to site staff requirements for intranasal treatment sessions. 
Synopsis;
6.2. Double -blind Induction 
Phase, Intranasal Study DrugThe text now states: On all intranasal treatment session days, a site staff member 
with training in cardiopulmonary resuscitation (eg, Basic Life Support course or 
equivalent courses) that is up to date per local regulations must be present with 
the subject during the intranasal treatment sessions and the postdose observation 
period.
Rationale: Inclusion of tests for measuring free thyroxine (FT4) and for determining rates of creatinine clearance
9.7. Safety Evaluations Inclusion of the following tests at time points specified in the Time & Events 
Schedule:
Free thyroxine (FT4), if applicable
Calculation of creatinine clearance
Rationale: Changes to Attachment 1, including the table listing of Prohibited Concomitant Medications :
Attachment 1 Inclusion of the following statement proceeding the table listing prohibited 
medications: “Note: If a medication is part of the antidepressant treatment 
regimen being taken at the time of signing the ICF (i.e., start of 
screening/prospective observational phase), it must be continued unchanged until 
the end of Week 4 of the screening/prospective observational phase, therefore 
this requirement is not applicable. In such cases the investigator may choose to 
taper the relevant medication during the 3-week taper period based on their 
clinical judgment”.
-Deletion of row referring to CYP3A4 inhibitors as prohibited concomitant 
medication.
-Additional exam ple of anorexiants (eg, phendimetrazine) that are prohibited 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 25Applicable Section(s) Description of Change(s)
as concomitant medication for reasons of safety.
-An additional example of anticonvulsants (eg, pregabalin) that are permitted 
as concomitant medication when used for indications other that seizures was 
added.
-Methylphenidate, modafinil, and armodafinil, were added as additional 
examples of prohibited psychostimulants. 
-A new row was added for prohibited non-stimulant ADHD medications (eg, 
.atomoxetine, guanfacine).
-Addition of new text to comments on the use of antidepressants in this study, 
stating that ”Even if used primarily for sleep, trazodone use is not perm itted 
during the treatment phase”.
-Deletion of text in comments on the use of Non-benzodiazepine sleeping 
medication.
-Clarification that benzodiazepine medication should be taken at dosages 
equal to or less than the equivalent of 6 mg/day of lorazepam.
-Addition of new text to comments on the use of Cough/cold 
preparations/nasal solutions containing vasoconstrictors, decongestants 
“pseudoephedrine –containing products should not be used within 12hours 
prior to an intranasal treatment session”. This is for reasons of safety and due 
to potential PD interactions.
-Added row for non-vitamin K antagonist oral anticoagulant agents (eg, 
dabigatran, rivaroxaban, apixaban) .
-Deletion of text in comments on the use of thyr oid hormone supplements .
Rationale: Clarification of procedures that need to be followed with respect sample collection and handling, on 
withdrawal of a subject from the study.
10.2. Withdraw al from the 
studyAddition of new text specifying that:
When a subject w ithdraws before completing the study, the reason for 
withdrawal must be documented in the CRF and in the source document.
Subjects who withdraw  will not be replaced.
If a subject w ithdraws before the end of the double- blind induction phase, a n 
early withdraw al visit is to be performed .
Deletion of the following text:
Study drug assigned to the withdrawn subject may not be assigned to another 
subject.
Rationale: Update and clarification to prohibited medications, substances, and restrictions during the double- blind 
induction phase.
Synopsis, Overview of Study 
Design,
Double -Blind Induction Phase;
3.1. Overview Study Design;
4.3. Prohibitions and 
RestrictionsRestrictions on the use of benzodiazepines during the double -blind induction 
phase:
-Subjects who were taking benzodiazepines “(at dosages equal to or less than 
the equivalent of 6mg/day of lorazepam) ”and/or permitted non-
benzodiazepine sleep medications (eg, zolpidem, zaleplon) “during the 
screening/prospective observational phase ”can continue these medications 
during the induction phase. 
-No dose increases “beyond the equivalent of 6 mg/day of lorazepam ”or new 
benzodiazepine medications are permitted during the induction phase, with 
the exception of the use of permitted benzodiazepine rescue medication.
-Benzodiazepines and non-benzodiazepine sleeping medication (eg, zolpidem, 
zaleplon, eszopiclone, and ramelteon) are prohibited within 12 hours prior to the 
start of each intranasal treatment session or cognition testing.
Removal of thefollowing restriction: ‘Subjects should not ingest grapefruit juice, 
Seville oranges, or quinine for 24 hours before an intranasal dose of study 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 26Applicable Section(s) Description of Change(s)
medication is to be administered.
An additional criterion has been added: A positive urine drug test for “lysergic 
acid diethylamide (LSD)” from Day 1 through to the final visit in the double-
blind induction phase will lead to discontinuation.
Rationale: Provide clarification that a llmedication(s) being used for depression must be discontinued after 
completion of the 4 -week prospective observational phase
Synopsis, Dosage and 
AdministrationText was clarified to indicate that “all medication(s) being used for depression” will 
be discontinued for subjects eligible to enter the double -blind induction phase.
Rationale: A diary has been added to record oral antidepressant use.  
Time & Events Schedule;
Synopsis, Dosage and 
Administration;
6.2. Double -Blind Induction 
Phase;
7. Treatment Compliance;
15. Study -Specific MaterialsText added to indicate that a diary will be provided for subjects to keep a record 
of oral antidepressant study medication use, to be reviewed and updated (if 
applicable), and returned at the end of the double- blind induction phase, in the 
event of an early withdraw al, or at the end of the follow -up phase.
Rationale: Update list of study -specific materials
15. Study -Specific Materials Guidance document for the use of the MGH -ATRQ and subject diary have been 
added.
Rationale: Clarification of criteria for w ithdrawal of consent .
10.2. Withdraw al from the 
StudyFor clarification the following additions to the text were made:
Withdrawal of consent :
Should only be selected as a reason for withdraw al if the subject does not agree 
to any further study assessments or procedures. If the subject is agreeable to 
participating in the Early Withdrawal visit and the follow -up phase, another 
reason for withdraw al should be selected.
If the subject withdraws from the study before the end of the double- blind 
induction phase, an Early Withdraw al visit is to be performed. 
If the subject is lost to follow -up, every reasonable effort must be made by the 
study site personnel to contact the subject and determine the reason for 
discontinuation/withdrawal . This should include at least 3 telephone calls, 
certified letters, email requests, etc,. To ensure access to follow-up subjects, the 
study site personnel should attempt to obtain both primary and secondary 
telephone contact numbers (eg, home, work, and mobile numbers) , as well as 
other contact information (eg, email addresses) from subjects before 
randomization. In addition, the study site should emphasize the importance of 
follow -up information to the subject before randomization. The measures taken 
to follow  up must be documented .
Subjects who withdraw  will not be replaced.
Every effort will be made in the study to ensure withdrawal of consent is not 
selected as a reason for discontinuation when in fact the subject withdrew for an 
identifiable reason (e.g. due to an adverse event or lack of efficacy).
Subjects who wish to withdraw  from the study should be asked if they are 
agreeable to be contacted to collect follow -up information. Subjects who are not 
agreeable to follow -up contact will be withdrawn from the study as “withdraw al 
of consent.” Subjects who no longer wish to take study drug but agree to provide 
follow -up information will be withdrawn from the study with the reason noted as 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 27Applicable Section(s) Description of Change(s)
“Other” and will specify the reason why. For a subject who “withdraw sconsent ”, 
it is recommended that the subject withdr aw consent in writing; if the subject 
refuses or is physically unavailable, the study site should document and sign the 
reason for the subject’s failure to withdraw consent in writing and maintain it 
with the subjects source records.
-The investigator will be responsible for making all required notifications to 
the Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC).
Rationale: Clarification of study site personnel availability for on -site monitoring visits.
17.8. Monitoring Revision of text, which now states that;
‘It is expected that study -site personnel will be available to provide an update on 
the progress of the study at the study site’
Rationale: Clarification of the content of electronic case report form(s) (eCRF)
17.11. Use of Information and 
PublicationIt is now stipulated that the Clinical Study Report generated by the sponsor will 
contain eCRF data from all study sites that participated in the study and “will 
represent uploaded data transferred from external service provider s”into the 
sponsor’s database.
Rationale: Clarification of procedures for correcting data entries in the eCRF
17.5. Case Report Form 
Com pletionClarification that: “ All data relating to the study must be recorded in CRF. All 
CRF entries, corrections, and alterations must be made by the investigator or 
authorized study -site personnel. The investigator must verify that all data entries 
in the CRF are accurate and correct ”.
If corrections to an eCRF are needed after the initial entry into the eCRF, this c an 
be done in either of the following ways:
Investigator and study site personnel can make corrections in the eDC tool at 
their own initiative or as a response to an auto query (generated by the eDC 
tool).
Sponsor or sponsor delegate can generate a query f or resolution by the 
investigator and study -site personnel.
Deletion of the following text: ‘Clinical data manager can generate a query for 
resolution by the study site personnel’.
Rationale: Drug accountability (oral antidepressant) , to be performed on visit 3.7 of the Follow -up Phase
Time & Event Schedule Drug accountability for oral study medication is to be performed on visit 3.7 
(Week 12 after last intranasal dose) of the Follow -up Phase.
Legend ‘e)’, which is applicable to this assessment was added :
e) For any remaining oral antidepressant study medication.
Rationale: Indicate that there is a required order of administration for intranasal devices.
6.2. Double -blind Induction 
Phase, 
Table 2A footnote ‘c)’ added, w hich states that ‘The 3 intranasal devices for each 
intranasal treatment session should be administered in the medication kit order 
provided by the IWRS.”
Rationale: Include published data 
1.1.2.3. Safety and Tolerability, 
Adverse events associated with 
short -term use of intranasal 
esketamine in patients with 
MDDSummary introduction paragraph :Additional text added to include published 
data relating summarize to adverse events associated with short -term use of 
intranasal esketamine in patients with MDD.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 28Applicable Section(s) Description of Change(s)
Rationale: Minor errors and clarification were noted .
Throughout the protocol Grammatical, formatting, or spelling changes were made.
10.3. Withdraw al from the use 
of Samples in Future ResearchNew  section 10.3. designated
Attachment 3 Global titration schedule: list of countries that are exempt (ie, Japan, Taiw an, 
South Korea, and Malaysia) is no longer applicable.
Tine & Events Schedule Changes to the text:
Study Drug: distinguish betw een study visits during the double- blind 
induction phase in which the subject diary is to be dispensed, reviewed, and 
returned to the subject. 
Cognition tests: clarification that the “practice sessions for computerized test 
battery” are distinct from the actual sessions in which the “Computerized test 
battery and the HVLT -R” recall cognition tests are performed.
Added foonote “r” to Visit 2.1 C-SSRS (Since Last Visit) assessment to 
indicate this is only perform ed for subjects who do not have Visit 1.3 and 2.1 
occur on the same day.
Synopsis, Oral Antide pressant 
Study MedicationText added to clarify that:
The subjects maximum tolerated dose of oral antidepressant, should not be low er 
than the minimum therapeutic dose “at the end of the induction phase”
4.2. Exclusion Criteria
9.3. PharmacokineticsThefollow ing text: “(ie, AHI<30)” w as added to exclusion criterion no. 23, to 
clarify the meaning of ‘effec tive’ treatment of sleep apnea.
The follow ing text was added:
“Whole blood samples will be used to evaluate the PK of esketamine. Serum 
collected for PK may additionally be used to evaluate safety or efficacy aspects 
that address concerns arising during or after the study period. Genetic analyses 
will not be performed on these serum samples. Subject confidentiality will be 
maintained. ”
9.2.1.1 Primary Efficacy 
EvaluationText w as added to indicate that the MADRS will be administered using the 
structured interview guide for the MADRS (SIGMA) .
9.2.1.1. Primary Efficacy 
Evaluation“(interest level)” was added after the MADRS item description of “inability to 
feel” to describe what this item will be assessing .
Synopsis, Primary and Key 
Secondary Efficacy Analyses;
11.4. Efficacy AnalysesThe third key secondary efficacy endpoint, change from baseline in SDS total 
score at w eek4 in the double -blind -induction -phase, will be analyzed using the 
same models described for the MADRS total score, and not using the ANOVA, 
as originally stated.
9.7. Safety Evaluations
9.7. Safety EvaluationsThe follow ing correction was made to Clinical Labor atory Tests:
Urine Drug Screen: cannabinoids (cannabinoids are only “exclusionary on” Day 
1 predose).
Administrative error correct ed to lipid panel which previously listed high density 
lipoprotein (HDL) -cholesterol tw ice. Text was updated to clarify it include slow 
density lipoprotein (LDL) and high density lipoprotein (HDL) -cholesterol. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 29SYNOPSIS
A Randomized, Double -blind, Multicenter, Active -controlled Study to Evaluate the Efficacy, Safety, 
and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult 
Subjects with Treatment -resistant Depression
Study Acronym: TRANSFORM -1
Major depressive disorder (MDD) ,a serious, recurrent, and disabling psychiatric illness ,is the second 
leading cause of years lostto disability worldwide . MDD is associated with excess mortality, and with 
years of potential life lost . About 30% of patients fail to achieve remission despite treatment with multiple 
antidepressant medications, and are considered to have treatment -resistant depressio n (TRD). There is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways underlying 
MDD for the rapid relief of symptoms of depression, especially in patients with TRD.
Ketamine and esketamine (S-ketamine, the Senanti omer of ketamine) areapproved and widely used for 
the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. 
The desired analgesic -anesthetic effects of ketamine and esketamine are attributed to the blockade of 
ionotropic N -methyl -D-aspartate (NMDA) glutamate receptors. The mechanism of action of ketamine and 
esketamine aredistinct from conventional monoaminergic antidepressant treatment s,in that they 
profoundly affect fast excitatory glutamate transmission, increases in brain- derived neurotrophic factor 
(BDNF) release, and stimulate synaptogenesis.
Janssen Research & Development (JRD) is developing intranasal esketamine as an antidepressant 
therapy .A higher NMDA receptor affinity of esketamine allows a lower volume of medication to be 
administered via the non- invasive, rapidly absorbed intranasal route.
The current study is being conducted to evaluate the efficacy, safety, and tolerability of 2 fixed doses of 
intranasal esketamine plus a newly initiate d oral antidepressant in adult subjects with TRD. The study 
will serve as a pivotal Phase 3 short -term efficacy and safety study in support of regulatory agency 
requirements for registration of intranasal esketamine for the treatment of TRD.
OBJECTIVES AND HYPOTHESIS
Primary Objective
The primary objective of this study is to evaluate the efficacy of switching adult subjects with TRD from  
a prior antidepressant treatment (to which they have not responded ) to intranasal esketamine (56mg or 
84mg) plus a newlyinitiated oral antidepressant ,compared with switching to a newlyinitiated oral 
antidepressant (active comparator) plus intranasal placebo, in improving depressive symptoms, as 
assessed by thechange from baseline in the Montgomery -Asberg Depression Rating Scale (MADRS )
total score from Day 1 (pre- randomization )to the end of the 4week double -blind induction phase.
Key Secondary Objective s
 The key secondary objective s are to assess the effect of intranasal esketamine plus a newly initiated 
oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo on the following parameters in adult subjects with TRD :
 Onset of clinical response by Day 2
 Function ingand associated disability
 Depressive symptoms (subject -reported)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 30Other Secondary Objectives
 To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant compared 
with a newly initiated oral antidepressant (active comparator) plus intranasal placebo onthe 
following parameters in adult subjects with TRD :
 Depression response rates
 Depression remission rates
 Overall severity of depressive illness
 Anxiety symptoms
 Health- related quality of life and health status
 To investigate the safety and tolerability of intranasal esketamine plus a newly initiated oral 
antidepressant compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo in adult subjects with TRD, including the followi ng:
 Treatment -emergent adverse events (TEAEs) , including AEs of special interest
 Local nasal tolerability
 Effects on heart rate, blood pressure, respiratory rate, and blood oxygen saturation
 Effects on alertness and sedation
 Potential psychosis -like effect s
 Dissociative symptoms 
 Potential e ffects on cognitive function
 Potential e ffects on suicidal ideation/behavior
 Potential t reatment -emergent symptoms of cystitis and/or lower urinary tract symptoms
 Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine 
treatment
 Potential e ffects on sense of smell
 To assess the pharmacokinetic s(PK) of intranasal esketamine in adult subjects with TRD receiving 
intranasal esketamine plus a newl y-initiated oral antidepressant
Exploratory Objectives
 To assess the PK/pharmacodynamic (PK/PD) relationship of intranasal esketamine and MADRS 
total score in adult subjects with TRD
 To assess the potential relationship of biomarkers with response/non -response to intranasal 
esketamine or oral antide pressants in adult subjects with TRD
 To assess medical resource utilizatio n
Hypothesis
The hypothesis for this study is that,in adult subjects with TRD ,switching from a failed antidepressant 
treatment to intranasal esketamine plus a newly initiated oral antidepressant is superior toswitching toa
newly initiated oral antidepressant treatment (active comparator) plus intranasal placebo in improving 
depressive symptoms.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 31OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, active -controlled, multicenter study in male and female adult subjects 
with TRD to assess the efficacy, safety, and tolerability of fixed dosed intranasal esketamine (56mg or 
84mg) plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant 
(active comparator) plus intranasal placebo. 
The study has3 phases which are briefly described below .
Screening/prospective observational phase (4-week duration +optional 3-week taper period )
This phase will prospectively assess treatment response to the subject’s current oral antidepressant 
treatment regimen.
At the start of the screening/prospective observational phase, the subject must have had documented non -
response to at least 1 antidepressant treatment (based on MGH -ATRQ criteria) in the current episode of 
depression, and the subject istaking adifferent oral antidepressant treatment (on the MGH -ATRQ ) for at 
least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, as 
well as any other ongoing medications being taken for depression at screening (including 
adjunctive /augmentation therapies) will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase. Dose adjustment is permitted per clinical judgment, but the 
oral antidepressant treatment is to remain at or abov e the minimum therapeutic dose (per the MGH -
ATRQ) through the end of Week 4.
After 4 weeks , subjects who are non-responders to the current oral antidepressant treatment may be 
eligible to proceed to the double -blind induction phase . Non-response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total score 
from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4 . Eligible subjects who 
are entering the double -blind induction phase will discontinue all of their current medication (s)being 
used for depression treatment , including adjunctive /augmentation therapies . Of note, subjects taking 
benzodiazepines (at dosages equal to or less than the equivalent of 6mg/day of lorazepam )and/or 
permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) during the 
screening/prospective observ ational phase , can continue these medications , but no dose increases beyond 
the equivalent of 6 mg/day oflorazepam or new benzodiazep ine medications are permitted during the 
screening/prospective observational phase .If clinically indicated, asubject’s current antidepressant
treatment (s)may be tapered and d iscontinued over an additional, optional period of up to 3 weeks per the 
local prescribing information or clinical judgment.
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant treatment (s) can proceed 
immediately into the double -blind induction phase .
Double -blind induction phase (4-week duration )
Approximately 348 subjects will be randomly assigned at a 1:1:1 ratio to receive double -blind intranasal 
treatment with either esketamine 56 mg, esketamine 84 mg, or placebo . The intranasal treatment sessions
(esketamine or placebo) will occur twice weekly. In addition, all subjects will initiate anew open -label 
oral antidepressant on Day 1 that will be taken daily for the duration of this phase. The assigned oral 
antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or 
venlafaxine extended release [XR]) , that the subject has not previously had a non-response to in the 
current depressive episode, has not been previously intolerant to (lifetime), and is available in the 
participating country.
Subjects who were taking benzodiazepines (at d osages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or permitted non-benzodiazepine sleep medications (e.g., zolpidem, zaleplon) during the 
screening/prospective observational phase can continue these medications during the induction phase. No 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 32dose increases beyond the equivalent of 6 mg/day of lorazepam or new benzodiazepine medications are
permitted during the induction phase, with the exception of the use of permitted benzodiazepine rescue 
medication.
At the end of the induction phase, subjects who are responders (defined as 50% reduction in the 
MADRS total score from baseline [Day 1 pre-randomization] to the end of the 4week double -blind 
induction phase) may be eligible to participate in the subsequent study ESKETINTRD3003 if they meet 
all other study entry criteria (ESKETINTRD3003 is alonger -term efficacy maintenance study involving 
repeate d treatment sessions of intranasal esketamine) .
If a subject withdraws from the study before the end of the double -blind induction phase for r easons other 
than withdrawal of consent, an Early Withdrawal visit should be conducted within 1 week of the date of 
discontinuation, followed by the follow -up phase.
Follow -up phase (24-week duration )
This phase will include all subjects who are not eligible or who choose to not participate in the 
maintenance of effect study ESKETINTRD3003 and have receive dat least 1 dose of intranasal study 
medication in the double -blind induction phase. There will be no intranasal treatment sessions 
administered during t his phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician. The decision to continue the 
oral antidepressant in this phase will be at the discretion of the investigator, however, in order to better 
assess potential withdrawal symptoms from intranasal study medication, the oral antidepressant 
medication should be continued for at least the first 2weeks of the follow -up phase unless determined as 
not clinically appropriate.
The follow -up phase will also allow collection of additional informative data to assess the course of the 
subject’s major depressive episode over a 6- month period.
An open -label safety extension study, 54135419TRD3008 , may be available (pending country and site 
approval) for eligible subjects participating in the ESKETINTRD3001 study. Please refer to the 
54135419TRD3008 protocol for full details when available.
Taking into consideration the optional tape r period of up to 3 weeks , the maximum duration of a subject’s 
study participation in the current study will be 11 weeks (for subjects continuing into 
ESKETINTRD3003) or 35 weeks (for subjects completing the follow -up phase).
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study.
STUDY POPULATION
The study population will include adult men and women, 18 (or older if the minimum legal age of consent 
in the country in which the study is taking place is >18) to 64 years of age (inclusive), who meet the 
Diagnostic and Statistical Manual of Mental Disorders (5th Edition; DSM -5)diagnostic criteria for 
single -episode MDD (if single -episode MDD, the duration of the episode must be 2years) or recurrent 
MDD without psychotic features, based upon clinical assessment, and confirmed by the 
Mini -International Neuropsychiatric Interview (MINI ).In addition, the subject must have an Inventory of 
Depressive Symptomatology- Clinician rated, 30-item (IDS-C30) total score of 34, which corresponds to 
moderate to severe depression.
At the start of the screening/prospective observational phase, subjects must have had non-response (ie, 
lack of clinically meaningful improv ement , defined as ≤25% improvement) to 1but 5 (if current 
episode is > 2 years, upper limit is only applicable to the last 2 years ) oral antidepressant treatment staken 
at adequate dosage and for adequate duration, as assessed using the Massachusetts General 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 33Hospital -Antidepressant Treatment Response Questionnaire (MGH -ATRQ) and documented by records 
(eg, medical /pharmacy /prescription records or a letter from treating physician , etc.) for the current 
episode of depression. In addition, the subject must currently be taking a different oral antidepressan t 
treatment (on the MGH -ATRQ )for at least the previous 2 weeks at or above the minimum therapeutic 
dose. This antidepressant treatment, as well as any other antidepressant medica tions being used for 
depression treatment (including adjunctive/ augmentation therapies), will continue from the start of 
Week 1 through the end of Week 4 of the screening/prospective observational phase. Dose adjustment is 
permitted per clinical judgment, but the oral antidepressant treatment is to remain at or above the 
minimum th erapeutic dose (per the MGH -ATRQ) through the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤ 25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on 
Week 2 a nd Week 4 . 
Treatment -resistant depression is defined as a lack of clinically meaningful improvement after treatment 
with at least 2 different antidepressant agents prescribed in adequate doses for adequate duration.
The subject’s current major depressive episode , depression symptom severity (Week 1MADRS total 
score ≥ 28 require d),and antidepressant treatment response in the ircurrent depressive episode 
(retrospectively assessed) must be deemed valid for participation in theclinical study based on a Site-
Independent Qualification Assessment. The Site Independent Qualification Assessment is a tool to 
facilitate subject selection for MDD clinical studies, with a goal to ensure enrollment of subjects who 
have symptoms that reflect the current state of illness ,and that these symptoms can be reliably measured 
with a ppropriate measurement tools .
Potential subjects will be excluded from participating in the study if they have previously demonstrated 
non-response of depressive symptoms to esketamine or keta mine in the current major depressive episode ,
or to all 4 of the oral antidepressant treatment options available for the double -blind induction phase 
(ie,duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major depressive episode 
(based on MGH -ATRQ) ,or an adequate course of treatment with electroconvulsive therapy (ECT) in the 
current major depressive episode, defined as at least 7 treatments with unilateral /bilateral ECT. Subjects ,
who in the current depressive episode have received vagal nerve stimulation (VNS) ordeep brain 
stimulation (DBS) , will be excluded . Subjects will also be excluded if they have a current or prior DSM -5 
diagnosis of a psychotic disorder or MDD with psychosis, bipolar or related disorders (confirmed by the 
MINI), obsessive compulsive diso rder(current only) , intellectual disability (DSM -5 diagnostic code s 317 , 
318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, antisocial 
personality disorder, histrionic personali ty disorder, or narcissistic personality disorder; if they have 
homicidal ideation/intent or suicidal ideation with some intent to act within 6 months prior to the start of 
the screening/prospective observational phase per the investigator’s clinical judgm ent and/or based on the 
Columbia Suicide Severity Rating Scale (C-SSRS) ; or if they have a history of moderate or severe 
substance or alcohol use disorder according to DSM -5 criteria.
DOSAGE AND ADMINISTRATION
Screening/ prospective observational phase
At the start of the screening/prospective observational phase, the subject must have had documented non -
response to at least 1 antidepressant treatment (based on MGH -ATRQ criteria) in the current episode of 
depression, and the subject istaking adifferent oral antidepressant treatment (on the MGH -ATRQ) for at 
least the previous 2 weeks at or above the minimum therapeutic dose.This antidepressant treatment, as 
well as any other ongoing antidepressant medications being taken for depression at screening (including  
adjunctive /augmentation therapies), will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase for prospective observation of response or non-response.
Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment is to remain at or 
above the minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 34The sponsor will not supply these antidepressant medications . Antidepressant treatment adherence during 
this phase will be assessed using the Patient Adherence Questionnaire (PAQ). Eligible subjects who are 
enter ingthe double -blind induction phase , after completion of 4weeks of prospective antidepressant 
treatment and assessment of the antidepressant treatment response, will discontinue all of their current
medication(s) being used for depression treatment, including adjunctive/augmentation therapies . Subjects 
taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of loraz epam) and/or 
permitted non-benzodiazepine sleep medications (e.g., zolpidem, zaleplon) during the 
screening/prospective observational phase can continue these medications, but no dose increases beyond 
the equivalent of 6mg/day of lorazepam, or new benzodi azepines or non-benzodiazepine sleep 
medications are permitted during the screening/prospective observational phase . If clinically indicated 
(eg, antidepressant treatment s with short half -lives, such as paroxetine and venlafaxine XR; or tolerability 
concer ns), the antidepressant medication (s)may be tapered off and discontinued over a period of up to 
3weeks per the local prescribing information or clinical judgment .
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant medication(s) can proceed 
immediately into the double -blind induction phase .
Double -blind induction p hase
During this phase, subjects will be randomized to receiv e double -blind intranasal treatment with 
esketamine or placebo . In addition, subjects will simultaneously initiate a new, open -label oral 
antidepressant on Day 1 that will be continued for the duration of this phase.
Intranasal Study Medication
All subject s will self-administer the intranasal study drug (esketamine or placebo) at treatment sessions 
twice a week for 4 weeks at the study site. The first treatment session will be on Day 1. Intranasal 
treatment sessions should not take place on consecutive days .
Prior to the first intranasal dose on Day 1, subjects will practice spraying (into the air, not intranasally) a 
demonstration intranasal device that is filled with placebo solution.
All subjects randomized to intranasal esketamine (56mg or 84mg) will start at 56mg on Day 1. In a 
blinded manner, if a subject is randomly assigned to 84mg, he or she will receive an 84-mg dose on 
Day 4 and for all subsequent intranasal treatment sessions. Subjects who are randomly assigned to 56mg 
will remain on that dose for all subsequent intranasal treatment sessions. No adjustment to the intranasal 
esketamine dose is permitted for the duration of the double -blind induction phase.
On all intranasal treatment session days, a site staff member with training in cardiopul monary 
resuscitation (eg, Basic Life Support course or equivalent course) that is up to date per local regulations ,
must be present with the subject during the intranasal treatment session sand the postdose observation 
period. In addition, equipment for supportive ventilation and resuscitation needs to be present. Subjects 
must remain at the site until study procedures have been completed and the subject is ready for discharge . 
At the time of discharge, subjects should be accompanied by a responsible adult when released from the 
clinical site. Subjects must not drive a car or work with machines for 24hours after receiving intranasal 
study drug.
Oral Antidepressant Study Medication
Starting on Day 1, a new, open -label oral antidepressant treatment will be initiated in all subjects. The 
oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or 
venlafaxine XR). The antidepressant medication will be assigned by the investig ator based on review of 
MGH -ATRQ and relevant prior antidepressant medication information , and will be one that the subject 
has not previously had a non-response to in the current depressive episode, has not been previously 
intolerant to (lifetime), and is available in the participating count ry.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 35Dosing of the oral antidepressant will begin on Day 1.A mandatory titration schedule is provided in 
Attachment 3. Doses are not to exceed the maximum dose defined in the titration schedule .If higher 
doses are not tolerated, a down -titration is permitted based on clinical judgment. However, the subject’s 
dose should not be lower than the follo wing minimum therapeutic doses at the end of the induction phase : 
Sertral ine (50 mg/day), venlafaxine XR (150 mg/day), escitalopram (10mg/day), and duloxetine 
(60mg/day). While subjects requiring lower doses can continue in the study and complete the double -
blind induction phase, such subjects will not be eligible to particip ate in the maintenance of effect study 
ESKETINTRD3003 and will proceed to the follow -up phase after completion of the induction phase.
All subjects will be provided with an additional 4week supply of the oral antidepressant medication to 
ensure that there is no interruption of oral antidepressant therapy during the transition to 
ESKETINTRD3003 or to further clinical/standard of care in the follow -up phase.
Study -site personnel will instruct subjects on how to store and take the oral antidepressant treatment
supplied during this study for at -home use. A subject diary will be provided to capture oral antidepressant 
study medication use .
On intranasal dosing days, it is recommended the oral antidepressant medication not be taken until at least 
3hours after the intranasal treatment session.
Follow -up phase
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician .
No intranasal study medication will be administered during this phase.
The decision to continue the oral antidepressant medication in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal study  
medication, the oral antidepressant medication should be continued for at least the first 2weeks of the 
follow -up phase unless determined as not clinically appropriate.
EFFICACY EVALUATIONS/ENDPOINTS
Primary Efficacy Evaluation and Endpoint
The primary efficacy evaluation will be the MADRS total score. The MADRS will be performed by 
independent remote raters during the study. The MADRS is a clinician- rated scale designed to measure 
depression severity and detects changes due to antidepre ssant treatment.
The primary efficacy endpoint will be change from baseline in MADRS total score from Day 1 
pre-randomization to the end of the 4- week double -blind induction phase.
Key Seconda ry Efficacy Evaluation sand Endpoints
1. MADRS: The first key secondary endpoint is the onset of clinical response by Day 2 that is 
maintained for the duration of the double -blind induction phase (50% improvement in MADRS 
total score by the day after taking the first dose [ie,Day 2] of double- blind intranasal medication that 
continued through the end of the 4week double -blind induction phase with one excursion allowed ).
Subjects who discontinue the study prior to end of the double -blind induction phase will not be 
considered to have maintained clinical response.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 362. Sheehan Disability Scale (SDS): The SDS is a subject -report ed outcome measure that will be used to 
assess functional impairment and associated disability. The second key secondary endpoint is the 
change in SDS total score as measured by the change from baseline (Day 1 prior to randomization) 
to the end of the 4- week double -blind induction phase.
3. Patient Health Questionnaire 9-item (PHQ -9): The PHQ -9 is a subject -reported outcome measure 
that will be used to assess depressive symptoms. The scale scores each of the 9 symptom domains of 
the DSM -5 MDD criteria and it has been used both as a screening tool and a measure of response to 
treatment for depression. The third key secondary endpoint is the change from baseline (Day 1 prior 
to randomization) to the end of the 4 week double -blind induction phase in the subject -reported 
depressive symptoms, using the PHQ -9 total score.
Other Secondary Efficacy Evaluations and Endpoints
 Proportion of responders (50% reduction from baseline in MADRS total score) at the end of the 
4week double -blind induction phase
 Proportion of subjects in remission (MADRS 12) at the end of the 4week double -blind induction 
phase
 Change from baseline (Day 1 prior to randomization) tothe end of the 4week double -blind 
induction phase in:
 Severity of depressive illness, using the Clinical Global Impression –Severity (CGI -S);
 Anxiety symptoms, using the Generalized Anxiety Disorder (GAD -7), and 
 Health- related quality of life and healt h status, as assessed by the EuroQol -5 dimension -5 level 
(EQ-5D-5L).
PHARMACOKINETIC EVALUATIONS
Plasma samples will be analyzed to determine concentrations of esketamine (and noresketamine , if 
warranted) using a validated, specific, achiral, and sensitive liquid chromatography -tandem mass 
spectrometry (LC-MS/MS )method by or under the supervision of the sponsor. Plasma samples may be 
analyzed to document the presence of circulating metabolites using a qualified research method. In 
addition, plasma PK sampl es may be stored for future analysis of the metabolite profile.
BIOMARKER, PHARMACOGENOMIC (DNA), AND EX PRESSION (RNA) EVALU ATIONS
Assessment of biomarkers and their potential relationship tothe different treatment groups and to 
maintenance/stabilization of response, non-response, and relapse will be explored. Blood samples will be 
collected to measure genetic and epigenetic markers (including but not limited to BDNF allelic variants)
and protein markers (including but not limited to growth factors, inflam mation, endocrine, or metabolic
markers ). Samples of deoxyribonucleic acid (DNA) and biomarker s(protein and RNA) may be used to 
help address emerging issues and to enable the development of safer, more effective, and ultimately 
individualized therapies.
MEDICAL RESOURCE UTILIZATION
Medical resource utilization data, associated with medical encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) during the follow -up phase. The HRUQ includes 
information regarding utilization of healthcare services (including the timing and type of services), 
enabling changes in level and quantity of services to be considered as a variable in economic models.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 37SAFETY EVALUATIONS
Safety evaluations will include:
 Monitoring of TEAEs , including TEAEs of special interest, clinical laboratory tests (including 
hematology, serum chemistry, and urinalysis ), pregnancy testing (for women of childbearing 
potential ), urine drug screen, 12- lead electrocardiogram , vital signs , pulse oximetry , phys ical 
examination, and body weight measurements
 Nasal examinations and nasal symptom questionnaire
 Columbia Suicide Severity Rating Scale ( C-SSRS ), to assess potential suicidal ideation and behavior
 Clinician Administered Dissociative States Scale (CADSS ), to assess treatment -emergent 
dissociative symptoms
 Four -item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+ ), to assess 
potential treatment -emergent psychotic symptoms
 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S ), to measure treatment -emergent 
sedation
 Clinical Global Assessment of Discharge Readiness (CGADR ), to document the subject’s current 
clinical status and is the clinician's assessment of the readiness to be discharged from the study site
 Physician Withdrawal Checklist (20 items; PWC- 20) to assess potential withdrawal symptoms 
following cessation of intranasal esketamine treatment
 Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC -SS), to monitor subjects for potential 
symptoms of cystitis, bladder pain, and interstitial cystitis
 Computerized cognitive battery and Hopkins Verbal Learning Test-Revised ( HVLT -R),to assess the 
effect of intranasal esketamine on cognition
 University of Pennsylvania Smell Identification Test (UPSIT )and Smell Threshold Test to assess 
any potential treatment -emergent effects on the sense of smell
STATISTICAL METHODS
Subject Information
The primary efficacy and safety analysis sets are defined below:
 Full Analysis Set: All randomized subjects who receive at least 1 dose of intrana sal study 
medication and 1 dose of oral antidepressant medication in the double -blind induction phase. 
 Safety Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication or 1 dose of oral antidepressant medication in the double -blind induction phase.
Sample Size Determination
The maximum sample size planned for this study was calculated assuming a treatment difference for the 
double -blind induction phase of 6.5 points in MADRS total score between any dose of esketamine and the 
active comparator, a standard deviation of 12, a 1-sided significance level of 0.0125, and a drop-out rate 
of 25%. A maximum of about 116subjects will need to be randomized to each treatment group to achieve 
90% power for comparison of each esketamine dose plus oral antidepressant arm with oral antidepressant 
(active comparator) plus intranasal placebo arm using a fixed design with no interim analysis .The 
treatment difference and standard deviation used in this calculation were based on results fr om Panel A of 
the ESKETINTRD2003 study and onclinical judgment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 38Interim Analysis for Sample Size Re -Estimation or Stopping for Futility
One unblinded interim analysis will be performed 4weeks after randomizing 120subjects in the study 
(approximately 40 subjects per treatment group). It is projected that at that time approximately 90 subjects 
in the full analysis set would have completed the double -blind induction phase of the study
(approximately 30subjects per treatment group) . The dropout rate will be monitored to ensure a sufficient 
number of subjects are included in the interim analysis. As the assumptions of the expected treatment 
difference and variability may or may not be upheld, the purpose of the interim analysis is to either 
re-estimate sample size or to stop the study due to futility. The sample size may be adjusted to achieve the 
desired power while maintaining control of the overall Type I error. The maximum sample size planned 
for this study is 116per treatment group. If the study is not stopped for futility, sample size re-estimation 
will be conducted for both doses of esketamine; ie, the analysis does not allow for stopping a dose based 
on the results of the interim analysis. The study team will be blinded to the results of the interim analysis 
and any adjustments that will be made to the samp le size; however, the clinical supplies group will be 
informed of the decision made at the interim analysis so that only the required amount of study 
medication will be packaged.
Primary and Key Secon dary Efficacy Analyses
With the exception of the European Union (EU) dossier, the primary efficacy  variable, change from 
baseline in MADRS total score at Week 4 in the double -blind induction phase, will be analyzed using 
mixed -effects model for repeated measures (MMRM ). The model will include baseline MADRS total 
score as a covariate, and treatment, country, class of antidepressant (Serotonin and Norepinephrine 
Reuptake Inhibitors [SNRI] or Selective Serotonin Reuptake Inhibitors [SSRI]) , day, and 
day-by-treatment interaction as fixed effects, and a random subject effect. Comparison of each
esketamine plus oral antidepressant arm versus oral antidepressant plus intranasal placebo will be 
performed using the appropriate contrast.
For the EU dossier, the primary efficacy analysis will be based on an analysis of covariance (ANCOVA) 
model using last observation carried forward (LOCF) data. The model will include factors for treatment, 
country, and class of oral antidepressant (SNRI or SSRI) and baseline MADRS total score as a covariate. 
Comparison of each esketamine plus oral antidepressant arm versus intranasal placebo plus oral 
antidepressant will be performed using the appropriate contrast.
For the analysis of the first of 3key secondary efficacy endpoints, the proportion of subjects showing 
onset of clinical response (by Day 2 that is maintained for the duration of the double -blind induction 
phase )in the esketamine plus oral antidepressant arm will be compared with the oral antidepressant plus 
intranasal placebo arm using a Cochran -Mantel- Haenszel chi-square test adjusting for country and class 
of antidepressant (SNRI or SSRI). Clinical response is defined as 50% improvement in MADRS total 
score by Day 2 (ie, the day after taking the first dose of double -blind intranasal medication ) that continues
through the end of the double -blind phase with one excursion allowed . Subjects who discontinue the 
study prior to end of the double -blind induction phase will not be considered to have maintained clinical 
response.
The second and third key secondary efficacy endpoint s, change from baseline in SDS total score at 
Week 4 and change from baseline in PHQ -9 total score at Week 4 (subject to regulatory acceptance of 
PHQ -9) in the double -blind induction phase, will be analyzed using the same models described above for 
the MADRS total score. 
Tostrongly control T ype I error across the primary and the 3 key secondary efficacy endpoints (change in 
MADRS total score, onset of clinical response, change in SDS, and change in PHQ -9 total score ), and 
across the 2 esketamine dose-placebo comparisons, a truncated fixed sequence parallel gatekeeping test 
procedure will be applied between families of hypotheses corresponding to the endpoints and between 
two dose-placebo comparisons within each family (where, 84 mg esketamine dose group will be tested 
first, and 56 mg esketamine dose group will be tested only if the 84 mg dose group is shown to be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 39significant). The 2 dose-placebo compariso ns corresponding to each efficacy endpoint are considered as a 
family of hypotheses. Further details of this approach will be provided in the statistical analysis plan 
(SAP).
Response and remission rates wil l be summarized at each visit.
Change from baseli ne in GAD -7 total scores and ranks of change from baseline in CGI-S scores at the 
end of the double -blind induction phase will be analyzed based on LOCF data using an ANCOVA model, 
with country and class of antidepressant (SNRI or SSRI) as factors, and the respective baseline score 
(unranked score in the case of CGI -S) as the covariate. 
Dimension scores of the EQ-5D-5L descriptive system, the health status index, and the EQ visual 
analog uescale (EQ-VAS) scores will be summarized over time.
Additionally, scores of all efficacy endpoints will be summarized for all visits in the double -blind 
induction phase. Summaries will be provided to show consistency of effect among relevant subgroups 
(eg, antidepressant class: SNR I and S SRI).
PKAnalyses
Plasma esketami ne (and noresketamine , if warranted )concentrations will be listed for all subjects. The 
plasma concentration- time data of esketamine (and noresketamine , if warranted) will be analyzed using  
population PK modeling. Data may be combined with those of other selected studies to support a relevant 
structural model. Typical population values of basic PK parameters will be estimated together with the 
inter-individual variability. Effects of subject demographics, laboratory parameter values, and other 
covariates on the PKof esketamine will be explored. The results of the population PK analyses may be 
reported separately.
PK/PD Analyses
The relationship between MADRS total score (and possibly selected adverse events as additional PD
parameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in graphical 
analysis, suitable models will be applied to describe the exposure -effect relationships. The results of the 
PK/PDanalyses may be reported separately.
Biomarker, Pharmacoge nomic (DNA), and Expression (RNA) Analyses
Baseline biomarker values and c hanges from baseline biomarker values to the time points specified in the 
Time and Events Schedule will be summarized. Exploratory biomarker analyses may include comparison 
of biomar ker measures between the treatment groups, correlation with efficacy and other measures , and 
relationship with clinical response, relapse, and non-response. The analysis plan and summarized results
from both biomarker and pharmacogenomics analyses will be reported separately .
Medical Resource Utilization Analyses
Medical resource utilization data will be descriptively summarized.
Safety Analyses
All safety data will be analyzed separately for the double -blind induction phase and the follow -up phase.
The verbatim terms used in the electronic case report form (eCRF )by investigators to identify adverse 
events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). All reported 
adverse events with onset during the double -blind induction phase (ie, TEAEs , and adverse events that 
have worsened since baseline) will be included in the analysis. For each adverse event, the percentage of 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 40subjects who experience at least 1 occurrence of the given event will be summarized by treatment group.
Adver se events occurring during the follow -up phase will be summarized separately .
TEAEs of special interest will be examined separately groupe d in the following categories: Drug abuse, 
dependence and withdrawal (standardized MedDRA  queries [SMQ]), increased blood pressure, increased 
heart rate, transient dizziness/vertigo , impaired cognition , anxiety ,and cystitis. AEs of special interest 
will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe or a 
serious adverse event will be summarized separately .
Laboratory data will be summarized by type of laboratory test. Reference ranges and markedly abnormal 
results (specified in the SAP) will be used in the summary of laboratory data. Descriptiv e statistics will be 
calculated for each laboratory analyte at baseline and at each scheduled time point in each phase of the 
study. Changes from baseline results will be presented. Frequency tabulations of the abnormalities will be 
provided. Listings of subjects with laboratory results outside the reference ranges and markedly abnormal 
results will also be provided.
Electrocardiogram (ECG) data will be summarized by ECG parameter . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time point. 
Frequency tabulations of the abnormalities will be made. The ECG variables that will be analyzed are 
heart rate, PR interval, QRS interval, QT interval, and corrected QT (QTc) interval using the following 
correction methods: QT corrected according to Bazett’ s formula (QTcB) and QT corrected according to 
Fridericia’ s formula (QT cF).
Descriptive statistics of QT c intervals and changes from double -blind baseline will be summarized at each 
scheduled time point. The percentage of subjects with QT c interval >450 msec, >480 msec, or >500 msec 
will be summarized as will the percentage of subje cts with QTc interval increases from baseline 
<30msec, 30 -60msec, or >60 msec.
Descriptive statistics of temperature, pulse/heart rate, respiratory rate, pulse oximetry, and blood pressure 
(systolic and diastolic) (supine) values and changes from baselin e will be summarized at each scheduled 
time point. The percentage of subjects with values beyond clinically important limits will be summarized.
Changes in findings from the baseline nasal examination (including the upper respiratory tract/throat) will 
be listed by treatment group. Examinations will provide ratings (absent , mild, moderate, or severe) that 
are based on a visual inspection of the nostrils, nasal mucosa, and throat for nasal erythema, rhinorrhea, 
rhinitis, capillary/blood vessel disruption and epistaxis. A shift table for changes from double -blind 
baseline in ratings for each examination will be presented by treatment group.
Scoring from the nasal symptom questionnaire will be summarized descriptively for each scheduled time 
point by treatment group.
Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by treatment group in 
incidence and shift tables. Separate endpoints for suicidal ideation and suicidal behavior will be defined 
and summarized descriptively by treatment group.
Descriptive statistics of the CADSS, BPRS+, and MOAA/S scores and changes from predose will be 
summarized at each scheduled time point.
Descriptive statistics of the CGADR , PWC-20, BPIC -SS, UPSIT, and Smell Threshold Test scores and 
changes and/or p ercent changes from baseline will be summarized at each scheduled time point.
Descriptive statistics of each cognitive domain scoreand changes from baseline will be summarized at 
each scheduled time point.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 41TIME A ND EVENTS SCHED ULE (Screening/Prospective Observational Phase and Double -blind Induction Phase)
Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Screening/Administrative
Informed consent (ICF) X
Medical hi story, psychiatric 
history, demographics , 
employment statusX
MINI X
MGH- ATRQ X
Site Indep endent Qualification 
AssessmentX
Height X
Inclusion/exclusion criteria X X
Prestudy therapy X
Preplanned surgery/procedures X
STOP -Bang q uestionnaire 
(including assessment of BMI 
and neck circumference)X
MGH- FemaleRLHQ: Module I X
IDS-C30 X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 42Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Study Drug
Randomi zation X
Dispensing of new oral 
antidepressant (duloxetine, 
escitalopram, sertraline, or 
venlafaxine XR)X XjX
Practice session for use of 
intranasal deviceXc
Intranasal esketamine or placebo X X X X X X X X
Drug accountability
(intranasal study medication)X X X X X X X X X
Drug accountability (oral 
antidepressant study medication)X X X
Dispense subject diary for oral 
antidepressantX
Revie w subject diary and update 
(if applicable)X X X X X X X X X
Oral antidepressant compliance 
checkX X X X X
Return of subject diary if not 
entering follow  up phaseX
Safety Assessments (Clinician)
Physical examination X X X X
Nasal examinationcX X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 43Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Vital signs: blood pressure, pulse, 
respiratory rate, temperaturec,q X X X X X X X X X X
Vital signs (postdose): blood 
pressure, pulse, respiratory ratee,q X X X X X X X X
Weight X X X X
12-lead ECGf,qX X X X X X
C-SSRS: Baseline/Screening 
versionX
C-SSRS: Since last visit versionqX X XrX X X X X X X X X
MOAA/S and pulse oximetryg,qX X X X X X X X X
BPRS+ h,qX X X X X X X X
CADSSh,qX X X X X X X X
CGADRi, X X X X X X X X
PWC -20 X X
Safety Assessments (Subject -completed)
Nasal symptom questionnairekX X X X X
BPIC -SScX X X X
Assessment of Sense of Sm ell
UPSITc, o X X X X
Smell Threshold Testc, oX X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 44Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Efficacy Assessments (Clinician)
MADRS (7 -day recall; performed 
by independent, remote raters)X XpXpXdXpXpXpXpX
MADRS (24 -hr recall; performed 
by independent, remote raters)X
CGI-S cX X X X X X X X
Subject -completed Assessments
PAQ X X X
PHQ -9cX X X X X
SDScX X X X X
GAD -7cX X X X
EQ-5D-5LcX X X X X
Cognition Testing
Practice sessions for computerized 
test batteryX
Com puterized test battery and 
HVLT -RX X X
Clinical Laboratory Assessments
TSH, HbA1c X
Lipid panel (fasting) X
Hem atology, chemistrycX X X X
Urine drug screencX X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 45Screening/ Prospective 
Observational Phase Double -blind Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 EW b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4 —
Study day — — —1
(baseline) 2 4 8 11 15 18 22 25 28 EW
Clinic visit window (in days) — ±2 ±2 — — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 —
Clinic visit ( C) or rem ote MADRS 
interview only (R M) C C C C RM C C C C C C C C C
Alcohol breath test X X
UrinalysiscX X X X X
Serum pregnancy test X
Urine pregnancy testcX X X X
Pharm acokinetics
Blood collectionlX X
Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations
Blood sample collection 
(protein )c, m X X X X X
Blood sample collection 
(DNA) c, m X X X
Blood sample collection 
(RNA) c, m X X X X X
Ongoing Subject Review
Concomitant therapy Ongoing
Adverse events Ongoing
Other
Menstrual cycle tracking
(start date of last menstrual period 
prior to study v isit)XnXn
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 46Footnotes:
Abbreviations: BMI, body mass index; BPIC -SS, Bladder Pain/Interstitial Cystitis Symptom Score; BPRS +, 4-item positive symptom s ubscale of the Brief Psychiatric 
Rating Scale; C, clinic visit; CADSS, Clinician Administered Dissociative States Scale; CGADR, Clinical Global Assessment of Discharge Readiness; CGI -S,Clinical 
Global Impression –Severity; C -SSRS, Columbia Suicide Severity Rating Scale; DNA, deoxyribonucleic acid; ECG, electrocardiogram; EQ-5D-5L,EuroQol -5
dimension - 5-level; EW, early w ithdrawal; GAD -7, Generalized Anxiety Disorder , 7-item scale; HbA1 c test, glyc ated hemoglobin test;  HVLT -R, Hopkins Verbal 
Learning Test -Revised; IDS -C30, Inventory of Depressive Symptomatology Clinician -rated , 30-item scale ; MADRS, Montgomery -Asberg Depression Rating Scale; 
MGH- ATRQ, Massachusetts General Hospital -Antidepressant Treat ment History Questionnaire; MGH -Female RLHQ, Massachusetts General Hospital -Female 
Reproductive Lifecycle and Ho rmones Questionnaire; MINI ,Mini -International Neuropsychiatric Interview; MOAA /S, Modified Observer ’s Assessment of 
Alertness/Sedation; PAQ, Patient Adherence Questionnaire; PHQ -9,Patient Health Questionnaire –9; PWC -20, Physician Withdrawal Checklist , 20-item scale ; 
RNA, ribonucleic acid; SDS, Sheehan Disability Scale; STOP -Bang, Snoring, Tired, O bserved Apnea, High Blood Pressure, Body mass index, Age, Neck Size, Gender 
(a questionnaire); TSH, thyroid -stimulating hormone
Note: On intranasal dosing days, time 0 is defined as the time of t he first intranasal spray. Therefore, postdose time points are referenced from this.
a)An additional, optional period of up to 3 weeks is permitted to taper and discontinue current antidepressant treatment (s) after completion of the Week 
4 (Visit 1.3) assessments, per the local prescribing information or clinical judgment. Subjects who do not require a taper an d are thus eligible to 
immediately proceed to the double- blind induction phase can have Visit 1.3 and Visit 2.1 occur on the same day or within 1 week of each other (if not 
occurring the same day, the antidepressant treatment regimen should be continued and discontinued prior to Visit 2.1) .
b)If a subject withdraws before the end of the double -blind indu ction phase (ie, before completing Visit 2.10/Day 28) for reasons other than withdrawal 
of consent, an early withdrawal visit should be conducted within 1 week of the date of discontinuation, followed by the follo w-up phase. If the early 
withdrawal visit i s conducted on the same day as a scheduled visit, duplicate assessments are not required.
c)Predose ( if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -
related procedures d uring a clinic visit .
d)Performed for subjects requiring a taper period during the screening/pro spective observational phase; the result will be considered as the subject’s 
baseline MADRS for the double -blind induction phase . For all other subjects, the baseline MADRS for the double -blind induction phase will be the 
MADRS performed at the end of Week 4 of the screening/prospective observational phase.
e)Postdose vital signs will be performed at 40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Sec tion6.2.1 for guidance for blood pressure 
monitoring on intranasal dosing days.
f)Twelve -lead ECG will be performed predose and at t=1 hour postdose at Visit 2.1. Twelve -lead ECG will be performed at t=1 hour postdose only (ie ,
no predose ECG required) at Visits 2. 4, 2.6 ,and2.9.A time window of ±15 minutes is permitted.
g)The MOAA/S will not be performed at Visit 1.1 (pulse oximetry only). The MOAA/S will be performed every 15 minutes from predose to 
t=+1.5 hours postdose (please refer to Section 9.7for further guidance on MOAA/S assessments). Pulse oximetry will be performed every 15 minutes 
from predose to t=1.5 hours postdose (please refer to Section 9.7for further guidance on timing of pulse oximetry assessments).
h)The BPRS+ and CADSS to be performed predose and at 40 minutes and 1.5 hours postdose. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 47i)CGADR to be performed at 1 hour and 1.5 hour postdose; if the response is not “Yes” at 1 .5hour postdose, the assessment will be repeated every 
15minutes until a “Yes” response is achieved or until the subject is referred for appropriate medical care if clinically indica ted.A subj ect should not 
be discharged prior to the 1.5 hour time point.
j)Performed only if the subject is not continuing into Study ESKETINTRD3003.
k)Nasal symptom questionnaire will be performed predose and at 1 hour postdose.
l)PK blood collection will be performed at t=40 minutes and t= 2 hours postdose (where time=0 is defined as the time of the first intranasal spray). 
m)Blood samples should be collected prior to dosing .It is preferred that subjects adhere to a low fat diet on the day of sample collection .
n)Only appli cable to women with a menstrual cycle.
o)If the subject has significant nasal congestion on the day of a scheduled assessment, the site should consider postponing the smell test assessment (s)to 
the next scheduled clinic visit.
p)The MADRS should be administered no more than 2 days prior to the subject’s targeted (not actual) clinic visit date (except Visit 2.10, which is 
within 1 day prior ).If performed on the day of the scheduled clinic visit for an intranasal treatment session , the MADRS must be performed prior to 
the intranasal treatment session.
q)If intranasal dosing is postponed (but occurs within visit window) due to vital sign results (eg, blood pressure elevation), all assessment time points 
(including predose) must be performed on the actual intranasal dosing day.
r)Performed only if Visit 1.3 and Visit 2.1 do not occur on the same day.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 48TIME A ND EVENTS SCHE DULE (Follow -up Phase)
Follow -up Phase
Visit number 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13
Weeks after last intranasal dose 1 2 4 6 8 10 12 14 16 18 20 22 24
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Clinic visit (C) or rem ote assessments only (RA) RAfC RAfRAfRAfRAfC RAfRAfRAfRAfRAfC
Oral antidepressant compliance a 
Oral antidepressant compliance check X
Drug accountability
Drug accountability (oral antidepressant study medication) X Xe
Return of subject diary X
Safety Assessments (Clinician -completed)
Physical examination X X
Nasal examination X
Vital signs: B lood pressure, pulse, respiratory rate, temperature X X
12-lead ECG X
C-SSRS: Since last visit version X X X
PWC -20 X cX
Safety Ass essments (Subject -completed)
BPIC -SS X
Efficacy Assessments (Clinician -completed)
MADRS (performed by independent, remote rater s) X X
CGI-S X X X
Efficacy Assessments (Subject -completed)
PHQ -9 X X X X X X X
SDS X X X X X X X
GAD -7 X X X X X X X
EQ-5D-5L X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 49Follow -up Phase
Visit number 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13
Weeks after last intranasal dose 1 2 4 6 8 10 12 14 16 18 20 22 24
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Clinic visit (C) or rem ote assessments only (RA) RAfC RAfRAfRAfRAfC RAfRAfRAfRAfRAfC
Cogniti on testing
Com puterized test battery and HVLT -R X
Medical Resource Utilization
HRUQ bX X X X X X X X X X X X
Clinical Laboratory Assessments
Hem atology, chemistry X
Urinalysis X
Serum preg nancy test X
Urine pregnancy test X X
Biom arker and Expression (RNA) Evaluations
Blood sample collection (protein) dX
Blood samp le collection ( RNA ) dX
Ongoing Su bject Review
Concomitant therapy Ongoing
Adverse events Ongoing
Footnotes:
Abbreviations: BPIC -SS, Bladder Pain/Interstitial Cystitis Symptom Score; C, clinic visit; CGI -S, Clinical Global Impression –Severity; C -SSRS, Columbia Suicide 
Severity Rating Scale; ECG, electrocardiogram; EQ -5D-5L, EuroQol -5D, 5 -level; GAD -7, Generalized Anxiety Disorder , 7-item scale; HRUQ, Healthcare Resource 
Use Questionnaire; HVLT -R, Hopkins Verbal Learning Test -Revised; PHQ -9, Patient Health Questionnaire –9; PWC -20, Ph ysician Withdraw al Checklist , 20-item 
scale ; RA, remote assessments only; RNA, ribonucleic acid; SDS, Sheehan Disability Scale.
Note: No intranasal study medication will be administered during the follow -up phase.
a)In order to better assess potential withd rawal symptoms from intranasal study medication, the oral antidepressant medication should be continued for 
at least the first 2 weeks of the follow -up phase unless determined to be not clinically appropriate.
b)For the HRUQ, a clinician- completed assessment may be required (based on subject -responses).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 20 16 50c)Performed by telephone by qualified site staff.
d)It is preferred that subjects adhere to a low fat diet the day of sample collection.
e)For any remaining oral antidepressant study medication.
f)At each “Remote Assessment ” visit, site staff will contact the subject by telephone to obtain information regarding adverse events and conco mitant 
therapies.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 51ABBREVIA TIONS
AHI
ANCOVAApnea-hypopnea index
analysis of covariance
ASA American Society of Anesthesiologists
AUC area under the plasma concentration -time curve
BDNF brain -derived neurotrophic factor
BMI body mass index
BPIC -SS Bladder Pain/ Interstitial Cystitis Symptom Score 
BPRS Brief Psychiatric Rating Scale
BPRS+ 4-item positive symptom s ubscale of the Brief P sychiatric Rating Scale
C clinic visit
CADSS Clinician Administered Dissociative States S cale
CGADR Clinical Global Assessment of Discharge Readiness
CGI-S Clinical Global I mpression – Severity
Cmax maximum plasma concentration
CRF
C-SSRSCase report form
Columbia Suicide Severity Rating S cale
CYP cytochrome P450 , with any appended letters (2B6, 3A4, etc .) indicating subtypes
DBP diastolic blood pressure
DBS deep brain stimulation
DNA deoxyribonucleic acid
DSM -5 Diagnostic and Statistical Manual of Mental Disorders (5thEdition)
ECG electrocardiogram
eCRF electronic case report form
ECT electroconvulsive therapy
eDC Electronic Data C apture
EQ-5D-5L European Quality of Life ( EuroQol )-5 dimension -5 level
EQ-VAS EuroQol g roup: Visual Analogue Scale
EU European Union
EW Early Withdrawal
FDA United States Food and Drug Administration
FT4 Free thyroxine
GAD -7 Generalized Anxiety Disorder 7 -item scale
GCP Good Clinical Practice
HbA1c test glycated hemoglobin test
HPA hypothalam icpituitary adrenal
HRUQ Healthcare Resource Use Questionnaire
HVLT -R Hopkins Verbal Learning Test -Revised
ICF informed consent form
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IDS-C30 Inventory of Depressive Symptomatology -Clinician rated, 30 -item scale
IEC Independent Ethics Committee
IM intramuscular
IRB Institutional Review Board
ITT
IVIntent -to-treat
intravenous
IWRS interactive web response system
LOCF last observation carried forward
MADRS Montgomery -Asberg Depression Rating Scale
MAO I monoamine oxidase inhibitor
MDD major depressive disorder
MedDRA Medical Dictionary for Regulatory Activities
MGH- ATRQ Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire
MGH- Female RLHQ Massachusetts General Hospital -Female Reproductive Lifecycle and Hormones 
Questionnaire
MINI Mini -International Neuropsychiatric Interview (mental status questionnaire)
MOAA/ S Modified Obs erver’s Assessment of Alertness/Sedation
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 52MMRM mixed -effects model for repeated measures
NMDA N-Methyl -D-Aspartate
PAQ Patient Adherence Questionnaire
PCP phencyclidine
PCP
PDPrimary care physician
pharmacodynamics
PHQ -9 Patient Health Questionnaire – 9
PK pharmacokinetic s
PQC product quality complaint
PWC -20 Physician Withdraw al Checklist ; 20-item
QTc QT interval corrected
QTcB QT interval corrected according to Bazett's formula
QTcF QT interval corrected according to Fridericia's formula
RA remote assessments only
RNA ribonucleic acid
SAP statistical analysis plan
SDS Sheehan Disability Scale
SmPC Summary of Product Characteristics
SMQ standardized MedDRA queries
SNRI Serotonin and Norepinephrine Reuptake Inhibitors
SSRI Selective Serotonin Reuptake Inhibitors
STOP -Bang snoring, tired, o bserved apnea, high blood pressure, body mass index, age, neck size, 
gender (questionnaire)
SUSAR suspected unexpected serious adverse reaction
SBP systolic blood pressure
TEAEs treatment -emergent adverse events
TRD treatment -resistant depression
TSH thyroid -stimulating hormone
UPSIT University of Pennsylvania Smell Identification Test
US United States
US FDA United States Food and Drug Administration
VNS vagalnerve stimulation
XR extended release 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 531. INTRODUCTION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness.90
MDD is the second leading cause of years lost to disability  worldwide and is associated with 
excess mortality ;and the estimated median years of potential life lost is 10 y ears.91,94About 30% 
of patients fail to achieve remission despite treatment with multiple antidepressant medications,
and are considered to have treatment -resistant depression (TRD).31,75In patients who respond to 
antidepressant treatment s, the time to onset of effect is ty pically  4 to 7weeks, during which time 
patients continue to suffer from their s ymptoms and continue to be at risk of self -harm, as well as 
being impacted by the associated harm to their personal and professional lives.75,78Therefore, 
there is a significant need to develop novel treatments based upon relevant pathoph ysiologic 
pathway s underly ing MDD for the rapid relief of depressive symptoms, especiall y in patients 
with TRD.16,24
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) are approved and widel y 
used for the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration.45The desired analgesic -anesthetic effects of ketamine and esketamine are 
attributed to the blockade of ionotropic N-methy l-D-aspar tate (NMDA) glutamate receptors.  
52,66,97
Monoamines (serotonin, norepinephrine, and/or dopamine) are only modulatory  transmitters.
Therefore, conventional monoaminergic antidepressant treatment s would not be expected to 
robustly  affect synaptic transmission, activity -dependent release of brain -derived neurotrophic 
factor (BDNF), or synaptogenesis.24In contrast, the mechanism of action of ketamine and 
esketamine is distinct from conventional antidepressant treatment s because both ketamine and 
esketamine profoundl y affect fast excitatory  glutamate transmission, increases BDNF release, 
and stimulates sy naptogenesis.24
Most literature reports of the antidepressant effects of ketamine describe studies using IV 
administration of the racemate, with a few exceptions.14,60Janssen Research & Development 
(JRD) is developing intranasal esketamine as an antidepressant therapy because it has higher 
NMDA receptor affinit y which allows a lower volume to be administered via the intranasal 
route .51,62,67  
For the most comprehensive nonclinical and clinical information regarding esketamine 
(JNJ-54135419), please refer to the latest edition of the Investigator's Brochure .42
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 541.1. Background
1.1.1. Summary  of Nonclinical Findings
Safety Pharmacology
The following text,quoted from the United States (US)prescribing information for anesthetic 
Ketalar®(ketamine hydrochloride injection )45: Intravenous Ketalar produces a fall in arterial 
blood pressure in the Rhesus monkey  and a rise in arterial blood pressure in the dog. In this 
respect the dog mimics the cardiovascular effect observed in man. The pressor response to 
Ketalar injected into intact, unanesthetized dogs is accompanied by a tachy cardia, rise in cardiac 
output and a fall in total peripheral resistance. The pressor response to Ketalar is reduced or 
blocked by chlorpromazine (central depressant and peripheral α-adrenergic blockade), by 
β-adrenergic blocka de, and by  ganglionic blockade.
Finding sfrom animal studies suggest that the increase in blood pressure produced by 
ketamine/esketamine is due to selective activation of central cardiac stimulating mechanisms 
leading to an increase in cardiac output.
In a 3-month repeat -dose toxicity  study with intranasall y administered esketamine in dogs, no 
relevant electrocardiogram (ECG )changes were noted up to the highest dose tested, 
ie,72mg/d ay.Heart rate was slightl y increased. The cardiovascular safety  of racemic ketamine 
and esketamine in humans and animals is summarized in the Investigator's Brochure.42
Toxic ology
Repeat -Dose Toxicity Studies
In repeat -dose toxicity  studies with intranasally  administered esketamine in rats up to 9 mg/day  
for 6 months, and dogs up to 72 mg/day for 3 months of duration , the clinical observations 
mainly  related to the central ner vous sy stem (eg, changes in activity  and gait) . No adverse effects 
were noted up to the highest dose tested, ie, 9 mg/day  in rats and 72 mg/day  in dogs. These 
observations reflected the (exaggerated) pharmacology  of the test compound. Minor histologic 
findings were noted in the nasal cavity . These tissue changes were not considered adverse.
In 3 -and 9month repeat -dose toxicity  studies with intranasally  administered esketamine in 
dogs, no relevant electrocardiogram (ECG) changes were noted up to 72mg/day . Heart rate was 
slightly  increased. 
Further details can be found in the Investigator's Brochure.42
Genetic Toxicity
A series of in vitro and in vivo genotoxicity  studies was conducted with ketamine and 
esketamine . The weight of evidence indicates that esketamine poses no genotoxic risk to 
humans .42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 55Neurotoxicity
Racemic ketamine has been reported to induce neurotoxicity  in animal fetuses, and in juvenile, 
adolescent, and adult animals, as evidenced by histopathologic brain lesions and functional 
sequelae. The precise thresholds for dose and duration of exposure causing neurotoxicity  in 
animals remain to be established. The relevance to humans of ketamine’s neurotoxic action in 
animals is unknown.
In studies exploring neurotoxic effects of ketamine on juvenile and prenatal monkey s, 
neuroapoptosis was observed to be more widespread in fetal brains than in neonatal brains, after 
administration of ketamine anesthesia IV for 5 hours. In fetal brains, the cerebellum, caudate 
nucleus, putamen, and nucleus accumbens were most severel y affected. In neonatal brains, the 
cerebellum was not affected; the strongest neuroapoptotic response was noted in the basal 
ganglia and several thalamic areas.
In juvenile rodents, ketamine induced apoptotic neurodegeneration was observed that was more 
widespread than in adult rodents, with the developing brain affected in several major regions. 
Neuronal cell death was induced in the dorsolateral thalamus at blood levels of ketamine of 
14µg/mL  (7 times the human anesthetic blood level of approximately  2 µg/mL ).
No significant neurotoxic effects occurred in juvenile Rhesus monkey s if the anesthesia was 
administered as IM induction followed by IV maintenance duration was 3 hours. Ketamine 
infusion for 9 or 24 hours increased neuronal cell death in the frontal cortex, but no significant 
changes were noted in the hippocampus, thalamus, striatum, or amygdala. Cognitive 
impairments were observed beginning around 10 months of age, and persisted at 3.5 years of 
age.
The clinical studies will exclude neonates, infants, childr en, pregnant women, and breastfeeding 
women. Therefore, ketamine’s neurotoxicity  in juvenile animals does not represent a safet y risk 
to eligible adult subjects. Moreover, the large dosages and prolonged treatment durations 
associated with neurotoxicity  injuvenile animals do not suggest a concern.
Chronic treatment with ketamine at high dose levels affected the brain of adolescent monkey s, as 
evidenced b y histopathologic lesions and functional impairment. 
The neurotoxicity  of ketamine in adult animals is also associated with high dose levels, in 
contrast to the relatively  low dose levels of esketamine associated with antidepressant efficacy  in 
humans. In single -dose and 14-day repeated -neurotoxicity  studies with intranasall y administered 
esketamine in rats, no histopathologic brain lesions were noted even upon high exposures, as 
achieved at 54 mg/day  in the 14-day study. In the 6-month rat and 9-month dog repeat -dose 
toxicology  studies with intranasall y administered esketamine, where the animals were of 
adolescent age at initiation of treatment, and in the pre-and post-natal developmental toxicit y 
study  in rats, no evidence of neurotoxicity  was found. Consequentl y, the risk of neurotoxicity  
associated with intranasal administration of esketamine to adult and adolescent patients is 
considered low .42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 56Abuse Potential
Animal studies with ketamine suggest that it would have abuse potential in humans. These 
studies included self -administration and withdrawal experiments in several species.42
Reproductive Toxicity
In a rat fertility  and early embry onic developmental toxicity  study  with intranasall y administered 
esketamine, no adverse effects on fertility  or reproductive capacity  or performance were found.
Rat and rabbit embry o-fetal developmental toxicity  studies with intranasall y administered 
racemic ketamine did not reveal evidence of reproductive toxicity . However, when monkey 
fetuses were exposed in utero to high dose levels of racemic ketamine, neurotoxicity  was 
observed. 
Intranasall y administered esketamine did not affect pre-and postnatal development in rats. 
However, high dose levels of racemic ketamine induced neurotoxicity  in early postnatal rat 
pups.42
Considering the neurotoxic potentia l of ketamine and esketamine , and the fact that no threshold 
for these effects has been demonstrated, female subjects of childbearing potential should be 
adequatel y protected from becoming pregnant and pregnant women should not be enrolled .
Cardiovascular toxicity
In guinea pig tissues, ketamine -induced negative inotropic effects and shortening of action 
potential duration at the 0-mV level was observed, likely  as a result of the suppression of inward 
calcium current, whereas in rat left atria and ketamine -induced positive inotropic effects and 
prolongation of action potential duration at the 0-mV level was observed, likely  as a result of a 
decrease in calcium -insensitive transient outward current.26The inhibitory action on membrane 
currents may  partl y explain the species and tissue differences in inotropic responses to ketamine.
Blood pressure responses to ketamine also vary with the laboratory  species and with 
experimental conditions. Blood pressure is increased in normotensive and renal hy pertensive rats 
with and without adrenalectom y and under pentobarbital anesthesia. The US prescribing 
information for the anesthetic Ketalar®(ketamine hydrochlori de [HCl]for injection) provides the 
following guidance. 
Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey  and a rise in 
arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect 
observe d in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is 
accompanied by a tachycardia, rise in cardiac output and a fall in total peripheral resistance. It 
causes a fall in perfusion pressure following a large dose. The tachycardia and increase in 
myocardial contractile force seen in intact animals does not appear in isolated hearts. These 
observations support the hypothesis that the hy pertension produced by  Ketalar is due to selective 
activation of central cardiac stimulating mechanisms leading to an increase in cardiac output. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 57The dog would be considered the most predictive species in terms of ketamine’s cardiovascular 
effects in humans, but the antidepressant effects of ketamine were studied only in rodent models. 
The myocardial contractility  effects and blood pressure responses to ketamine vary between 
species.42Consequently , a margin of safety  could not be reliably  derived from the available 
animal data.
Overall Conclusion
The currentl y available nonclinical safety  studies support chronic intranasal administration of 
esketamine in human subjects up to a dosage of 84 mg/day .
Further details can be found in the Investigator's Brochure .42
1.1.2. Clinical Studies
1.1.2.1. Pharmacokinetics and Product Metabolism
Metabolism
Ketamine (and esketamine) undergoes extensive metabolism byhepatic cytochrome P450 
(CYP). In humans, N-demethy lation to norketamine is the major route of metabolism, which can 
undergo further metabolism to form hydroxy norketamine. Ketamine and norketamine are 
extensively  hydrox ylated to a series of 6 hydroxy norke tamine metabolites and 
2hydroxyketamine metabolites.93Like ketamine, norketamine is a noncompetitive antagonist at 
the NMDA receptor.25Norketamine has a half-life in plasma of approximately  5  hours.37The 
major human hepatic CYPs that catal yze ketamine N-demeth ylation in vitro are CYP2B6 and 
CYP3A4.38,68,95The CYP enzymes responsible for the formation of norketamine metabolites 
include CYP2A6 and CYP2B6.68Published results of a clinical pharmacokinetics (PK)study 
indicate that esketamine does not invert to the R -enantiomer.34
Excretion
Racemic ketamine and its metabolites have been previously  shown to be predominantly  excreted 
in the urine. An average of 91% and 3% of a tritium -labeled dose (1mg/kg) administered to 
6healthy  subjects was recovered in urine and feces, respectiv ely.5Less than 3% of an 
administered dose was excreted in urine as parent drug.92
A summary  of the PK of esketamine administered by the IV and intranasal routes is provided 
below.
Intravenous Esketamine 
Subjects with TRD received 0.2 mg/kg or 0.4 mg/kg esketamine as a 40-minute IVinfusion 
during Study  ESKTIV TRD2001.10Maximum concentrations of esketamine were observed at the 
end of the infusion. Mean values for maximum plasma concentration (Cmax) and area under the 
concentration -time curve (AUC )increased with an increase in the esketamine dose administered 
(80.9 and 135 ng/mL, respectively , and 150 and 218 ng*h/mL, respectively , for 0.2mg/kg and 
0.4 mg/kg esketamine ). The mean plasma clearance of esketamine was high (109 L/h and 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 58141L/h for the 0.2 mg/kg and 0.4 mg/kg doses, respectivel y),as it was similar to or exceeded 
hepatic blood flow in humans .10The large volume of distribution suggests that esketamine 
distributes widely  into tissues (236 L and 303 L, respectively ). The half-life of esketam ine in 
plasma was 2.14 and 2.65 hours, respectively , for the 2doses . 
Intranasal Esketamine
Plasma esketamine PK results from Studies ESKETINTRD1001, ESKTINTRD1002, 
ESKETINTRD1003, and the double blind phase of Panel A of the ESKETI NTRD2003 that 
inform dose selection for the Phase 3 program are described below. The results demonstrate that 
plasma esketamine concentrations produced by effective IVregimens (0.2 mg/kg and 0.4 mg/kg 
as 40 minute infusions) may  be achieved by  the intranasal route. 
Study  ESKETINTRD1001 included 3 cohorts of subjects who were healthy male and female 
subjects.7The intranasal esketamine treatments were self-administered under the direct 
supervision of the investigator or designee. Subjects in Cohorts 1 and 3 received esketamine 
doses that ranged from 28 to 112 mg. The regimens were self-administered in the uprig ht 
position. No instructions were given with regards to sniffing after administration. The reported 
median time of Cmax(Tmax)of esketamine ranged from 0.37 to 0.83 hours from the time the first 
spray  was administered (ie, 0.33 to 0.5 hours after the last spray  was administered). The doses of 
28 to 112mg produced mean Cmaxvalues ranging from 63.3 to 151 ng/mL, whereas mean 
AUC ∞ values ranged from 164 to 565 ng*h/mL. Mean Cmaxand AUC values of esketamine 
increased in a less than dose-proportional manner across the dose regimens. Further more, there 
was substantial overlap in the range of individual Cmaxand AUC values among the 3 doses. The 
mean terminal half-life of esketamine ranged from 5.86 to 9.83 hours across all treatments.
Subjects in Cohort 2 rece ived 84 mg in a semi -reclined position and were instructed to sniff after 
each spray . Higher mean Cmaxand AUC ∞values were observed in this cohort (174 ng/mL and 
437ng*h/mL, respectively ) compared with the same esketamine dose self-administered by 
subjec ts in Cohort 1 (107 ng/mL and 400ng*h/mL , respectivel y). The semi -reclined position of 
the head and the instruction to subjects to sniff gently following intranasal dosing are believed to 
be the cause for the increase in exposure observed in Cohort 2 compared with Cohort 1. As a 
result, the instructions for self-administration of intranasal esketamine were adapted to include 
the semi -reclined position of the head and sniffing following dosing for all future studies.
During the Phase 1 study ESKETINTRD1002 ,healthy  Japanese and Caucasian subjects received 
single intranasal doses of esketamine 28 mg, 56 mg, and 84 mg in a crossover manner.8On 
average, plasma esketamine Cmaxand AUC values were up to 48% higher in Japanese subjects 
compared with Caucasian subjects.
Study  ESKETINTRD1003 compared the PK, safety , and tolerability  of intranasall y administered 
esketamine in healthy  elderly  (65 years of age) and younger adult subjects (18 to 55 years of 
age, inclusive).9Subjects received a single intranasal treatment of esketamine 28 mg. Median 
time toreach the maximum plasma concentration (Tmax) of esketamine was approximately 
30minutes for both age groups. The geometric means of Cmaxand area under the plasma 
concentration -time curve from time 0 to infinite time, AUC ∞, for esketamine were approximately 
21% and 17% higher, respectivel y, in the elderl y compar ed with younger adult subjects.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 59Study  ESKETINTRD2003 is an ongoing 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the United States and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
esketamine (28, 56, and 84 mg) administ ered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56 -mg dose strengths. 
Results of a preliminary  analysis of data from the double -blind phase of Panel A indicate mean 
(standard deviation) esketamine concentra tions at 40 minutes postdose were 36.4 ng/mL (16.4), 
58.1 ng/mL  (24.5), and 72.5 ng/mL  (34.2), respectively , for the 3 doses (data on file). The mean 
esketamine concentrations in plasma samples collected on Days 1 and 11 were similar ,
suggesting that the PK are consistent after repeated administration.
1.1.2.2. Pharmacody namics and Efficacy
The efficacy  of subanesthetic doses (0.5 mg/kg IV administered over 40 minutes ) of IVketamine 
has been evaluated in approximately  192 subjects with MDD (cases andcontrols), and 2 studies 
in bipolar depressed subjects (meta -analyses).32This recent meta -analy sis of studies suggests that 
ketamine has a rapid onset (within 1 day ) of antidepressant efficacy ,including in those who have 
not benefitted from other antidepressant treatment s, used as monotherapy  or in combina tion with 
oral antidepressant treatment s.
Esketamine (0.2 and 0.4 mg/kg administered over 40 minutes) has similar, rapid, and robust 
antidepressant effect as that seen with IV ketamine. Adouble -blind, double -randomization, 
placebo- controlled study (ESKETIV TRD2001) enrolled 30 adult subjects with TRD : 10 in the 
IV placebo group, 9 in the IV esketamine 0.20 mg/kg group, and 11 in the IV esketamine 
0.40 mg/kg group (based on Day 1  randomization).10The intent -to-treat (ITT) analysis of the 
primary  efficacy  variable (change in Montgomery -Asberg Depression Rating Scale [MADRS ]
total score from baseline Day 1  to Day 2)indicated that the improvement in both esketamine 
dose groups was statistically  significant (1-sided p-value=0.001 in both dose groups) compared 
with the placebo group. The mean (standard deviation) change from baseline Day 1 to Day 2 in 
MADRS total score was -4.9 (4.72) in the placebo group, -16.8 (10.12) in the esketamine 
0.20 mg/kg group, and -17.8 (9.45) in the esketamine 0.40 mg/kg group. 
The studies listed above assessed the efficacy  of ketamine or esk etamine after a single dose as 
the primary  endpoint. The average duration of response to a single dose of ketamine (0.5mg/kg) 
wasapproximately  5 days. Anopen -label study  demonstrated that the response to the first dose 
could be maintained by multiple infusions 3times a week over 2 weeks. The duration of 
response lasted for approximately  19 day s.1
The KETIVTRD2002 study  assessed whether multiple doses of ketami ne given twice a week 
would also maintain the antidepressant response ;the data from this study  suggest thatketamine 
(0.50 mg/kg IV over 40 minutes) administered twice a week was sufficient for maintain ing the 
initial effect over a 4 -week treatment period.11
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 60As noted above, Study ESKETI NTRD2003 is a 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the United States and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
esketamine (28, 56,and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56- mg dose strengths. In 
Panel A, subjects in period 1 (1-week duration) were randoml y assign ed in a 3:1:1:1 ratio to 
placebo (33 subjects), esketamine 28 mg (11 subjects), esketamine 56 mg (11subjects) ,or 
esketamine 84 mg (12 subjects). An initial analysis of the data from the double -blind phase of 
Panel A indicates that of the 67 subjects randomized in Period 1, 63 entered Period 2(1-week 
duration), in which 28 placebo subjects who were eligible for re-randomization at the end of 
Period 1, were randoml y assigned in a 1:1:1:1 ratio to placebo (N=6), esketamine 28 mg (N=8), 
esketamine 56 mg (N=9), or esketamine 84 mg (N=5) (data on file). Subjects eligible for re-
randomization had to have a Quick Inventory  of Depressive Symptomatology  –Self Report 
(QIDS-SR16) total score >11 at the end of Period 1. 
The improvement (with respect to change inMADRS total score from baseline Day 1 to Day 8) 
in all 3 esketamine dose groups reached statistical significance (p=0.021, p=0.001 ,and p<0.001 
for esketamine 28 mg, 56 mg,and 84 mg, respectively ) compared with placebo. The results of 
the 2periods were consistent. The mean differences from placebo on Day 8(after 1 week of 
treatment), estimated using data from the combined periods ,were: 
Esketamine 28 mg: -4.2 (SE 2.09)
Esketamine 56 mg: -6.3 (SE 2.07)
Esketamine 84 mg: -9.0 (SE 2 .13)
The effect size s in P eriod 1 for esketamine compared with placebo were:
Esketamine 28 mg: 0.43 (CI  -0.259 -1.118)
Esketamine 56 mg: 0.92 (CI 0.201-1.621)
Esketamine 84 mg: 1.19 (CI  0.473-1.883)
The duration of effect with the 28mg dose appears to be shorter ,with the MADRS total score 
higher on D ay 8 than on D ay 2. The duration of effect for the 56 mgand 84mg doses appears to 
support twice -a-week dosing .
These data with intranasal esketamine support the hypotheses that intranasal esketamine is 
effective as a treatment fordepressi on, that it has rapid onset of effect within 2 hours,and that 
multiple repeated sessions dose-dependently  show sustained response throughout the study 
duration. A clear dose response was seen in the double -blind data in Panel A,and the point 
estimates and confidence interval ssuggest a high effect size (Cohen’s D) with the 56mg and 
84mg dose groups , supporting further development.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 611.1.2.3. Safety  and Tolerability
Ketamine is a rapidl y acting general anesthetic that is approved and wid ely used intravenousl y or 
intramuscularl y for the induction and maintenance of anesthesia in children and adults at a dose 
of 1 to 3 mg/kg given as a bolus. Ketamine is marketed as a racemic mixture and inEurope also 
as the S-enantiomer, esketamine. Ketam ine was first introduced as an anesthetic in 1963 and is 
considered to have an excellent medical safety  profile (Ketalar®Summary  of Product 
Characteristics [S mPC] 2011; Ketanest®S SmPC 2011 ).3644
In the US prescribing information for ketamine HCl for injection and the SmPC for esketamine 
HCl for injection, the following adverse reactions were listed as very common, common, or 
frequent occurrences: Emergence or recovery  reactions, elevated blood pressure and pulse rate, 
stimulation of respiration, nausea, and vomiting. See Table 1 for details.
Table 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in the Product 
Inform ation of Anesthetic Ketam ine and Esketamine
System  
Organ Class"Frequent" Adverse Reactions
Per Anesthetic Ketam ine USPI45,a"Very Comm on" or "Common" Reactions
Per Anesthetic Esketamine SmPC89,b
Psychiatric 
disordersFrequency: Emergence reactions occurred in 
approximately 12% of patients.
Characteristics: Severity varied from pleasant 
dreamlike states, vivid imagery, hallucinations, 
and emergence delirium. Some states were 
accompanied by confusion, excitement, and 
irrational behavior, which some patients 
recalled as an unpleasant experience.Frequency: Recovery reactions w ere common. 
When esketamine was the sole anesthetic, up to 
30% of patients displayed dose- dependent 
recovery reactions.
Characteristics: Reactions included vivid dreams 
(including nightmares), nausea and vomiting, 
increased salivation, blurred vision, dizziness, 
and motor restlessnessc
Cardiac 
disordersBlood pressure and pulse rate were frequently 
elevated after administration. How ever, 
hypotension and bradycardia have been 
observed. Arrhythmia has also occurred.Common occurrences were temporary 
tachycardia and increase in blood pressure and 
heart rate (approximately 20% of the initial value 
was typical).
Respiratory, 
thoracic, and 
mediastinal 
disordersAlthough stimulation of respiration was a 
frequently observed effect, severe depression 
of respiration or apnea also could occur after 
rapid intravenous administration of high doses.Common effects were increase in vascular 
resistance in pulmonary circulation and increase 
in mucus secretion. Increased oxygen 
consumption, laryngospa sms, and temporary 
respiratory depression were common; the risk of 
respiratory depression was noted to depend on 
dose and injection speed.
Gastro -
intestinal 
disordersNo gastrointestinal effects were listed as 
frequent, but the USPI stated that anorexia,
nausea, and vomiting have been observed.Common effects included nausea and vomiting.
Abbreviations: SmPC, Summary of Product Characteristics; USPI, United States Prescribing Information
a)"Frequent" w as not defined numerically, except in the case of em ergence reactions (12%). The terms "very 
common" and "common" did not appear in the adverse effects section of the USPI.
b)"Very common" w as defined in the SmPC as 1/10 and "common" w as defined as 1/100 to <1/10.
c)The incidence of these events can be greatly reduced by the administration of a benzodiazepine .
Source: Investigator's Brochure for esketamine (JNJ -54135419).42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 62Adverse Events Associ ated with Short -term Use of Intranasal Esketamine in Patients with 
MDD
According to the SmPC for esketamine,46the following are reported as common adverse effects: 
transient tach ycardia, vivid dreams (including nightmares), nausea and vomiting, increased blood 
pressure, increased salivation, blurred vision, dizziness, motor unrest, increase in vascular 
resistance in pulmonary  circulation and increase in mucus secretion, increased oxygen 
consumption, laryngospasms, and temporary  respiratory  depression. It is reported that the risk of 
respiratory  depression t ypically depends on the dosage and injection speed.44
Administration of esketamine is associated with a number of adverse events, which are transient 
in nature and t ypically resolve in 2 h ours or less from thestart of drug administration. In Panel A 
of the Phase 2 study  with intranasal esketamine (ESKETINTRD2003), the most common 
treatment -emergent adverse events (TEAE s) (>10% of subjects in the pooled esketamine 
treatment groups ) during the double -blind phase were : Dizziness, headache, dissociation, 
dysgeusia (metallic taste), nausea, dissociative disorder, and oral hypoesthesia.76Dissociative 
symptoms were the most typical of these adverse events observed post dose and were 
characterized by feeling unreal or detached from reality  or byperceptual changes. Transient 
perceptual changes (dissociation), dizziness, and nausea were typically  seen immediatel y after 
drug administration, resolving by 2hours. No deaths were reported in ESKETINTRD2003 study 
during the double -blind phase . One subject experienced a serious adverse event of esophagitis in 
Panel A (double -blind phase, placebo/placebo treatment group). A total of 3subjects withdrew 
during the double- blind phase because of adverse events. One subject in esketamine 28 mg group 
experienced a TEAE of syncope of severe intensity  on Day 2 of Period 1, 1 day after receiving 
the first dose of study  medication. The subject discontinued from the study  and received no 
further study  medication. The event, resolved on the same day, andthe investigator considered 
the event to be possibly  related to the study  agent. Another subject in the placebo/esketamine 
56mg group experienced a TEAE of headache of moderate intensit y on Day 11 of Period 2.
Study medication was stopped following this event, which resolved on the same day. The 
investigator considered the event to be very likely  related to the study  agent. A third subject in 
the esketamine group (84 mg/esketamine 84mg) experienced a TEAE of dissociative disord er 
(verbatim term: Dissociative syndrome) of moderate intensity  on Day 8of Period 2 (day of the 
third esketamine 84 mg dose in the study ). The subject discontinued from the study  due to the 
event of dissociative disorder, which resolved on the same day. The investigator considered the 
event to be very  likel y related to the st udy agent.76
Dissociative symptoms measured on the Clinician Administered Dissociative States Scale 
(CADSS) were dose-dependent and were observed to reduce significantly  with multiple doses 
over 2 weeks. No psychotic symptoms were seen. Transient increases in mean blood pressure
(systolic and diastolic) were observed post dose following the intranasal esketamine
administration.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 63The mean (standard deviation; SD) peak systolic blood pressure after the first administration in 
each dose group was :
Placebo: 124.2 (11.51 )mmHg ; mean increase of 5.4 (7.84 )mmHg
Esketamine 28 mg: 131.8 (15.49) mmHg ; mean increase of 10.4 (10.44) mmHg
Esketamine 56 mg: 130.4 (18.64) mmHg ; mean increase of 11.2 (15.01) mmHg
Esketamine 84 mg: 146.1 (19.9) mmHg ; mean increase of 17.1 (15.5 )mmHg
Mean (SD) p eak diastolic blood pressure after the first administration in each dose group was:
Placebo: 81.2 (8.36) mmHg ; mean increase of 3.8 (7.99) mmHg
Esketamine 28 mg: 85.7 (9.16 )mmHg ; mean increase of 6.5 (7.00 )mmHg
Esketamine 56 mg: 86.5 (11.34) mmHg ; mean increase of 7.2 (9.67) mmHg
Esketamine 84 mg: 87.8 (10.62 )mmHg ; mean increase of 8.1 (9.12 )mmHg
The blood pre ssure increase ty picall y resolve dwithin 2 hours. Unlike dissociative sy mptoms , the 
blood pressure changes observed do not appear to attenuate over time with multiple doses . 
Transient increases in heart rate were also observed in parallel with blood pressure change . There 
was no clinicall y meaningful change in blood ox ygen level.
Adverse Events Associated with Chronic Use of Ketamine
There are no controlled studies of long-term use with esketamine/ketamine in patients with 
MDD. Much of the literature on chronic use of ketamine comes from data gathered from 
street /illegal use of the drug ,rather than sy stematically  conducted clinical studies. Data therefore 
should be interpreted with caution, as in many  cases, no baseline pre-drug data are available and
drug exposure is poorly  documented. 
In a 1- year longitudinal study , 150 subjects were divided into 5 groups of 30subjects each: 
Frequent ketamine users (more than 4 times per week), infrequent ketamine users (at least once a 
month), abstinent users (abs tinent for at least 1 month), poly drug controls, and non- users of illicit 
drugs.58Eight y percent of the participants were retested at the end of 1year. Cognitive deficits 
(including impairment in spatial working memory , pattern recognition memory  and category 
fluency ) were mainl y observed in frequent users and not with the infrequent users. Short -lasting ,
dose-dependent effects of psychosis were associated with ketamine users. There was no increase 
in symptoms over time,and symptoms were completely  reversible upon stopping use of 
ketamine. As noted, these data should be interpreted with caution, as baseline data predating 
drug use were not available . Furthermore, in their recent review, Morgan and Curran report that 
there is little evidence of any link between chronic, heav y use of ketamine and diagnosis of a 
psychotic disorder.57
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 64The principal action of ketamine is at the NMDA receptor, and the consequences of ketamine use 
on cognition have been fairly widel y investigated. Several studies have examined cognitive 
function in infreque nt and frequent ketamine users .13,56,58,61Overall, infrequent or recreational 
ketamine use does not appear to be associated with long-term cognitive impairment .58The most 
robust findings are that frequent ketamine users (more than 5 times a week) exhibit impairments in 
both short -and long-term memory .56Although dosages have varied, dosages reported by ketamine 
users in this study  were much higher than the dosages of ketamine or equivalent doses of 
esketamine intended for use in treating TRD. Memory  impairments may be reversible when 
individuals stop using the drug, as they  were not found in a group of 30 ex -ketamine users who had 
been abstinent for at least a y ear.57,58
Ketamine -induced ulcerative cystitis is a recentl y identified complication.57The most common 
symptoms are frequency and urgency  of urination, dysuria, urge incontinence , and occasionall y 
painful hematuria (blood in urine). Computerized tomograph yscans of these subjects revealed a 
marked thickening of the bladder wall, a small bladder capacit y,and perivesicular stranding 
consistent with severe inflammation. At cystoscopy ,all patients had severe ulcerative cystitis. 
Biopsies in 4of these cases found denuded urothelial mucosa with thin layers of reactive and 
regenerating epithelial cells,and ulcerations with vascular granulation tissue and scattered 
inflammatory  cells. Cessation of ketamine use provided some relief of symptoms. Most of the 
descri bed cases are in near-daily users of ketamine for recreational purposes. The prevalence is 
difficult to determine ,as it is seen in recreational users who often do no t seek help.
The majority  of cases resolve after stopping ketamine use, one -third remaini ng static.
Abuse Liability, Dependence , and Withdrawal
There are a number of reports of ketamine dependence in the literature41,43,55,65but no large -scale 
studies, and so the incidence of ketamine dependence is largel y unknown.57An interview study  
of 90 ketamine users found that 57% of frequent users, 43% of infrequent users, and 60% of 
ex-users expressed concerns about ketamine addiction.59The majority  of frequent users in that 
study  reported using the drug without stopping until supplies ran out, so compulsive patterns of 
behavior are also a concern. Oral ketamine has also been evaluated as a positive control in 
human abuse potential studies, with dosages of 65 mg and 110 mg reported as appropriate for 
use as positive controls for future abuse potential studies of compounds with a similar 
mechanism of action or with possible perception- altering effects.82There is conflicting evidence 
of the existence of a "withdrawal syndrome" after cessation of ketamine use.57Cravings seem to 
be a key problem in frequent users: 28 of the 30 daily  users in 1 study  reported having tried to 
stop taking the drug but failed; all reported ketamine cravings as the reason for failure.57The 
same study  found that 12 of the 30 daily  users reported withdrawal symptoms characterized by 
anxiety , shaking, sweating, and palpitations when they stopped using. A few published case 
studie s also show craving and somatic and psychological aspects of anxiety  as withdrawal 
symptoms.12,50However, a specific ketamine withdrawal s yndrome has not y et been described.57
Please refer to the Investigator's Brochure for a summary  of the adverse events reported in 
ketamine and esketamine studies.42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 651.1.3. Marketing Experience
No intranasal formul ation of esketamine is currently  marketed.
1.2. Active Comparator sin Double -blind Induction Phase
This study  will evaluate fixed doses ofintranasal esketamine (56 mg or 84 mg) plus a newl y 
initiated oral antidepressant compared with a newly  initiated oral antidepressant (active 
comparator) plus intranasal placebo.
In the double -blind induction phase, subjects will be assigned to receive 1 of 4 commerciall y 
available oral antidepressant medications from 2 different classes of antidepressant medications, 
selective serotonin reuptake inhibitors (SSRI s: Escitalopram orsertraline ),or serotonin and 
norepinephrine reuptake inhibitors (SNRI s:Duloxetine or venlafaxine extended release [ XR]).
The indications and safety information provided below for each oral antidepressant are from the 
US prescribing information.22,27,79,87For further information, please refer to the appropriate 
package insert applicable to the local country  in which the study  is being conducted.
In the US, all of the oral antidepressant options include a black box warning in the prescribing 
information regarding suicidality  and antidepressant drugs. The black box warning informs the 
prescriber that antidepressant treatment s increased the risk compared with placebo of suicidal 
thinking and behavior (suicidality ) in children, adolescents, and young adults in short -term 
studies of MDD and other psychiatric disorders. It states that anyone considering using the 
antidepressant in this population must balance the risk with the clinical need. Refer to the US 
prescribing information for the entire content of the black box warning.22,27,79,87
1.2.1. Selective Serotonin Reuptake Inhibitors
1.2.1.1. Escitalopram
Escitalopram is indicated in adults for acute and maintenance treatment of MDD and acute 
treatment of generalized anxiety  disorder.27
The starting dosage for MDD in the US prescribing information is 10 mg once daily , with a 
maximum of 20 mg once daily . If the dosage is increased to 20 mg, this should occur after a 
minimum of 1 week. No additional benefits hav e been seen at 20 mg/day  dose .
In adult MDD subjects treated with escitalopram, the most commonly  observed adverse reactions 
with escitalopram (incidence of approximately  5% or greater and approximately  twice the 
incidence in placebo subjects) were insomni a, ejaculation disorder (primarily  ejaculatory  delay), 
nausea, sweating increased, fatigue, and somnolence.
Contraindications to the use of escitalopram include serotonin s yndrome and monoamine oxidase 
inhibitor (MAOI) use (concomitant use with MAOIs intended to treat psychiatric disorders, 
linezolid, or IVmethy lene blue; use within 14 days of stopping treatment with an MAOI 
intended to treat psychiatric disorders [in addition, an MAOI should not be used within 14days 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 66of stopping escitalopram]); concomita nt use with pimozide; and known hypersensitivity  to 
escitalopram or citalopram or any  of the inactive ingredients.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation of 
escitalopram treatment is recommended whenever possible.
1.2.1.2. Sertraline
Sertraline hydrochloride is indicated in adults for the treatment of MDD, obsessions and 
compulsions in patients with obsessive compulsive disorder, panic disorder (with or without 
agoraphobia), post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiet y 
disorder.79
According to the US prescribing information, sertraline should be administered at a dose of 
50mg once daily for the treatment of MDD . While a relationship between dose and effect has 
not been established for MDD , obsessive compulsive disorder , panic disorder, post-traumatic 
stress disorder , or social anxiety  disorder, patients were dosed in a range of 50-200 mg/day  in the 
clinical trials demonstrating the effectiveness of sertraline for the treatment of these indications. 
Consequently , a dose of 50 mg, administered once daily, is recommended as the initial 
therapeutic dose. Patients not responding to a 50 mg dose may benefit from dose increases up to 
a maxi mum of 200 mg/day . Given the 24-hour elimination half-life of sertraline, dose changes 
should not occur atintervals of less than 1 week. The maximum dose of ser traline in the current 
study  is200 mg/day.
Contraindications to the use of sertraline include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stopping treatment with an MAOI intended to treat psychiatric 
disorders); concomitant use with pimozide; and known hy persensitivity  to sertraline or any  of the 
inactive ingredients. 
In adult subjects, the most common TEAEs associated with the use of sertraline (incidence of at 
least 5% for sertrali ne or at least twice that for placebo within at least one of the indications) 
were ejaculation failure, dry mouth, increased sweating, somnolence, tremor, dizziness, fatigue, 
pain, malaise, abdominal pain, anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, 
agitation, insomnia, and decreased libido.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation treatment is 
recommended whenever possible.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 671.2.2. Serotonin and Norepinephrine Reuptake Inhibitors
1.2.2.1. Duloxetine
Duloxetine is indicated in adults for MDD, generalized anxiety  disorder ,diabetic peripheral 
neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.22
The starting dosage for MDD in the US prescribing information is 40 to 60 mg/day . The dosage 
for acute treatment is 40 to 60mg/day , with maintenance treatment at 60mg/day .For some 
patients, it may  be desirable to start at 30 mg once daily  for 1 week, to allow patients to adjust to 
the medication before increasing to 60 mg once daily .91
In the current study , subject s should be initiated with 60mg/da y. Subjects thathave in the past 
shown increased sensitivity  towards SSRI /SNRI scan,at the discretion of the treating physician,
be started on a 30 mgdose and up-titrated to the therapeutic range of 60mg by the start of 
Week2of the double -blind induction phase .
The maximum dosage is 120mg/day , although there is no evidence that dosages greater than 
60mg/day  confer any additional benefits. The maximum dose to be used in this study  is 
60mg/day .
For pooled studies for all approved indications, the most commonly  observed adverse reactions 
in duloxetine -treated subjects (incidence of at least 5% and at least twice the incidence in 
placebo subjects) were nausea, dry  mouth, somnolence, fatigue, constipation, decreased appetite, 
and hyperhidrosis. As observed in diabetic peripheral neuropathy  studies, duloxetine treatment 
worsens gl ycemic control in some subjects with diab etes.
Contraindications to the use of duloxetine include use of an MAOI  concomitantly  or within 
2weeks of MAOI use ; and use in patients with uncontrolled narrow -angle glaucoma.
A gradual reduction in the dosage rather than abrupt cessation is recommended whenever 
possible.
1.2.2.2. Venlafaxine Extended-r elease
Venlafaxine XR is indicated in adults for MDD and social anxiety  disorder.87
The starting dosage for MDD in the US prescribing information is 75 mg/day  (in some patients, 
37.5 mg/day  for 4 to 7 days), with a dosage increase by 75 mg/day at intervals of 4 days or 
longer, and a maximum dosage of 225 mg/day. 
Dosage reductions are recommended for hepatic impairment (including mild) and renal 
impairment.
Contraindications to the use of venlafaxine XR include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stopping treatment with an MAOI intended to treat psychiatric 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 68disorders ); concomitant use with pimozide; and known hy persensitivity  to venlafaxine XR or an y 
of the inactive ingredients.
In adult subjects with MDD, adverse events in short -term studies that occurred in at least 5% of 
the subjects receiving venlafaxine hydrochloride XRcapsules and at a rate at least twice that of 
the placebo group were abnormal ejacula tion, gastrointestinal complaints (nausea, dry mouth, 
and anorexia), central nervous sy stem complaints (dizziness, somnolence, and abnormal dreams), 
and sweating.
Sustained hypertension is noted within the Warnings and Precautions section. Preexisting 
hypertension should be controlled before treatment with venlafaxine XR. It is recommended that 
patients receiving venlafaxine XRtablets have regular monitoring of blood pressure. For patients 
who experience a sustained increase in blood pressure while receivi ng venlafaxine XR, either 
dosage reduction or discontinuation should be considered.
Across most indications, a dose-related increase in supine systolic and diastolic blood pressure 
was evident in venlafaxine XR-treated patients. Across all clinical studies , 1.4% of subjects in 
the venlafaxine XR-treated groups experienced a 15-mmHg increase in supine diastolic blood 
pressure ,with blood pressure 105 mmHg ,compared with 0.9% of subject s in the placebo 
groups. Similarly , 1% of subjects in the venlafaxine XR-treated groups experienced a 
20mmHg increase in supine systolic blood pressure ,with blood pressure 180mmHg ,
compared with 0.3% of subjects in the placebo groups. 
A gradual dosage reduction, individualized as necessary , is recommended to avoid 
discontinuation sy mptoms.
1.3. Overall Rationale for the Study
This study  is being conducted to evaluate the efficacy , safet y, and tolerability of 2 fixed doses of 
intranasal esketamine (56 mg or 84 mg) plus anewly initiated oral antidepressant in adult 
subjects with TRD . The study  will serve as a pivo talPhase 3 short -term efficacy  and safet y study  
in support of regulatory agency  requirements for registration of intranasal esketamine for the 
treatment of TRD .
2. OBJECTIVE SAND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary  objective of this study  is to evaluate the efficacy  of switching adult subjects with 
TRD from a prior antidepressant treatment (to which they have not responded) to intranasal 
esketamine (56 mg or 84 mg) plus a newly  initiated oral antidepress ant compared with switching 
to a newly  initiated oral antidepressant (active comparator) plus intranasal placebo, in improving 
depressive symptoms, as assessed by the change from baseline in the MADRS total score from 
Day 1 (pre -randomization) to the end o f the 4- week double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 69Key Secondary Objective s
The key secondary  objective s are to assess the effect of intranasal esketamine plus a newl y
initiated oral antidepressant compared with a newly initiated oral antidepressant (active 
compar ator) plus intranasal placebo on the following parameters in adult subjects with TRD :
-Onsetof clinical response by  Day  2
-Function ingand associated disability
-Depressive s ymptoms (subject -reported)
Other Secondary Objectives
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant 
compared with a newl yinitiated oral antidepressant (active comparator) plus intranasal 
placebo on the following parameters in adult subjects with TRD :
-Depression response rates
-Depression remission rates
-Overall s everity  ofdepressive illness
-Anxiety  symptoms
-Health-related qualit y of life and health status
To investigate the safet y and tolerability  of intranasal esketamine plus a newly initiated oral 
antidepressant compared with a newl yinitiated oral antidepressant (active comparator) plus 
intranasal placebo in adult subjects with TRD, including the following parameters:
-TEAEs , including AEs of special interest
-Local nasal tolerability
-Effects on heart rate, blood pressure, respiratory  rate, and blood oxy gen sat uration
-Effects on alertness and sedation
-Potential p sychosis -like effects
-Dissociative sy mptoms 
-Potential e ffects on cognitive function 
-Potential e ffects on suicidal ideation/behavior 
-Potential t reatment -emergent s ymptoms of cy stitis and/or lower urinary  tract symptoms 
-Potential withdrawal and/or rebound symptoms following cessation of intranasal 
esketamine treatment
-Potential e ffects on sense of smell 
To assess the PKof intranasal esketamine in adult subjects with TRD receiving intranasal 
esketamine plus a newly -initiated oral antidepressant.
Exploratory Objectives
To assess the pharmacokinetic /pharmacody namic (PK/PD) relationship of intranasal 
esketamine and MADRS total score in adult subjects with TR D
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 70To assess the potential relationship of biomarkers with response/non- response to intranasal 
esketamine or oral antidepressants in adult subjects with TRD
To assess medical resource utilization
2.2. Hypothesis
The hypothesis for this study  is that,in adult subjects with TRD ,switching from a failed 
antidepressant treatment to intranasal esketamine plus a newly  initiated oral antidepressant is 
superior to switching to a newly  initiated oral antidepressant treatment (active comparator) plus 
intranasal placebo in improving depressive s ymptoms .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, double -blind, active -controlled, multicenter study  in male and female adult 
subjects with TRD to assess the efficacy , safety , and tolerability  of fixed dosed intranasal 
esketamine (56mg or 84mg) plus a newly  initiated oral antidepre ssant compared with a newly 
initiated oral antidepressant (active comparator) plus intranasal placebo. 
The study  has 3 phases which are briefl y described below.
Screening/prospective observational phase (4-week duration + optional 3-week taper 
period )
This phase will prospectivel y assess treatment response to the subject’s current oral 
antidepressant treatment regimen . 
At the start of the screening/prospective observational phase, the subject must have had 
documented non-response to at least 1 antidepress ant treatment (based on MGH -ATRQ) in the 
current episode of depression, and subject istaking adifferent oral antidepressant treatment (on 
the MGH -ATRQ) for at least the previous 2 weeks at or above the minimum therapeutic dose . 
This antidepressant treatment, as well as any other ongoing medications being taken for 
depression at screening (including adjunctive/ augmentation therapies), will continue from the 
start of Week 1 through the end of Week 4 of the screening/prospective observational phase.
Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment is to 
remain at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end of 
Week 4.
After 4 weeks, subjects who are non-responders to their current oral antidepressant treatment 
may be eligible to proceed to the double -blind induction phase. Non-response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4.
Eligible subjects who are entering the double -blind induction phase will discontinue all of their 
current antidepressant treatment (s), including adjunctive/ augmentation therapies . Of note, 
subjects taking benzodi azepines (at dosages equal to or less than the equivalent of 6mg/day of 
lorazepam ) and/or permitted non-benz odiazepine sleep medications (eg, zolpidem, zaleplon) 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 71during the screening/prospective observational phase can continue these medications. No dose 
increases beyond the equivalent of 6mg/day  lorazepam , ornew benzodiazepine are permitted
during the screening/prospective observational phase . If clinically  indicated, a subject’s current 
antidepressant treatment (s) may be tapered and discontinued over an additional, optional period 
of up to 3 week s per the local prescribing information or clinical judgment.
As a new oral antidepressant will be initiated on Day 1  of the double -blind induction phase, 
eligible subjects who do not require a tapered discontinuation of their antidepressant treatment s) 
can proceed immediatel y into the double -blind induction phase .
Double -blind induction phase (4-week duration)
Approximately  348 subjects will be randomly  assigned at a 1:1:1 ratio to receive double -blind 
intranasal treatment with either esketamine 56 mg, esketamine 84 mg, or placebo. The intranasal 
treatment sessions (esketamine or placebo) will occur twice weekl y. In addition, all subjects will 
initiate a new open -label oral antidepressant on Day 1 that will be taken daily  for the duration of 
this phase. The assigned oral antidepressant will be 1 of 4 oral antidepressant medications 
(duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]), that the subject has 
not previously  had a non-response to in the current depressive episode, has not been previously  
intolerant to (lifetime), and is available in the participating country .
Subjects taking benzodiazepines (at dosage s equal to or less than the equivalent of 6mg/day of 
lorazepam) and/or permitted non-benzod iazepine sleep medications (eg, zolpidem, zaleplon) 
during the screening/prospective observational phase can continue these medications during the 
induction phase. No dose increases beyond the equivalent of 6mg/day  of lorazepam, or new 
benzodiazepine medications are permitted during the induction phase, with the exception of the 
use of permitted benzodiazepine rescue medication.
At the end of the induction phase, subjects who are responders (defined as 50% reduction in the 
MADRS total score from baseline [Day  1  p re-randomization] to the end of the 4 week 
double -blind induction phase) may be eligible to participate in the subsequent study  
ESKETINTRD3003 if they meet all other study  entry criteria (ESKETINTRD3003 is a 
longer -term efficacy  maintenance study  involving repeated treatment sessions of intranasal 
esketamine).
If a subject withdraws from the study  before the end of the double -blind induction phase for 
reasons other than withdrawal of consent, an Early  Withdrawal visit should be conducted within 
1 week of the date of discontinuation, followed by the follow -up phase.
Follow -up phase (24- week duration)
This phase will include all subjects who are not eligible or who choose to not participate in the 
maintenance of effect study  ESKETINT RD3003 and have received at least 1 dose of intranasal 
study  medication in the double -blind induction phase. There will be no intranasal treatment 
sessions administered during this phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 72At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study  investigator and/or the subject’s treating physician. The 
decision to continue the oral antidepressant in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal 
study  medication, the oral antidepressant medication should be continued for at least the first 
2weeks of the follow -up phase unless determined as not clinically appropriate.
The follow -up phase will a lso allow collection of additional informative data to assess the course 
of the subject’s major depressive episode over a 6 month period.
An open -label safet y extension study , 54135419TRD3008 , may be available (pending country  
and site approval) for eligib le subjects participating in the ESKETINTRD30 01 study . Please 
refer to the 54135419TRD3008 protocol for full details when available.
Taking into consideration the optional taper period of up to 3weeks , the maximum duration of a 
subject’s study  participati on in the current study  will be 11weeks (for subjects continuing into 
ESKETINTRD3003) or 35 weeks (for subjects completing the follow -up phase).
A diagram of the stud y design is provided in Figure 1.
Figure 1: Study Design for ESKETINTRD300 1
Abbreviations: AD, antidepressant; D/C, discontinued; MDD, major depressive disorder; OL,open -label; 
PBO, placebo . Note: Subjects who withdraw  early from the double -blind induction phase and receive at least 1 dose 
of intranasal study medication in the double -blind induction phase will have an Early Withdraw al visit performed 
and then proceed into the follow -up phase .
A planned interim anal ysis is described in Section 11.3.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 73An Independent Data Monitoring Committee (IDMC) will be commissioned for this study . 
Please r efer to Secti on 11.10 , Independent Data Monitoring Committee, for details.
3.2. Study Design Rationale
3.2.1. Study Population
The study  population will include adult men and women , therefore the age range of 18 (or older if 
the minimum legal age of consent in the country  in which the study  is taking place is >18) to 64 
years of age (inclusive) is considered appropriate.
The subjects will meet the Diagnostic and Statist ical Manual of Mental Disorders (5th Edition; 
DSM -5) diagnostic criteria for single -episode MDD (if single -episode MDD, the duration of the 
episode must be 2years) or recurrent MDD, without psychotic features, based upon clinical 
assessment, and confirme d by the Mini -International Neurops ychiatric Interview (MINI). In 
addition , the subject must have an Inventory  of Depressive Sy mptomatology -Clinician rated, 30 -
item (IDS -C30) total score of  34, which corresponds to moderate to severe depression. 
Treatmen t-resistant depression is defined as a lack of clinicall y meaningful improvement after 
treatment with at least 2 different antidepressant agents prescribed in adequate dosages for 
adequate duration. At the start of this study , subjects must have had non- response (defined as 
≤25% improvement) to 1but 5 (if current episode is > 2 years, upper limit is applicable to 
only the last 2 years) oral antidepressant treatments taken at adequate dosage and for adequate 
duration, as assessed on the Massachusetts General Hospital –Antidepressant Treatment 
Response Questionnaire (MGH -ATRQ) and documented by records (eg, 
medical /pharmacy /prescription records / or a letter from the treating physician , etc.), forthe 
current episode of depression. Subjects who have had some initial response but then lose the 
response (eg,tolerance effects/bra dyphylaxis) to an antidepressant treatment will not be 
considered to have failed that antidepressant treatment. The use of historical data to define 
non-response to treatment prior to patient enrollment in a treatment study  is considered practical 
and valid. The MGH -ATRQ is a validated tool assessing treatment response. 
In addition, at the start of the screening/prospective observational phase, the subject is taking a
different oral antidepressant treatment (on the MGH -ATRQ ) for at least the previous 2 weeks at 
or above the minimum therapeutic dose.This antidepressant treatment, as well as any other 
ongoing medications being taken for depression at screening (including adjunctiv e/augmentation 
therapies), will continue from the start of Week 1 through the end of Week 4 of the 
screening/prospective observational phase. Dose adjustment ispermitted per clinical judgment, 
but the oral antidepressant treatment is toremain at or abov e the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤ 25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total score of ≥ 
28 on Week 2 and Week 4.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 74The subject’s current major depressive episode, depression symptom severity (Week 1 MADRS
total score ≥28 require d), and antidepressant treatment response in their current depressive 
episode (retrospectivel y assessed) must be deemed valid for participation in the clinical study  
based on a Site-Independent Qualification Assessment. The Site Independent Qualification 
Assessment is a tool to facilitate subject selection for MDD clinical studies, with a goal to ensure 
enrollment ofsubjects who have symptoms that reflect the current state of illness and that these 
symptoms can be reliably  measured with appropriate measurement tools, as well as to minimize 
placebo response.
3.2.2. Study Phases
The 4 week duration of the screening/prospectiv e observational phase will provide adequate time 
to assess subject eligibility  according to the study  entry criteria, while also allowing for a 
prospective confirmation of non-response to the current antidepressant treatment(s) that is 
continued for the duration of this phase. This method of recruitment allows subjects to enter the 
study  on a variet y of different antidepressant medications that they hadbeen taking, which 
mimics clinical practice and yet allows for prospective demonstration of treatment resistance to 
the current antidepressant treatment. Even though there is no depression rating score available at 
the start of the antidepressant treatment, the subjects at screening will have to meet criteria for 
moderate to severe depression. After 4 weeks of prospective observation of continuation of the 
current antidepressant treatment and assessment of treatment response, subjects who meet the 
predefined non-response criteria and are eligible to enter the double -blind induction phase will 
discontinue all of the current antidepressant treatment s, including adjunct ive/augmentation 
therapies, prior to starting the next phase. Non -responders who are eligible to enter the double -
blind induction phase are permitted to have up to 3additional weeks to taper and discontinue 
their current antidepressant treatment prior to entry  into the double -blind induction phase per the 
local prescribing information or clinical judgment (eg, tolerability  concerns). The optional taper 
period of up to 3weeks is expected to provide an adequate amount of time for taper and 
discontinuation.
As described in Section 1.1.2 , the duration of the 4week double -blind induction phase was 
selected based upon the onset of effect of typical antidepressant treatment sand the duration is 
considered to be sufficiently  long to show the antidepressant effects of the active comparator. 
Preliminary  findings from an analysis of antidepressant treatment s were prese nted recently , as 
well as a completed analy sis of 24 recent MDD studies that compared study durations of 4, 6,
and 8weeks. Exploratory  analyses were conducted for each of the study  duration susing 
mixed -effects model for repeated measures (MMRM) , but excl uding data beyond the duration of 
interest. These preliminary  findings suggest that it is plausible to shorten the study duration 
down to 4weeks.48,96Similarly , it has been demonstrated that improvement of 25% on the 
Hamilton Depression 17-item rating scale on Day 14 was a significant cutoff value to predict 
response after 5 weeks of treatme nt and a lack of improvement (ie, <25%) by Day 14 predicted 
poor response after 5 weeks of treatment.63All togethe r, these results suggest that a 4 week 
duration should be adequate to assess antidepressant response.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 75For subjects entering the follow -up phase, the 24week duration following the last dose of 
intranasal study  medication will allow sufficient time to assess safet y and tolerability after 
cessation of intranasal study  medication , including potential withdrawal symptoms. During this 
phase, further clinical/standard of care for the treatment of depression will be arranged by the 
study  investigator and/or the subject’s treating physician. In addition, this phase will allow 
collection of additional informative data to assess the course of the subject’s major depressive 
episode over a 6 month period.
3.2.3. Blinding and Randomization
Blinded intranasal treatment will be used to reduce potential bias during data collection and 
evaluation of clinical endpoints.
An intranasal placebo control will be used in the double -blind induction phase to establish the 
frequency  and magnitude of changes in clinical endpoints that may occur in the absence of 
intranasal active treatment.
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (eg, demographic and 
baseline characteristics) are evenly  balanced across treatment groups, and to enhance the validity 
of statistica l comparisons across treatment groups. The randomization will be stratified by 
country  and class of antidepressant (SNRI or S SRI) with an allocation ratio of 1:1:1 to intranasal 
placebo, intranasal esketamine 56 mg, or intranasal esketamine 84mg.The stratification is aimed 
at balancing t reatment groups across country  and class of antidepressant .
3.2.4. Treatment Groups and Dose Selection
The 3 treatment groups in the double -blind induction phase are:
Intranasal esketamine (56mg)
Intranasal esketamine (84 mg)
Intranasal placebo
In all treatment groups, subjects will switch to a new, oral antidepressant, initiated on Day 1 of 
the double -blind induction phase, that will continue for the duration of the phase and longer, if 
applicable.
The treatment groups will allow for an evaluation of the efficacy , safety , and tolerability  of 
2fixed doses of intranasal esketamine plus a newly initiated oral antidepressant as compared 
with a newl y initiated oral antidepressant treatment (active comparator) plus intranasal placebo 
in adult subjects with TRD .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 76Intranasal Study Drug
The dose selection (56 mg and 84 mg) and administration interval ( 2treatment sessions per week 
for 4 weeks) for this study  were based on the sponsor’s previous clinical data, in particular the 
results from Studies ESKETIVTRD2001, KET IVTRD2002, ESKETINTRD1001, and Panel A 
of Study ESKETINTRD2003, described above in Section 1.1.2 . 
The data from Study  ESKETINTRD2 003 Panel A support the hypotheses that both the 56mg 
and 84mgdoses are effective as a treatment for depression in subjects with TRD , that they have 
a rapid onset of effect, and that 2 treatment sessions per week can sustain the response 
throughout the 4week duration of the double -blind induction phase . In addition, the 56mg and 
84mg dosages were generall y well tolerated b y subjects.
To improve tolerability , subjects who will berandomly  assigned to esketamine 84mg will start 
at 56mg on Day 1 and then, in a blinded manner, increase to 84 mg on Day 4. The rationale for 
this approach is that using the lower dose (56 mg) initially , and then increasing to 84mg, may 
allow subjects to adjust to the effects of the lower dose before going to the higher dose (84mg). 
Thereafter, no further dose adjustments will be permitted. For example, internal data from the 
CADSS suggest a dose response, with the greatest effect seen initially  on the 84mg dose 
(ESKETINTRD2003). However, on subsequent repeated dosing, dissociative symptoms lessen. 
Starting with a lower dose may therefore limit the number of subjects discontinuing the study  
treatment because of intolerability  in the 84 mg dose gr oup.
Oral Antidepressant
On Day 1 of the double -blind induction phase , a new, open -label oral antidepressant treatment 
will be initiated in all subjects. Each subject will be assigned to receive 1 of 4 oral antidepressant 
medications from 2 different classes of antidepressant treatments, an SSRI  (escitalopram or 
sertraline) or an SNRI (duloxetine or venlafaxine XR). 
The antidepressant medication will be assigned by the investigator based on review of 
MGH -ATRQ and relevant prior antidepressant medication information.
These 2 classes were selected because they are the most commonly  prescribed antidepressant 
classes in this population and are generall y well- tolerated. The oral antidepressant treatment
assigned will be one that the subje ct has not previously  had a non-response to in the current 
depressive episode, has not been previously  intolerant to (lifetime), and is available in the 
participating country . Dosing of the oral antidepressant will begin on Day 1.A mandatory 
titration schedule is provided in Attachment 3. Doses are not to exceed the maximum dose 
defined in the titration schedule , to ensure that the oral antidepressant is taken at an adequate 
dosage and duration for efficacy  assessment at the end of the double -blind induction phase , as 
well as for potential maintenance of effect (in the subsequent ESKETINTRD3003 study ).If 
higher doses are not tolerated, a down -titration is permitted based on clinician’s judgment. 
However, the subject’s dose should not be lower than the follow ing minimum therapeutic doses
at the end of the induction phase : Sertraline (50mg/day ), venlafaxine XR (150 mg/day ), 
escitalopram (10mg/day), and duloxetine (60 mg/day ). While subjects requiring lower doses can 
continue in the study  and complete the doub le-blind induction phase, such subjects are not 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 77eligible to participate in the ESKETINTRD3003 study  and will proceed to the follow -up phase 
after completion of the double -blind induction phase .
3.2.5. Efficacy  Measures
MADRS
The 10-item clinician -administered MADRS was designed to be used in subjects with MDD to 
measure the overall severity  of depressive symptoms .53,54The MADRS scale has been selected
as the primary  efficacy  measure for this study  because it is validated, reliable, and acceptable to 
regulatory  health authorities as a primary  scale to deter mine efficacy  in major depression. 
The primary  efficacy  endpoint is the change in the MADRS total score from baseline (Day 1 
prior to randomization) to the end of the 4 week double -blind induction phase.
In this study , subjects in any of the 3 treatment groups who respond to the study  medication 
(ie,responders) are defined as subjects who meet the criterion for response defined as 50% 
reduction in the MADRS total score from baseline (Day  1 pre-randomization) to the end of the 
4week double -blind inductio n phase.
In addition to being the primary  efficacy  measure, the MADRS will also be used to evaluate the 
key secondary  efficacy  endpoint of onset of clinical response (ie, antid epress ant effect) byDay 2
that is maintained for the duration of the double -blind induction phase . Onset of c linical response 
is defined as 50% improvement in MADRS total score by Day 2 (ie, the day after taking the 
first dose of double -blind intranasal medication) that continues through theend of the 
double -blind phase with one excursion allowed.
MADRS will also be used to evaluate a secondary  objective assessing proportion of subjects 
with response and those in remission (defined as subjects with a MADRS total score 12) at the
end of the 4- week double -blind induction phase.
Patient Health Questionnaire – 9 (PHQ -9)
The PHQ -9 will be used as a subject -reported outcome measure of depressive sy mptomatology .84
Please refer to Section 9.2.1.3.2 foradditional information regarding PHQ-9.
SDS
The Sheehan Disability  Scale (SDS) isa subject -reported outcome measure and is included as an
assessment of functional impairment and associated disability .49,81Please refer to 
Section 9.2.1.3.1 for additional information regarding SDS.
Clinica l Global Impression –Severity (CGI-S)
The CGI-S is included to rate the severity  of the subject’s illness at the time of assessment, 
relative to the clinician’s past experience with subjects who have the same diagnosis and 
improvement with treatment .35Please refer to Section 9.2.1.4.1 for additional information 
regarding CGI- S.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 78Generalized Anxiety Disorder 7 -item Scale (GAD-7 )
GAD-7 is included as a brief and validated measure of overall anxiety .83Please refer to 
Section 9.2.1.5.1 for additional information re garding GAD -7.
EuroQol -5 Dimension -5 Level ( EQ-5D-5L)
The EQ-5D- 5L is included as a standardized subject -completed instrument for use as a measure 
of health-related quality of life and health status.29,30Please refer to Section 9.2.1.5.2 for 
additional information regarding EQ -5D- 5L.
3.2.6. Safety  Evaluations
Physical examination, body  weight, vital signs (including blood pressure measurements) , 12-lead 
ECG, pulse oximetry , clinical laboratory  tests, nasal examinations, and evaluation of TEAEs and 
concomitant therapies will be performed throughout the study  to monitor subject safet y. 
TEAEs of special interest will be examined separately  groupe d in the following categories: D rug 
abuse, dependence and withdrawal (standardized Medical Dictionary  for Regulatory  Activities 
[MedDRA ] queries [SMQ] ), increased blood pressure, increased heart rate, transient 
dizziness/vertigo , impaired cognition , anxiety ,and cy stitis.
A subject -completed nasal symptom questionnaire will also be conducted as per the Time and 
Event Schedule to assess for an y treatment -emergent nasal tolerability  symptoms .
The Columbia Suicide Severity  Rating Scale (C-SSRS )will be performed to assess suicidal 
ideation and behavior, the CADSS will be administered to assess treatment -emergent 
dissociative symptoms, the Brief Psychiatric Rating Scale (BPRS+ ; four-item positive symptom 
subscale) will be administered to assess treatment- emerge nt psychotic symptoms, the Modified 
Observer’s Asse ssment of Alertness/Sedation (MOAA/ S)will be used to measure 
treatment -emergent sedation, the CGA DRwill be used to measure the subject’s readiness for 
discharge based on parameters including sedation, blood pressure, and adverse events, and the 
Physician Withdrawal Checklist; 20-item (PWC-20 )will be administered (as applicable) to 
assess potential withdrawal symptoms after cessation of esketamine treatment.
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study  and at multiple 
time points on dosing days. Specific guidance to be followed on intranasal dosing days is 
provided in Section 6.2.1 .
Even though it is anticipated that the potential risk for treatment -emergent cystitis is very low 
based upon the doses to be used in this study , subjects will be monitored for symptoms of 
cystitis ,bladder pain, and interstitial cystitis using the subject -completed Bladder Pain/ 
Interstitial Cystitis Symptom Score (BPIC-SS) at specific time points.40A score >18 on the 
BPIC-SS scale is considered as probable cystitis ,and any subjects meeting this cut-off will have 
a urinal ysis and culture conducted at that visit to assess for potential urinary  tract infection .
Those without evidence of an ongoing urinary  tract infection will be referred to a specialist for 
diagnostic workup. There are no definitive tests for diagnosing ulcerative cystitis. If a subject is 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 79determined to have a diagnosis of ulcerative cystitis , the subject must be discontinued from the 
study  and followed up with appropriate medical care. 
The effect of intranasal esketamine on cognition over the 4week double -blind induction phase 
will be assessed using the computerized cognitive battery  and Hopkins Verbal Learning 
Test-Revised (HVLT -R). The cognitive battery  will provide assessment of multiple cognitive 
domains, including attention, visual learning and memory , and executive function. The HVLT -R
isa measure of verbal learning and memory .
The University  of Pennsylvania Smell I dentification Test ( UPSI T)and Smell Threshold Test will 
be performed to assess any  treatment -emergent effects on the sense of smell.
On all intranasal dosing days, subjects must remain at the site until study  procedures have been 
comple ted and the subject is ready for discharge , and should be accompanied by a responsible 
adult when released from the clinical site. Subjects must not drive a car or work with machines 
for 24 hours after receiving intranasal study  drug.
A list of prohibited medications is provided inAttachment 1asgeneral guidance for the 
investigator (but is not all inclusive).
3.2.7. Medical Resource Utilization 
Superior and sustained response and remission rates to the current antidepressant medication (s) 
areexpected to result in low utili zation of services, whereas non-response is expected to result in 
higher utilization of healthcare services (such as outpatient visits, emergency  room visits, or 
hospitalization), as assessed using the Health care Reso urce Use Questionnaire (HRUQ)during 
the follow -up phase . The HRUQ includes information regarding utilization of healthcare 
services , including the timing of services, enabling changes in level and quantity  of services to 
be considered as a variable in eco nomic models.
3.2.8. Other A ssessments
Patient Adherence Questionnaire
During the screening/prospective observational phase, the subject -reported Patient Adherence 
Questionnaire (PAQ )will be used to assess how often the subject has taken, and whether he or 
she has made any changes to, his or her antidepressant treatment regimen in the last 2week s. 
This assessment will provide confirmation of medication adherence when evaluating 
antidepressant treatment response. Subjects who report missing 4days of antidepressant 
medication treatment(s) during a 2- week recall period will be discontinued because of inadequate 
adherence.
3.2.9. Pharmacokinetic Assessments
PKsamples will be obtained during the study  for measurement of the plasma concentration sof 
esketami ne, noresketamine, and/or additional metabolites, if warranted.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 803.2.10. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA )
Evaluation s
Assessment of biomarker s(protein and RNA) and their potential relationship to the different 
treatment groups and to maintena nce/stabilization of response , non- response, and relapse will be 
explored. Blood samples will be collected to measure genetic and epigenetic markers (including 
but not limited to BDNF allelic variants) and protein markers (including but not limited to 
grow th factors, inflammation, endocrine, or metabolic). Samples of deox yribonucleic acid 
(DNA) and biomarker smay be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized therapies.
Genetic variation can be an important contributory  factor to inter-individual differences in drug 
distribution and response and can also serve as a marker for disease susceptibility  and prognosis. 
Pharmacogenomic research may help to explain inter-individual varia bility  in clinical outcomes 
and may help to identify population subgroups that respond differentl y to a drug or subgroups 
that are more susceptible to relapse . In addition, pharmacogenomics research may allow for the 
identification of genetic factors that influence the PK, PD, efficacy , safet y, or tolerability  of the 
different treatment groups ,and for the identification of genetic factors associated with TRD or 
MDD. Specifically , genetic and epigenetic changes in genes known to be in pathway s relevant to 
depression (eg,hypothalam icpituitary -adrenal [HPA ]axis, inflammation, growth factors, 
monoamine transporters, ion channels, and circadian rhy thm) will be evaluated.
Protein, metabolite, and ribonucleic acid (RNA )biomarkers may aid in the elucidation of the 
mechanism of action of the different treatment groups or help to explain inter-individual 
variability  in clinical outcomes or may help to identify  population subgroups that respond 
differentl y to a drug or may help to identify  subgroups that are more susceptible to relapse . The 
goal of the biomarker analy ses is to evaluate the PDof the different treatment groups , and aid in 
evaluating the drug- clinical response relationship.
On the day of biomarker sample collection, it is preferred that subjects adhe re to low fat diet (as 
an alternative to fasting) to reduce the level of postprandial lipemia in blood samples, since 
moderatel y or grossl y lipemic specimens may  interfere with assay  results.
4. STUDY POPULA TION
The inclusion and exclusion criteria for enroll ing subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolli ng a subject in the study . Waivers are not allowed. 
4.1. Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study . 
1.At the time of signing the informed consent form (I CF), s ubject must be a man or woman 1 8 
(or older if theminimum legal age of consent in the country in which the study  is taking 
place is >18) to 64 y ears of age, inclusive.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 812. At the start of the screening /prospective observational p hase, subject must meet theDSM -5 
diagnostic criteria for single -episode MDD (if single -episode MDD, the duration must be 
2years) or recurrent MDD, without psy chotic features, based upon clinical assessment and 
confirmed b y the MINI.
3.Criterion modified per amendment 1
3.1.Criterion modified per a mendment 2
3.2. At the start of the screening /prospective observational p hase, subject must have had 
non-response (≤25% improvement) to 1but 5 (if current episode is >2 years, upper limit 
is applicable to only the last 2 years) oral antidepressant treatments in the current episode of 
depression, assessed using the MGH -ATRQ and confirmed by documented records (eg, 
medical /pharmacy /prescription records or a letter from a treating physician , etc.). In 
addition, the subject is taking adifferent oral antidepressant treatment (on the MGH -ATRQ ) 
for at least the previous 2 weeks at or above the minimal therapeutic dose .
For specific tricy clic antidepressants which are ongoing and being taken at a dose below 
the MGH -ATRQ minimum therapeutic dose, a blood level that is within the therapeutic 
(antidepressant) range, is acceptable to establish the adequacy  of the antidepressant 
treatment.
Subjects must be adherent to the continued oralantidepressant treatment medication (s)
through the screening/prospective observational phase, as documented on the PAQ. 
Missing 4days of antidepre ssant medication in the prior 2-week period will be 
considered as inadequate adherence.
Subjects who are n on-responders to the ir current oral antidepressant medication (s)from 
the screening/prospective observational phase (as assessed by independent, remote 
raters) may be eligible for randomization if all other entry  criteria are met.Non-
response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of ≥28 on Week 2 and Week 4. 
4. At the start of the screening /prospective observational p hase, subject must have an IDS-C30
total score of 34.
5. Criterion modified per amendment 1
5.1. The subject’s current major depressive episode ,depression symptom severit y (Week 1 
MADRS total score ≥28 require d), and antidepressant treatment response in the current 
depressive episode, must be confirmed using a Site I ndependent Qualification Assessment .
6.Subject must be medically  stable on the basis of phy sical examination, medical history , vital 
signs (including blood pressure ),pulse oximetry ,and 12-lead ECG performed in the
screening /prospective observational phase . If there are any abnormalities that are not 
specified in the inclusion and exclusion criteria, the determination of their clinical 
significance must be determined by the investigator and recorded in the subject's source 
documents and initialed by  the investigator.
7.Criterion modified per amendment 1
7.1. Criterion modified per amendment 2
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 827.2. Subject must be medically  stable on the basis of clinical laboratory  tests performed in 
the screening /prospective observational phase . If the results of the serum chemistry  panel, 
hematology , or urinal ysis are outside the normal reference ranges, the subject may be 
included only if the investigator judges the abnormalities or deviations from normal to be 
not clinically  significant or to be appropriate and reason able for the population under study . 
This determination must be recorded in the subject's source documents and initialed by the 
investigator.
Subjects with a pre-existing history  of thyroid disease/disorder who are treated with 
thyroid hormones must be on a stable dosage for 3 months prior to the start of the 
screening /prospective observational phase.
For any subject (regardless of thyroid history ), if the thyroid-stimulating hormone 
(TSH )value is out of range, a free thyroxine (FT4)will be conducted. If the FT4 value 
is abnormal and considered to be clinically  significant (after discussion with the medical 
monitor) , the subject is not eligible.
8.Subject must be comfortable with self -administration of intranasal medication and be able to 
follow the intra nasal administration instructions provided .
9.Criterion modified per amendment 1
9.1.Criterion modified per amendment 2
9.2. Contraceptive use by men or women should be consistent with local regulations 
regarding the use of contraceptive methods for subjects participating in clinical studies.
A woman must be either :
a.Not of chi ldbearing potential defined as:
oPostmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimu lating hormone (FSH) level 
(>40 IU/L or mIU/mL  in the postmenopausal range) will be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy , however in the absence of 12months of amenorrhea, a single 
FSH measurement is insufficient.
opermanentl y sterile
Permanent sterilization methods include hysterectomy , bilateral salpingectomy , 
bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy .
b.Of childbearing potential and
opracticing a highl y effective method of contraception (failure rate of <1% per year 
when used consistentl y and correctly).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 83Examples of highly  effective contraceptives include 
user-independent methods:
implantable progestogen- only hormone contraception associated with inhibition of 
ovulation; intrauterine device (IUD); intrauterine hormone -releasing system (IUS); 
vasectomized partner; sexual abstinence (sexual abstinence is considered a highly 
effective method only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study drug. The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifesty le of the subject.)
user-dependent methods:
combined (estrogen -and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation: oral, intravaginal, and transdermal; progestogen -only 
hormone contraception associated with inhibi tion of ovulation: oral and injectable
Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods 
for subjects participating in clinical studies.
Hormonal contraception may be susceptible to interaction with the study drug, which 
may reduce the efficacy of the contraceptive method.
oagrees to use a highl y effective method throughout the study  and for at least 6 
week s after the last dose o f study  drug
Note: If the childbearing potential c hanges after start of the study or the risk of pregnancy 
changes (eg, a wom an who is not heterosexually  active becomes active,) a woman must 
begin a highl y effective method of contraception, as described throughout the inclusion 
criteria.
10.Criterion modified per amendment 1
10.1. A woman of childbearing potential must have a negative highly  sensitive serum 
(β-human chorionic gonadotropin [β-hCG]) at the start of the screening /prospective 
observational phase and a negative urine pregnancy  test must be obtained before the first 
dose of study  drug on Day 1 of the double -blind induction phase prior to randomization.
11.Criterion modified per amendment 1
11.1. Criterion modified per amendment 2
11.2. D uring the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately 
90days)after receiving the last dose of intranasal study  medication, a man who is sexually  
active wit h a woman of childbearing potential
must be practicing a highly  effective method of contraception with his female partner 
from those listed above (see examples of highly  effective methods of contraception 
provided for female subjects).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 84must use a condom if his partner is pregnant .
must agree not to donate sperm .
Note: If the childbearing potential changes after start of the study , a female partner of a male 
study  subject, must begin a highl y effective method of birth control, as described above.
12. Subject must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol.
13.Each subject must sign an ICF indicating that he or she understands the purpose of and 
procedures required for the study  and is willing to participate in th e stud y.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded f rom participating 
in the study .
1.Criterion modified per amendment 1
1.1.The s ubject’s depressive sy mptoms have previously  demonstrated non response to:
Esketamine or ketamine in the current major depressive episode per clinical judgment, or
Allof the oral antidepressant treatment options available in the respective country for the 
double -blind induction phase (ie,duloxetine, escitalopram, sertraline, and venlafaxine XR)
in the current major depressive episode (based on MGH- ATRQ) , or
An adequate course of treatment with electroconvulsive therap y (ECT) in the current major 
depressive episode, defined as at least 7 tr eatments with unilateral /bilateral ECT. 
2.Criterion modified per amendment 1
2.1. Subject has received vagal nerve stimulation (VNS) or has received deep brain 
stimulation (DBS) in the current episode of depression.
3.Criterion modified per amendment 1
3.1. S ubject has a current or prior DSM -5 diagnosis of a psychotic disorder or MDD with 
psychotic features bipolar or related disorders (confirmed by the MINI), obsessive 
compulsive disorder (current only), intellectual disability (DSM -5 diagnostic code s 317, 
318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
disorder, antisocial personality  disorder, histrionic personality  disorder, or narcissistic 
personality  disorder.
4. Subject has homicidal ideation/intent, per the investigator’s clinical judgment, or has
suicidal ideation with some intent to actwithin 6 months prior to the start of the 
screening/prospective observational phase , per the investigator’s clinical judgment or based 
on the C-SSRS, corresponding to a respons e of “Yes” on Item 4 (active suicidal ideation 
with some intent to act, without specific plan) or Item5 (active suicidal ideation with 
specific plan and intent) for suicidal ideation on the C-SSRS, or a history  of suicidal 
behavior within the past yearprior to the start of the screening/prospective observational 
phase. Subjects reporting suicidal ideation with intent to actor suicidal behavior prior to the 
start of the double blind induction phase should be excluded.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 855. Subject ha s a history  of moderate or severe substance or alcohol use disorder according to 
DSM -5 criteria, except nicotine or caffeine, within 6 months before the start of the 
screening /prospective observational phase. 
A history  (lifetime) of ketamine, phency clidine (PCP), lysergic acid diethy lamide 
(LSD), or 3, 4-methy lenedioxy -methamphetamine (MDMA) hallucinogen -related use 
disorder is exclusionary .
6. Subject has a current or past history  of seizures (uncomplicated childhood febrile seizures 
with no sequelae are not exclusionary ).
7. Subject has an UPSI T total score 18, indicative of anosmia , in the screening/prospective 
observational phase .
8.Criterion modified per amendment 1
8.1. Subject has one of the following cardiovasc ular-related conditions:
Cerebrovascular disease with a history  of stroke or transient ischemic attack.
Aneury smal vascular disease (including intracranial, thoracic ,or abdominal aorta, or 
peripheral arterial vessels )
Coronary  artery  disease with myocardi al infarction, unstable angina, or 
revascularization procedure (eg, coronary  angioplasty  or bypass graft surgery ) within 
12months before the start of the screening /prospective observational phase .Subjects 
who have had a revascularization performed ˃12months prior to screening and are 
clinically  stable and symptom -free, per investigator’s clinical judgment, can be 
included.
Hemody namicall y significant valvular heart disease such as mitral regurgitation, aortic 
stenosis, or aortic regurgitation. 
New York Heart Association (NYHA) Class III-IV heart failure of any etiology (refer 
to Attachment 2).
9.Criterion modified per amendment 1
9.1. Subject has ahistory  of uncontrolled hypertension despite diet, exercise, or
antihy pertensive therapy  at the start of the screening/prospective observational phase or any 
past history  of hy pertensive crisis or ongoing evidence of uncontrolled hypertension defined 
as a supine systolic blood pressure (SBP)>140 mmHg or diastolic blood pressure (DBP )
>90 mmHg during screening/prospective observational phase which continues to be above 
this range with repeated testing during this phase. Note: On Day 1 of the double -blind
induction phase prior to randomization a supine SBP >140 mmHg or DBP >90 mmHg is 
exclusionary .
A potential subject may have his/her current antihy pertensive medication (s)adjusted 
during the screening/prospective observational phase and be re-evaluated to assess their 
blood pressure control .The subject must be on a stable regimen for at least 2weeks 
before Day 1 of the double -blind induction phase.
10.Subject has a current or past history  of significant pulmonary  insufficiency /condition or with 
an arterial blood oxygen saturation (SpO 2) of <93% at the start of the screening/prospective 
observational phase or Day  1 prior to randomization. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 8611.Criterion modified per amendment 1
11.1. Criterion modified per a mendment 2
11.2. Subject h as clinically  significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the double -blind induction phase 
prior to randomization , defined as:
During screening, a QT interval corrected according to Fridericia’s formula (QTcF): 
≥450 msec; if the QTcF is prolonged on the initial ECG, the average QTcF of 
three ECGs, recorded 4 minutes apart, must not be ≥450 msec.
On Day 1 (predose), a QT interval correcte d according to Fridericia’s formula (QTcF): 
≥450 msec based on the site-evaluated ECG; if the QTcF is prolonged on the initial 
ECG, the average QTcF of three ECGs, recorded 4 minutes apart, must not be 
≥450 msec.
Evidence of 2nd and 3rd degree AV block, complete left bundle branch block (LBBB) ,
or complete right bundle branch block (RBBB) .
Features of new isch emia .
Arrh ythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs]) .
12.Criterion modified per amendment 1
12.1. Subject has a history  of additional risk factors for Torsades des Pointes (eg, heart 
failure, h ypokalemia, family  history  of Long QT Sy ndrome ).
13.Criterion modified per amendment 1
13.1 Subject has a history  of, or symptoms and signs suggestive of,liver cirrhosis (eg,
esophageal varices, ascites, and increased prothrombin time) OR alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) values 2x the upper limit of normal or total 
bilirubin >1.5 times the ULN in the screening/prospective observational phase.
Repeat of screening test for abnormal ALT and AST is permitted once during the 
screening period provided per investigator discretion and provide there is an alternative 
explanation for the out of range value.
For elevations in bilirubi nif, in the opinion of the investigator and agreed upon by the 
sponsor’s medical officer, the elevation in bilirubin is consistent with Gilbert’s disease , 
the subject may  participate in the study .
14.Criterion modified per amendment 1
14.1. Criterion modifie d per a mendment 2
14.2. Subject h as positive test result(s) for drugs of abuse (including barbiturates, 
methadone, opiates, cocaine, phency clidine, and amphetamine/methamphetamine) at the 
start of the screening /prospective observational p hase or Day 1 of the double -blind induction 
phase prior to randomization.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 87 Subjects who have a positive test result at screening due toprescribed psychostimulants (eg, 
amphetamine, methylphenidate, etc.) taken for an indication other than MDD are permitted 
to continue t o take this medication during the study in accordance with Attachment 1.
Otherwise, subjects who have a positive test result at screening due to prescr ibed/over -
the-counter opiates or barbiturates may be permitted to continue in the 
screening /prospective observational phase if the medication is discontinued at least 1
week or 5half-lives, whichever is longer, before Day 1 of the double -blind induction 
phase (prior to randomization) in accordance with Attachment 1restrictions. The result 
of the Day 1 (prior to randomiza tion) test for drugs of abuse must be negative for the 
subject to be randomized.
oRetesting is not permitted for positive test result(s) , except for reasons stated above .
Prior intermittent use of cannabinoids prior to the start of the screening /prospective
observational phase is not exclusionary  as long as the subject does not meet the criteria 
for substance use disorder. Apositive test for cannabinoids at the start of the 
screening /prospective observational phase is not exclusionary ; however, a positive test 
result for cannabinoids predose on Day 1 of the double -blind induction phase is 
exclusionary .
15.Criterion modified per amendment 1
15.1. Subject has uncontrolled diabetes mellitus ,as evidenced by HbA1c >9% in the
screening /prospective observational phaseor history  in the prior 3 months prior to the start 
of the screening/prospective observational phase of diabetic ketoacidosis, hypergl ycemic 
coma ,or severe h ypogl ycemia with loss of consciousness.
16. Subject has untreated glaucoma, current penetrating or perforating eyeinjury , brain injury , 
hypertensive encephalopathy , intrathecal therapy  with ventricular shunts, or any other 
condition associated with increased intracranial pressure or increased intraocular pressure or 
planned ey e surgery .
17.Criterion modif ied per amendment 1
17.1 Subject h as any anatomical or medical condition that, per the investigator’s clinical 
judgment based on assessment, may impede delivery  or absorption of intranasal study  drug
18. Criterion deleted per amendment 1
19. Subject has a history of malignancy  within 5 years before the start of the 
screening /prospective observational phase (exceptions are squamous and basal cell 
carcinomas of the skin and carcinoma in situ of the cervix, or malignancy  that,in the 
opinion of the investigator, with concurrence with the sponsor's medical monitor, is 
considered cured with minimal risk of recurrence).
20. Subject has known allergies, hypersensitivity , intolerance, or contraindications to 
esketamine/ketamine and/or its excipients or allof the available oral antidepressant 
treatment options for the double -blind induction phase .
21. Subject has taken any prohibited therapies that would not permit dosing on Day 1,as noted 
in Section 8(Prestudy  and Concomitant Therapy) and Attachment 1.
22. Subject is taking a total daily  dose of benzodia zepines greater than the equivalent of 
6mg/day  of lorazepam at the start of the screening/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 8823. Subject h as a score of 5 on the STOP -Bang questionnaire , in which case obstructive sleep 
apnea must be ruled out (eg, apnea -hypopne a index [AHI]must be <30). A subject with 
obstructive sleep apnea can be included if he or she is using a positive airway  pressure 
device or other treatment/therapy  that is effectively  treating (ie, AHI<30) his or her sleep 
apnea .
24.Criterion modified per amendment 1
24.1. Subject has received an investigational drug (including investigational vaccines) or 
used an invasive investigational medical device within 60 days before the start of the 
screening/prospective observational phase, or hasparticipated in 2 or more MDD or other 
psychiatric condition clinical interventional studies (with different investigational 
medication) in the previous 1 y earbefore the start of the screening/prospective observational 
phase , or is currentl y enrolled in an investigationa l interventional study .
25. Subject is a woman who is pregnant, breast -feeding, or planning to become pregnant while 
enrolled in this study  or within 6 weeks after the last dose of intranasal study  drug.
26. Subject has a diagnosis of acquired immunodeficiency  syndrome (AIDS). Human 
immunodeficiency  virus ( HIV)testing is not required for this study .
27. Subject has any condition or situation/circumstance for which, in the opinion of the 
investigator, participation would not be in the best interest of the subject (eg, compromise 
the well -being) or that could prevent, limit, or confound the protocol- specified assessments.
28.Subject has had major surgery , (eg, requiring general anesthesia) within 12 weeks before the 
start of the screening /prospective observational phase , orwill not have fully  recovered from 
surgery  or has surgery  planned during the time the subject is expected to participate in the 
study . 
Note: Subjects with planned surgical procedures to be conducted under local anesthesia may 
participate .
29. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  members of the employ ees or the investigator.
30.Subject has severe renal impai rment (creatinine clearance <30 ml/min).
NOTE: Investigators should ensure that all study  enrollment criteria have been met. If a subject's 
status changes (including laboratory  results or receipt of additional medical records ) before the 
first dose of study  drug is given such that he or shenolonger meet sall eligibility  criteri a, then 
the subject should be excluded from participation in the study . Section 17.4, Source 
Documentation, describes the required documentation to support meeting the enrollment criteria .
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a 
case-by-case basis.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 894.3. Prohibit ions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
Refer to Section 4.1(Inclusion Criteria) and Section 4.2(Exclusion Criteria) for information 
regarding contraception requirements.
Refer to Section 8(Prestudy  and Concomitant Therap y) and Attachment 1(Prohibited 
Concomitant Medicatio ns for Intranasal Study  Medication [Esketamine or Placebo]) for 
further information on prohibited therapies.
Subjects who were taking benzodiazepines (at dosages equal to or less than the equivalent of 
6mg/day  of lorazepam) and/or permitted non-benz odiaze pine sleep medications (eg, 
zolpidem, zaleplon) during the screening/prospective observational phase can continue these 
medications during the induction phase. No dose increases beyond the equivalent of 
6mg/day  oflorazepam, or new benzodiazepine medicati ons are permitted during the 
induction phase, with the exception of the use of permitted benzodiazepine rescue 
medication. Benzodiazepines and non-benzodiazepine sleeping medication (e.g., zolpidem, 
zaleplon, eszopiclone, and ramelteon) are prohibited within 12 hours prior to the start of 
each intranasal treatment session or cognition testing.
A positive urine drug screen for use of phency clidine (PCP), or cocaine from Day 1 of the 
induction phase through the final visit in the double -blind induction phase will lead to 
discontinuation.
Subjects must abstain from using alcohol within 24 hours before and after each intranasal 
treatment session. If a subject appears intoxicated, dosing should not occur (delay ed per the 
permitted visit window; see the Time and E vents Schedule).
On all intranasal study  drug dosing days, all subjects must remain at the clinical study  site 
until study  procedures have been completed and the subject is ready for discharge . Subjects
should be accompanied by a responsible adult when released from the clinical study  site. 
Subjects must not drive a car or work with machines for 24 hours after study drug dosing.
ECT, DBS, transcranial magnetic stimulation (TMS), and VNS are prohibited from study  
entry  through the end of the double -blind ind uction phase .
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can 
continue receiving ps ychotherap y; however, CBT must have been ongoing for the last 
3months prior to the start of thescreening/prospective observational phase. With the 
exception of new CBT, which is prohibited, new psy chotherap y is allowed during this study . 
Any change in existing therap y or new therap y must be documented on the concomitant 
therapies form.
5. TREA TMENT ALLOCA TION A ND BLINDIN G
Treatment Allocation and Randomization
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 3treatment groups in a 1:1:1 ratio based on a computer -generated randomization schedule 
prepa red before the study  by or under the supervision of the sponsor. The randomization will be 
balanced by using randomly  permuted blocks and will be stratified by country  and class of oral 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 90antidepressant (SNRIorSSRI) to be initiated in the double -blind induction phase . The 
interactive web response system (IWRS) will assign a unique treatment code, which will dictate 
the treatment assignment and matching study  drug kitsfor the subject . After the investigator 
selects the oral antidepressant treatment for the double -blind induction phase, the site will enter 
this information into IWRS. The requestor must use his or her own user identification and 
personal identification number when contact ing the IWRS, and will then give the relevant 
subject details to uniquely identify  the subject.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (eg, intranasal study  drug plasma 
concentrations , treatment allocation) will be handled with special care to ensure that the integrity  
of the blind is maintained and the potential for bias is minimized. This can include making 
special provisions, such as segregating the data in question from view by the investigators, 
clinical team, or others as appropriate until the time of database lock an d unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be dictate d by knowing the treatment status of the 
subject. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  contacting the I WRS. It is recommended that the investigator contact the sponsor or 
its designee ,if possible ,to discuss the particular situation, before breaking the blind. Telephone 
contact with the sponsor or its designee will be available 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date and
time of the unblinding will be documented by the IWRS, and reason for the unblinding must be 
documented by the electronic case report form (eCRF )and in the source document. The 
documentation received from the IWRS indicating the code break must be retained with the 
subject's source documents in a secure manner .
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled earl y withdrawal and follow up visits .
In general, randomization codes will be disclosed fully only if the study is completed and the 
clinical database is closed. Forinterim analy sis, the randomization codes and, if required, the 
translation of randomization codes into treatment and control groups will be disclosed to those 
authorized and only for those subjects included in the interim anal ysis.
At the end of the double -blind induction phase the database will be locked for the analy sis and 
reporting of this phase. The subject treatment assignment will be revealed only to sponsor’s 
study  staff. The investigators and the site personnel will be blinded to the treatment assignment 
until all subjects have completed study  participation through the follow -up phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 91To maintain the blinding of intranasal study  medication , the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the physical characteristics of the study  drugs and devices. In order to manage 
clinical supplie s, the clinical supplies group will be informed of the decision made at interim 
analysis so that onl y the required amount of stud y medication will be packaged.
6. DOSA GE A ND A DMINISTR ATION
6.1. Scree ning/Prospective Observational Phase
As described in Section 9.1.2 , at the start of screening/ prospective observational phase, the 
subject is to be taking adiffere nt oral antidepressant treatment (on the MGH -ATRQ ) for at least 
the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, 
as well as any other ongoing medications being taken for depression at screening (including 
adjunctive/augmentation therapies), will continue from the start of Week 1 through the end of 
Week 4 of the screening/prospective observational phase ,to confirm nonresponse. Dose 
adjustment is permitted per clinical judgment, but the oral antidepressant treatment is toremain 
at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4. 
The sponsor will not supply  these antidepressant medication(s).
During this phase, antidepressant treatment adherence will be assessed using the PAQ.
After 4 weeks subjects who are non- responders to their current oral antidepressant treatment may 
be eligible to proceed to the double -blind induction phase. Non-response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4.
After the completio n of 4weeks of prospective antidepressant treatment and assessment of the 
antidepressant treatment response, eligible subjects who are entering the double -blind induction 
phase will discontinue all of their medication(s) , including adjunctive/augmentation therapies .Of 
note, subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day  
of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) 
during the screening/prospective observational phasecan continue these medications. No dose 
increases beyond the equivalent of 6mg/day  lorazepam or new benzodiazepine medications are 
permitted during the screening/prospective observational phase . If clinically  indicated, the 
antidepressant medication may be tapered and discontinued over a period of up to 3 week sper 
the local prescribing information or clinical judgment (eg, antidepressant treatments with short 
half-lives, such as paroxetine and venlafaxine XR; or tolerability  concerns) .Eligible subjec ts 
who do not require a taper ed discontinuation of their antidepressant treatment (s)can proceed 
immediately  into the double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 926.2. Double -Blind Induction Phase
During this phase, subjects will self-administer double -blind intranasal treatment with 
esketamine (56 mg or 84 mg) or placebo twice per week for 4 weeks as a fixed dose regimen at 
the study  site. In addition, subjects will simultaneously  initiate a new, open -label oral 
antidepressant (ie,duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be 
continued for the duration of this phase .
Intranasal Study Drug
On all intranasal treatment session days, a site staff member with training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivale nt course) that is up to date per local 
regulations must be present with the subject during the intranasal treatment session and the 
postdose observation period. In addition, equipment for supportive ventilation and resuscitation 
needs to be present.
Table 2describes how each intranasal treatment session will be administered in the double -blind 
induction phase. Please refer to Section 6.2.1 for guidance on blood pressure monitoring on 
intranasal dosing day s.
Table 2: Intranasal Treatment Administration during the Double -blind Induction Phase
Intranasal TreatmentTime of Intranasal Device Administrationc
0a5 minutes 10 m inutes
Intranasal deviceb1st2nd3rd
Placebo 1 spray of placebo to 
each nostril1 spray of placebo to 
each nostril1 spray of placebo to 
each nostril
Esketamine 56 m g 1 spray of esketamine to 
each nostril 1 spray of esketamine to 
each nostril1 spray of placebo to 
each nostril
Esketamine 84 m g 1 spray of esketamine to 
each nostril1 spray of esketamine to 
each nostril1 spray of esketamine to 
each nostril
a)Time 0 is defined as the time of administration of the first intranasal spray to one nostril from the first intranasal 
device. 
b)One device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays)
c)The 3 intranasal devices for each intranasal treatment session should be administered in the medication kit order 
provided by the IWRS
Instructions for use documents (subject and healthcare provider versions) for intranasal study 
drug administration will be provided as separate documents. Details regarding study  drug 
administration will be recorded in the source documents and the eCRF.
Prior to the first intranasal dose on Day 1, subjects will practice spraying (into the air, not 
intranasall y) a demonstration intranasal device that is filled with placebo solution.
All subjects will self-administer the intranasal study  drug (esketamine or placebo) at treatment 
sessions twice a week for 4 weeks at the study  site. The first treatment session will be on Day 1. 
Intranasal treatment sessions should not take place on consecutive day s.
All subjects randomized to intranasal esketamin e (56 mg or 84 mg) will start at 56 mg on Day 1. 
In a blinded manner, if a subject is randomly  assigned to 84 mg, he or she will receive an 84mg 
dose on Day 4 and for all subsequent intranasal treatment sessions. Subjects who are randoml y 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 93assigned to 56 m g will remain on that dose for all subsequent intranasal treatment sessions. No 
further adjustment to the intranasal esketamine dose is permitted for the duration of the 
double -blind induction phase.
Food will be restricted for at least 2 hours before each administration of study  drug. Drinking of 
any fluids will be restricted for at least 30 minutes before the first nasal spray .
If the subject has nasal congestion on the dosing day, an intranasal decongestant can be used to 
reduce congestion or the dosing day be delay ed (per the permitted visit window ; see the Time 
and Events Schedule ). If an intranasal decongestant is used to reduce congestion, it cannot be 
used within 1 hour prior to intranasal study  drug dosing .
On all intranasal treatment sessions, subjects must remain at the clinical site until study  
procedures have been completed and the subject is ready for discharge . Subjects should be 
accompanied by a responsible adult when released from the clinical study  site. Subjects must not 
drive a car or work with machines for 24 hours after the intranasal treatment session.
Oral Antidepressant Medication
Starting on Day 1, a new , open -label oral antidepressant treatment will be initiated in all subjects
and continued for the duration of this phase .The oral antidepressant will be 1 of 4 oral 
antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR). The 
antidepressant medication will be assigned by the investigator based on review of the 
MGH -ATRQ and relevant information regarding prior antidepressant treatments, and will be one
that the subject has not previously  had a non-response to in the current depressive episode, has 
not been previously intolerant to (lifetime), and is available in the participating country . 
Dosing of the oral antidepressant will begin on Day 1. A mandatory titration schedule is 
provided in Attachment 3. Doses are not to exceed the maximum dose defined in the titration 
schedule. If higher doses are not tolerated, a down -titration is permitted based on clinical 
judgment. However, the subject’s dose should not be lower than the following minimum 
therapeutic doses at the end of the induction phase: Sertraline (50 mg/day), venlafaxine XR 
(150 mg/day ), escitalopram (10 mg/day ), and duloxetine (60 mg/day ). While subjects requiring 
lower doses can continue in the study  and complete the double -blind induction phase, such 
subjects will not be eligible to participate in the maintenance of effect study  ESKETINTRD3003 
and will proceed to the follow -up phase after completion of the double-blind induction phase.
All subjects will be provided with an additional 4week suppl y of the oral antidepressan t 
medication to ensure there is no interruption of antidepressant therapy  during the transition to 
further clinical/standard of care.
Study -site personnel will instruct subjects on how to take and store the oral antidepressant
treatment s supplied during this study  for at-home use. A subject diary  to capture oral 
antidepressant stud y medication use will be provided.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 94On intranasal dosing days, it is recommended theoral antidepressant medication not be taken 
until at least 3 hours after an intranasal treatment session. 
6.2.1. Guidance on Blood Pressure Monitoring on Intranasal Treatment 
Session Days
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be fo llowed on intranasal dosing day s:
If subsequent to fulfilling the inclusion and exclusion criteria on Day  1(ie, applicable for all 
other intranasal treatment session days after Day 1), a subject’s pre-dose systolic blood 
pressure (SBP) is ˃140 mmHg and/or diastolic blood pressure (DBP) is ˃90mmHg, it is 
recommended to repeat the blood pressure measurement after subject rests in sitting or 
recumbent position. If after rest and repeated measurements, pre-dose SBP is ˃140mmHg 
and/or DBP is ˃90mmHg, then dosing should be postponed and the subject scheduled to 
return on the following day or within the given visit window. If the blood pressure elevation 
still persists on the next visit, the subject will be scheduled for a consultation by  cardiologist , 
other specialist, or primary  care phy sician, prior to further dosing.
If at any postdose time point on thedosing day, the SBP is 180 mmHg but <200 mmHg 
and/or the DBP is 110 mmHg but <120 mmHg, further intranasal dosing should be 
interrupted and the subject should be referred to a cardiologist , other specialist, or primary 
care ph ysician for a follow -up assessment.
-After the assessment by a  cardiologist, other specialist, or primary  care physician , if 
recommended b y the referring doctor and considered appropriate according to the clinical 
judgment for the subject to continue in the study , the subject may continue with 
intranasal dosing if the pre-dose blood pressure at the next scheduled visit is within the 
acceptable range (see bullet point above).
If at any postdose time point on the dosing day the SBP is 200 mmHg and/or the DBP is 
120 mmHg, the subject must discontinue from further dosing and the subject should be 
referred to a cardiologist , other specialist, or primary  care physician for a follow -up 
assessment.
During the double -blind induction phase, at 1.5 hours postdose, if the SBP is 160 mmHg and/or 
the DBP 100 mmHg, assessments should continue every  30 minutes until :
the blood pressur e is<160 mmHg SBP and <100 mm Hg DBP , or 
in the investigator’s clinical judgment ,the subject it is clinically  stable and can be 
discharged from the study site, or 
the subject is referred for appropriate medical care, if clinically  indicated.
if the blood pressure remains ≥180 mmHg SBP and/or ≥110 mmHg DBP, 2hours after 
dosing, the subject should be referred for immediate medical treatment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 956.3. Follow -up Phase
Subjects who receive at least 1 dose of intranasal study  medication in the double -blind induction 
phase ,but do not enter the subsequent maintenance clinical study  ESKETINTRD3003, will 
proceed into the 24 week follow -up phase . 
No intranasal stud y medication will be administered during this phase.
At the start of the follow -up phase , further clinical/standa rd of care for the treatment of 
depression will be arranged by  the study  investigator and/or the subject’s treating phy sician.
The decision to continue the oral antidepressant medication in this phase will be at the discretion 
of the investigator; however, in order to better assess potential withdrawal symptoms from 
intranasal study  medication, the oral antidepressant medication should be continued for at least 
the first 2 weeks of the follow -up phase unless determined as not clinicall y appropriate.
7. TREA TMENT COMPLIA NCE
The investigator or designated study -site personnel will maintain a log of all intranasal study 
drug and oral antidepressant medication dispensed and returned. Drug supplies for each subject 
will be inventoried and acco unted for throughout th e study .
Subjects will receive instructions on compliance with the oral antidepressant treatment . During 
the course of the study , the investigator or designated study -site personnel will be responsible for 
providing additional instruction to re-educate anysubject to ensure complian cewith taking the 
oral antidepressant .A subject diary  will be provided to capture oral antidepressant study 
medication use. 
Antidepressant treatment adherence during the screening/prospective observational phase will be 
assessed using the PAQ. Missing  4days of antidepressant medication in the prior 2 week period 
will be considered as inadequate adherence.
Antidepressant treatment compliance during the double -blind induction and follow -up phase s
will be assessed b y performing pill counts (ie, compliance check) and drug accountabilit y.
All doses ofintranasal study  drug will be self-administered by the subjects at the investigative 
site under the direct supervision of the investigator or designee , and will b e recorded .
8. PRESTUDY AND CONCOMI TANT THERAPY
Prestudy  non-antidepressant therapies administered up to 30 days before the start of the 
screening/prospective observational phase must be recorded at the start of this phase. 
All antidepressant treatment(s), including adjunctive treatment for MDD, taken during the 
current depressive episode (ie,including those taken more than 30 days prior to the start of the 
screening/prospective observational phase) will be recorded at the start of the 
screening/prospective observational phase. In addition, information will also be obtained 
regarding any history  of intolerance to any of the 4 antidepressant choices (ie, duloxetine, 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 96escitalopram, sertraline, and venlafaxine XR). Antidepressant treatments which are not listed on 
the MGH -ATRQ but were used, or are currently being used as antidepressant treatment in the 
current depressi ve episode must be recorded in ‘Concomitant Therapy ’ eCRF.
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for an indication other than depression (eg, insomnia) 
should be continued during the screening/prospective observational phase but must be 
discontinued before the start of the double- blind induction phase.
Concomitant therapies must be recorded throughout the study , beginning with signing of the 
informed consent and continuing up to the last visit. Information on c oncomitant therap ies 
should also be obtained beyond this time only in conjunction with new or worsening adverse 
events until resolution of the event.
Subjects should continue to take their permitted concomitant medications (eg, antihy pertensive 
medications) at their regula r schedule; however, restrictions as outlined in Section 4.3and 
Attachment 1should be taken into account. Of note, if a subject has routinely  taken his/her oral 
antihy pertensive medications in the morning on dosing days,the morning dose should be taken 
prior to intranasal dosing.
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can continue 
receiving psychotherap y, however, CBT must have been ongoing for the last 3months prior to 
the start of the screening/prospective observational phase . With the exception of new CBT,
which is prohi bited, new psychotherap y is allowed during the study . Any change in existing 
therap y or new therap y must be documented on the concomitant therapies form.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; nonpharmacologic therapies, such as psychotherapy , electrical stimulation, 
acupuncture, special diets, and exercise regimens) dif ferent from the stud y drug must be recorded 
in the eCRF. Modification of an effective preexisting therap y should not be made for the explicit 
purpose of entering a subject into the study , unless permitted by protocol (eg, adjustment of 
blood pressure medications.
Rescue Medications
Rescue medications will not be supplied by the sponsor . In case of treatment-emergent adverse 
events that cannot be resolved by stopping further administration of intranas al 
esketamine/placebo, the following rescue medications may  be considered:
For agitation or anxiety : As required, midazolam (maximum dose 2.5 mg orally or IM) or 
short act ing benzodiazepine
For nausea: As required, ondansetron 8 mg sublinguall y, metoclopramide (10 mg orally or 
IV or IM) or dimenhy drinate (25 to 50 mg, IV or IM)
Unless clinically  indicated, itis recommended that transient increase sin blood pressure not 
be treated, as the blood pressure typically  returns to predose values in 2 hours. The effect of 
any treatm ent may  result in hy potension.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 97Prohibited Medications
A list of prohibited medications is provided in Attachment 1as general guidance for the 
investigator (but is not all inclusive).
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibit ed therapies are administered.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, biomarker, 
pharmacogenomic, medical resource utilization, health economic, and safet y measurements 
applicable to this study .
With the exception of postdose assessments, visit-specific subject -reported outcomes
assessments should be conducted or completed before any tests, procedures, or other 
consultations for that clinic visit to prevent influencing subject perceptions. A recommended 
order of stud y procedures will be provided to sites as a separate document.
Actual dates and times of assessments will be recorded in the source documentation and eCRF.
The approximate total blood volume to be collected from each subject will be 116.0 mL (Table 3). 
Repeat orunscheduled samples may be taken for safet y reasons or for technical issues with the 
samples. Additional serum or urine pregnancy  tests may be performed, as determined necessary 
by the investigator or required by local regulation, to establish the absence of pregnancy  at any 
time during the subject's participation in the study .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 98Table 3: Volume of Blood to Be Collected From Each Subject
Type of Sam pleVolume per 
Sample (mL)No. of Samples 
per SubjectTotal Volum e of 
Blood (mL)a
Screening/Prospective Observational Phase
Serum chemistryb5 1 5
TSH 3.5 1 3.5
Hem atologyc2 1 2
Biomarker: protein 10 1 10
Biomarker: DNA 6 1 6
Biomarker: RNA 2.5 1 2.5
Tricyclic Antidepressant Blood levele
FT4f6
3.51
16
3.5
Double -blind Induction Phase
Serum chemistry 2.5 2 5
Hem atology 2 2 4
Pharm acokinetics 2 4 8
Biomarker: protein (at Visits 2.1 , 2.4, and 2.9)    10 3 30
Biomarker: DNA 6 1 6
Biomarker: RNA 2.5 3 7.5
Follow -up Phase
Serum chemistry 2.5 1 2.5
Hem atology 2 1 2
Biomarker: protein 10 1 10
Biomarker: RNA 2.5 1 2.5
Approxim ate volume of blood collected during the study 116.0 mL
Abbreviations: DNA, deoxyribonucleic acid; RNA, ribonucleic acid; TSH, thyroid -stimulating hormone
a)Calculated as number of samples multiplied by amount of blood per sample.
b)Serum chemistry includes serum -hCG pregnancy tests (for w omen of childbearing potential) and lipid panel.
c)As needed, HbA1c will be measured from the sample collected for hematology .
e)For specific tricyclic antidepressants wh ich are being taken at a dose below  the MGH -ATRQ minimum 
therapeutic dose, a blood level that is within therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressant treatment.
f)For any subject (regardless of thyroid h istory), if the TSH value is out of range, a free th yroxine (FT4) will be 
conducted .
Note: An indw elling IV cannula may be used for blood sample collection.
Note: Repeat or unscheduled samples may be taken for safety reasons or technical issues with the sa mples.
9.1.2. Screening /Prospective Observational Phase
Prior to conducting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written ICF to each subject. After signing the ICF, subjects who are 18 
(or older if the minimum legal age of consent in the country  in which the study  is taking place is 
>18) to 64 years of age (inclusive) will be screened to determine eligibility  for study 
participation (please refer to the study  entry  criteria listed in Section 4). 
Subjects must meet DSM -5 diagnostic criteria for single -episode MDD (if single -episode MDD, 
the duration must be  2 years) or recurrent MDD, without psy chotic fea tures, based upon clinical 
assessment and confirmed by the MINI. In addition, at the start of the screening/prospective 
observational phase, the subject must have an IDS -C30total score  34.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 99At the start of this phase, subjects must have had non-response (≤ 25% improvement) to 1but 
5 (if current episode is > 2 years,upper limit is applicable to only the last 2 years) oral
antidepressant treatments taken at adequate dosage and for adequate duration, asassessed using 
the MGH -ATRQ and documented by records (eg, medical /pharmacy /prescription records or a 
letter from treating physician , etc.), for the current episode of depression. In addition, at the start 
of the screening/prospective observational phase, the subject is taking a different oral
antidepressant treatment (on the MGH -ATRQ) for at least the previous 2 weeks at or above the 
minimum therapeutic dose. This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/ augmentation therapi es), will 
continue from the start of Week 1 through the end of Week 4 of the screening/prospective 
observational phase to confirm non-response prospectively . Dose adjustment is permitted per 
clinical judgment, but the oral antidepressant treatment is toremain at or above the minimum 
therapeutic dose (per the MGH- ATRQ) through the end of Week 4.
Antidepressant treatment adherence will be assessed using the PAQ. Missing 4days of 
antidepre ssant medication in the prior 2 -week period will be considered as inadequate adherence.
The subject’s current major depressive episode , depression symptom severity (Week 1 MADRS
total score ≥28 require d),and antidepressant treatment response inthe current depressive episode 
must beconfirmed using aSite I ndependent Qualification Assessment.
An independent, blinded rater will perform remote MADRS assessments to assess depressive 
symptoms during this phase. 
After 4 weeks, subjects who are non-responders to the current oral antidepressant treatment may 
be eligible to proceed to the double -blind induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤ 25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥ 28 on Week 2 and Week 4 . Eligib le 
subjects (determined b y remote blinded rater s) who are entering the double -blind induction phase 
will discontinue all of their current medication(s) being used for depression treatment, including 
adjunctive/augmentative therapies, and any other prohibit ed psychotropic medications, including 
adjunctive atypical antipsy chotics. Subjects who were taking b enzodiazepines (at dosages equal 
to or less than the equivalent of 6mg/day  of lorazepam) and/or permitted nonbenzodiazepine 
sleep medications (eg, zolpide m, zaleplon) during the screening/prospective observational phase 
can continue these medications during the induction phase. No dose increases beyond the 
equivalent of 6mg/day  of lorazepam or new benzodiazepine medications are permitted during 
the induction phase , with the exception of the use of permitted benzodiazepine rescue 
medication. Benzodiazepines and non-benzodiazepine sleeping medications (eg, zolpidem, 
zaleplon, eszopiclone, and ramelteon) are prohibited within 12hours prior to the start of each 
intranasal treatment session or cognition testing . All other subjects who do not proceed to the 
double -blind induction phase will end study participation at this time.Nofurther study  visits or 
follow-up isrequired.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 100Optional Antidepressant Taper Period
Since all non-responder subjects will be starting a new oral antidepressant during the double -
blind induction phase, no washout or drug-free period is required after discontinuing the current 
antide pressant treatment. However, an additional, optional period of up to 3 weeks is permitted 
to taper and discontinue the current oral antidepressant medication per the local prescribing 
information or clinical judgment.
The taper period should not start until after the completion of 4 weeks of prospective 
antidepressant treatment and assessment of the antidepressant treatment response.
9.1.3. Double -Blind Induction Phase
During this phase, subjects will self-administer double -blind intranasal treatment with 
esketami ne (56 mg or 84 mg) or placebo twice per week for 4 weeks as a fixed dose regimen. In 
addition, subjects will simultaneously  initiate a new, open -label oral antidepressant (please refer 
to Section 6, Dosage and Administration).
Approximately  348 eligible subjects with TRD will be random ly assigned to 1 of the following  
3double -blind intranasal treatment groups ata 1:1:1 ratio (approxim ately 116 subjects per 
group):
Intranasal placebo
Intranasal esketamine (56 mg)
Intranasal esketamine (84 mg)
On the same day (ie, Day 1), subjects will be switched to a new, open -label oral antidepressant 
treatment. The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine XR). The antidepressant medication assigned by the 
investigator (based on review of the MGH -ATRQ and relevant prior antidepressant treatment 
information) will be onethat the subject has not previously  had a non-response to in the current 
depressive episode, has not been previously  intolerant to (lifetime), and is available in the 
participating country . Dosing of the oral antidepressant will begin on Day 1. A mandatory 
titration schedule is provided inAttachment 3. Doses arenot to exceed the maximum dose 
defined in the titration schedule.
For information obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. During telephone contact visits with the 
subject b y site personnel , adverse event and concomitant therapy  information will be obtained. In 
addition, specified clinician -administered assessments will be performed by appropriatel y 
qualified staff.
At the end of the double -blind induction phase, subjects who are responder s (defined as 50% 
reduction in the MADRS total score from baseline [Day  1 pre-randomization] to the end of the 
4-week double -blind induction phase ) may be eligible to enter the subsequent maintenance 
clinical study  (Study  ESKETINTRD3003). To main tain study  blinding, all responder subjects, 
including responders to the active comparator (ie, oral antidepressant plus intranasal placebo),
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 101may be eligible to enter Study  ESKETINTRD3003. Participation in ESKETINTRD3003 will 
begin immediatel y after the completion of the double -blind induction phase . Subjects will 
receive oral antidepressant medication and will be instructed to continue taking their oral 
antidepressant medication through their next study visit (ie, first study visit of the stabilization 
phase in Study  ESKETINTRD3003).
Those subjects who do not enter Study  ESKETINTRD3003 will proce ed into the follow -up 
phase. 
Early Withdrawal
If a subject withdraws before the end of the double -blind induction phase for reasons other than 
withdrawal of consen t, the Early  Withdrawal visit should be conducted within 1 week of the date 
of discontinuation, followed by the follow up phase .If the Early Withdrawal visit occurs on the 
same day as a scheduled visit, the early withdrawal visit can be performed on the same day and 
duplicate assessments are not required.
Further clinical/standard of care for the treatment of depression will be arranged by the study 
investigator and/or the subject’s treating physician. The study  investigator and/or treating 
physician will determine whether or not the current oral antidepressant medication will continue.
If applicable, subjects who withdraw earlywill receive additional oral antidepressant medication 
and it will be recommended that theycontinue taking the oral antidepressant medication for at 
least the first 2 weeks of the follow -up phase unless determined as not clinically  appropriate.
9.1.4. Follow -up Phase
All subjects who receive at least 1 dose of intranasal study  medication in the double -blind 
induction phase and are not participating in the subsequent ESKETINTRD3003 study  will 
proceed into the 24-week follow -up phase. Clinic visits and remote assessment visits will be 
performed as specified in the Time and Events Schedule . During this phase , safet y and 
tolerability , including potential withdrawal symptoms, following discontinuation of intranasal 
esketamine will be assessed . In addition, data will be collected to assess the course of the 
subject’s current major depressive episode over a 6 month period.
Further clinical/standard of care for the treatment of depression will be arranged by the study 
investigator and/or the subject’s treating physician. No intranasal study  medication will be
administered during this phase. In order to better assess potential withdrawal sy mptoms from the 
intranasal medication, the oral antidepressant medication should be continued for at least the first 
2 weeks of the follow up phase unless determined as not clinically  appropriate. T he decision to 
continue the antidepressant will be at the discretion of the investigator.
An open -label safet y extension study , 54135419TRD3008, may be available (pending country  
and site approval) for eligible subjects participating in the ESKETINTRD3001 study . Please 
refer to the 54135419TRD3008 protocol for full details when available.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 102If information is obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. 
Any clinicall y significant abnormalities persisting at the end of the study  will be followed by  the 
investigator until resolution or until a clinicall y stable endpoint is reached. All adverse events 
and special reporting situations, whether serious or non- serious, will be reported until comple tion 
of the subject's last study -related procedure.
9.2. Efficacy
9.2.1. Evaluations
It is recommended that the various subject -reported outcome assessment s be completed prior to 
other procedures.
9.2.1.1. Primary  Efficacy  Evaluation
The primary  efficacy  evaluation will be the MADRS total score. The MADRS will be performed 
by independent remote raters during the study , using the Structured Interview Guide for the 
Montgomery  Asberg Depression Rating Scale (SIGMA: Williams 2008) .
The MADRS is a clinician -rated scale designed to measure depression severit y and detects 
changes due to antidepressant treatment .53The scale consists of 10 items, each of which is 
scored from 0 (item not present or normal) to 6 (severe or continuous presence of the s ymptoms), 
for a total possible score of 60. Higher scores represent a more severe condition. The MADRS 
evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, 
lassitude, inability  to feel (interest level ), pessimistic thoughts, and suicidal thoughts. The test 
exhibits high inter -rater reliability .
The typical recall period for the MADRS is 7 daysand will be used for the primary  efficacy 
evaluation.
9.2.1.2. Key Secondary  Efficacy  Evaluation (Clinician -completed )
The MADRS will also be administered using a modified recall period of 24 hours for the key 
secondary  efficacy  evaluation related to onset of clinical response by Day 2 that is maintained 
for the duration of the double -blind induction phase with one excursion allowed.
The MADRS with a 24- hour recall period will be used on Day  2. The feasibility  of this shortened 
recall period has been confirmed with patients, and physicians, and there are data supporting the 
psychometric properties of this shortened recall period (data on file). The MADRS with a 7day 
recall will be used for all subsequent MADRS assessments used for the key secondary  efficacy 
evaluation (maintenance of clinical response achieved on Day 2  for duration of double -blind 
induction phase).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 1039.2.1.3. Key Secondary  Effica cy Evaluation (Patient -reported Outcome )
9.2.1.3.1. SDS
The SDS will be used to assess the secondary  objective of functional impact and associated 
disability . The SDS is a subject -reported outcome measure and is a 5-item questionnaire which 
has been widel y used and accepted for assessment of functional impairment and associated 
disability .49,81,The first three items assess disruption of (1) work/school, (2) social life, and 
(3)famil y life/home responsibilities using a 0-10 rating scale. The score for the first three items 
are summed to create a total score of 0-30 where a higher score indicates greater impairment. It 
also has one item on days lost from school or work and one item on day s when underproductive. 
The recall period for this study  is 7 day s.
9.2.1.3.2. PHQ -9 
The PHQ -9 is a 9-item, subject -report ed outcome measure that will be used to assess depressive 
symptoms.84The scale scores each of the 9 sy mptom domains of the DSM -5 MDD criteria and it 
has been used both as a screening tool and a measure of response to treatment for depression. 
Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, 
and 3=nearl y every  day). The subject’s item responses are summed to provide a total score 
(range of 0 to 27) with higher scores indicating greater severit y of depressive symptoms. The 
recall period is 2 weeks. 
9.2.1.4. Other Secondary  Efficacy  Evaluations (Clinician -completed)
9.2.1.4.1. CGI-S
The CGI-S provides an overall clinician -determined summary  measure of the severit y of the 
subject’s illness that takes into account all available information, including knowledge of the 
subject’s history , psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the subject’s abilit y to function.35The CGI-S evaluates the severit y of 
psychopathology  on a scale of 0 to 7. Considering total clinical experience, a subject is assessed 
on severity  of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at 
all ill); 2=borderline mentally  ill; 3=mildly  ill; 4=moderatel y ill; 5=markedly  ill; 6=severel y ill; 
7=among the most extremely  ill patients. The CGI-S permits a global evaluation of the subject’ s 
condition at a given time.
9.2.1.5. Other Secondary  Efficacy  Evaluations (Patient -reported Outcomes)
9.2.1.5.1. GAD-7 
The 7-item subject -reported GAD -7 will be used to measure the secondary  objective of 
symptoms of anxiety . The GAD-7 is a brief and validated measure of overall anxiety . Each item
is rated on a 4-point scale (0=not at all; 1=several days; 2=more than half the days; 3=nearl y 
every  day).83Item responses are summed to yield a total score ( range of 0 to 21), with higher 
scores indicat ingmore anxiety . The recall period is 2 weeks.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 1049.2.1.5.2. EQ-5D-5L
The EQ-5D- 5L is a standardized instrument for use as a measure of health outcome, primarily 
designed for self -completion by  respon dents. It consists of the EQ -5D- 5Ldescriptive sy stem and 
the EQ visual analogue scale (EQ- VAS). The EQ-5D- 5L descriptive system compris es the 
following 5 dimensions: Mobility , self-care, usual activities, pain/discomfort and 
anxiety /depression. Each of the 5 dimensions is divided into 5 levels of perceived problems 
(Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, and L evel 5 indicating extreme problems).
The subjec t selects an answer for each of the 5 dimensions considering the response that best 
matches his or her health “today .” The descriptive system can be represented as a health state. 
The EQ-VAS self-rating records the respondent’s own assessment of his or heroverall health 
status at the time of completion, on a scale of 0 to 100 . 
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely  to be around 1 minute.
9.2.2. Endpoints
9.2.2.1. Primary  Endpoint
The primary  efficacy  endpoint is the change in the MADRS total score as measur ed by the 
change from baseline (Day  1  p rior to randomization) to the end of the 4week double -blind 
induction phase.
9.2.2.2. Secondary  Endpoints
The first key secondary  endpoint is the proportion of subjects showing onset of clinical response 
by Day 2 that is maintained through the end of the 4week double -blind induction phase . Onset 
of clinical response is defined as 50% reduction in the MADRS total score by the day after 
taking the first dose of double -blind medication (Day 2)that continued through the end of the 4-
week double -blind induction phase with one excursion allowed. Subjects who discontinue the 
study  prior to the end of the double-blind induction phase will not be considered to have 
maintained clinical response.
The second key secondary  endpoint is the change in SDS total score as measured by the change 
from baseline (Day  1 prior to randomization) to the end of the 4-week double -blind induction 
phase.
The third key secondary  endpoint is the change from baseline (Day  1 prior to randomization) to 
the end of the 4-week double -blind induction phase in subject -reported depressive symptoms, 
using the PHQ -9 total score.
Other secondary  efficacy endpoint s include:
Proportion of responders (50% reduction from baseline in MADRS total score) atthe end 
of the 4 week double -blind induction phase
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 105Proportion of subjects in remission (MADRS 12) at the end of the 4week double -blind 
induction phase
Change from baseline (Day  1 prior to randomization) to the end of the 4 week double -blind 
induction phase in: 
–Severity  ofdepressive illness, using the CGI -S
–Anxiety  symptoms, as measured by  the GAD -7
–Health-related qualit y of life and health status , as assessed b y the EQ -5D- 5L
9.3. Pharmacokinetics
Whole blood samples will be used to evaluate the PK of esketamine. Plasma collected for PK 
may additionally  be used to evaluate safet y or efficacy  aspects that address concerns arising 
during or after the stud y period. Genetic analyses will not be performed on these serum samples. 
Subject confidentiality will be maintained.
9.3.1. Evaluations
Venous blood samples of approximately 2 mL will be collected for measurement of plasma 
concentrations ofesketamine, noresketamine, and other metabolites (if warranted) at the time 
points specified in the Time and Events Schedule. The exact dates and times of PK blood 
sampling must be recorded.
9.3.2. Analytical Procedures
Plasma samples will be analyzed to determi ne concentrations ofesketamine (and noresketamine , 
if warranted) using a validated, specific, achiral, and sensitive liquid chromatograph y-tandem 
mass spectrometry  (LC-MS/MS ) method by or under the supervision of the sponsor. If required, 
some plasma samples may be analy zed to document the presence of other analy tes 
(eg,circulating metabolites or denatonium) using a qualified research method. In addition, 
plasma PK samples may  be stored for future anal ysis of the metabolite profile.
The bioanaly tical report, including a description of the assay  and a summary  of the assay  
performance data, will be included in the final clinical study  report as an addendum.
9.3.3. Pharmacokinetic Parameters
The plasma concentration -time data of esketamine (and noresketamine , if warranted) will be 
analyzed using population PKmodeling. Typical population values of basic PKparameters 
(eg,esketamine clearance distribution volume) will be estimated together with the 
inter-individual variability . Effects of subject demographics, laboratory  parameter values, and 
other covariates on the PKof esketamine will be explored. The results of the population PK
analyses may  be reported separately .
9.4. Pharmacokinetic/Pharmacody namic Evaluations
The relationship between MADRS total score (and possibly  selected adverse events as additional 
PDparameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 106graphical analysis, suitable models will be applied to describe the exposure -effect relationships. 
The results of the exposure-response evaluations will be presented in a separate report.
9.5. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA )Evaluations
During the study , blood will be collected for the assessment of biomarkers at the time points 
indicated in the Time and Events schedule. The biomarker blood samples should be collected 
prior to dosing . It is preferred that subjects adhere to a low fat diet on the day of sample 
collection.
In blood, biomarkers (protein, metabolite, and ribonucleic acid [ RNA ])related to (but not limited 
to) the immune system activity , hypothalamus pituitary  adrenal (HPA) axis activation, 
neurotrophic factors ,and metabolic factors will be investigated. Biomarkers may be added or 
deleted based on scientific information or techn ical innovations under the condition that the total 
volume of blood c ollected will not be increased.
The biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to investigate the relationship between depression severity and phenot ypes and 
biomarkers.
Blood samples for DNA analyses will be collected at the time points indicated in the Time and 
Events Schedule for the assessment of genetic and epigenetic variation in genes in pathway s 
relevant to depression (eg, HP A axis, inflammation, growth factors, monoamine transporters, ion 
channels, and circadian rhy thm).
Genoty ping will be conducted onl y on the screening sample; pharmacogenomic and epigenetic 
evaluations may  be performed on an y/all collected samples.
DNA samples will be used for research related to esketamine , oral antidepressants, TRD, or 
MDD . They  may  also be used to develop tests/assay s related to esketamine , oral antidepressants, 
TRD, or MDD . Pharmacogenomic research may consist of the analy sis of 1or more candidate 
genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to 
esketamine , oral antidepressants, TRD, or MDD clinical endpoints.
Further information regarding handling, shipment, and labeling of biological samples will be 
provided in a separate laboratory  manual.
9.6. Medical Resource Utilization
Medical resource utilization data, associated with healthcare encounters, will be collected during 
the follow -up phase of the study . Protocol -mandated procedures, tests, and encounters are 
excluded. The data collected may be used to conduct exploratory  economic analyses and will 
include:
Number ,duration, and t ypeof healthcare encounters (inpatient and outpatient)
Duration of hospitalization (total day s length of stay , including duration by wards )
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 1079.7. Safety  Evaluations
Details regarding the Independent Data Monitoring Committee are provided in Section 11.10 .
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and E vents Schedule.
There may  be instances where a subject has started a sche duled clinic visit in which an intranasal 
treatment session is planned, but due topredose vital sign measurements (e.g., blood pressure 
value) , a decision has been made to postpone/d elay the intranasal treatment session within the 
visit window permitted per protocol. In such cases, all time points (including predose) of the 
following assessments must be repeated on the actual intranasal treatment session day: vital sign 
(ie, blood pressure, pulse, respiratory  rate, andtemperature) , 12- lead ECG, C- SSRS (since last 
visit), MOAA/S, pulse oximetry , BPRS+, and CADSS .
Adverse Events
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  the investigator as specified in Section 12, Adverse Event Reporting.
TEAEs of special interest will be examined separately  (please refer to Sections 3.2.6 and 11.9).
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and a urine sample for urinal ysis will be 
collected. The investi gator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the adverse event section of the 
eCRF. The laboratory  reports must be filed with the source documents.
The use of local laboratories is allowed in cases where initiation of treatment or safety  follow -up 
is time-critical and the central laboratory  results are not expected to be available before the need 
to begin dosing or if actions need to be taken for safet y reasons.
The f ollowing tests will be performed by  the central laboratory , unless noted otherwise:
Hematology Panel
-hemoglobin -platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell (WBC) count with differential
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 108Serum Chemistry Panel
-sodium -alkaline phosphatase
-potassium -creatine phosphokinase (CPK)
-chloride -calcium
-bicarbonate -phosphate
-blood urea nitrogen (BUN) -albumin
-creatinine -total protein
-glucose -total bilirubin
-aspartate aminotransferase (AST)
-alanine aminotransferase (ALT)
-gamma -glutam yltransferase (GGT)
Urinalysis
Dipstick Sediment (if dipstick result is abnormal)
-specific gravit y -red blood cells
-pH -white blood cells
-glucose -epithelial cells
-protein -crystals
-blood -casts
-ketones -bacteria
-bilirubin
-urobilinogen
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cytometry  or microscop y will be used to measure 
sediment. In case of discordance between the dipstick results and the flow cytometric 
results, the sediment will be examined microscopically .
The following tests will be done at time points specified in the Time and Events Schedule or as 
required based on subject status (noted below) :
Lipid panel: Total cholesterol, low density  lipoprotein (LDL)-cholesterol, high density  
lipoprotein ( HDL )-cholesterol , and trigl ycerides
Serum and u rine pregnancy  testing (for women of childbearing potential only )
Urine Drug Screen: Barbiturates, methadone, opiates, cocaine, cannabinoids (cannabinoids 
are only exclusionary  o n Day 1  p redose) , phency clidine, and 
amphetamine/methamphetamine
Alcohol breath test 
Thyroid- stimulating hormone (TSH)
Free thyroxine (FT4) , only if required for abnormal TSH (refer to Inclusion 
criteria) Calculation of creatinine clearance
Glycated hemoglobin ( HbA1c ) test
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 109A serum follicle stimulating hormone (FSH) level test, only if required for documentation
that a female subject is not of childbearing potential (refer to Inclusion Criteria No. 9)
Single, 12-Lead ECG
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg,television, cell phones). Subjects should rest in a supine position for at least 5minutes 
before ECG collection and should refrain from talking or moving arms or legs.
All ECG tracings will be sent to a central ECG laboratory . The ECGs will be read at the 
scheduled time points and summarized by  a central ECG laboratory . The cent ral ECG laboratory 
will send the sponsor an electronic copy of the data for inclusion in the clinical database. In 
addition, the investigator or sub-investigator is required to review all ECGs at the study  visit to 
assess for any potential safet y concerns or evidence of exclusionary  conditions.
The subject must be discontinued at an y time point after baseline (Day 1, predose), if :
- QTcF change from baseline is ≥ 60 msec andQTcF > 480 msec, or 
-QTCF > 500 msec.
Vital Signs (temperature, pulse/heart rate , respiratory rate, blood pressure)
Blood pressure and pulse/ heart rate measurements will be assessed supine with a completely 
automated device or using manual techniques.
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of 
rest in a quiet setting without distractions (eg, television, cell phones).
For further details regarding blood pressure, please see Guidance on Blood Pressure Monitoring 
on Intranasal Dosing Day s (Section 6.2.1 ).
Tympanic temperature is recommended.
An automated device will be used for measurement of respiratory  rate.
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation. On each dosing day, the 
device will be attached to the finger, toe, or earbefore the first nasal spray  and then, after the 
first spray  it will be monitored and documented. Any arterial oxygen saturation (SpO 2) <93% 
should be confirmed b y an additional measurement on another part of the body .
On intranasal treatment session days, pulse oximetry  will be recorded every  15 minutes from 
predose to t=1.5 hours postdose. Ifoxygen saturation levels are <93% at any time during the 
1.5hour postdose interval, pulse oximetry  will be recorded every  5 minutes until levels return to 
93% or until the subject is referred for appropriate medical care, if clinically  indicated.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 110Physical Examination , Height, Body Weight , and Neck Circumference
Physical examinations, body  weight , and height will be performed /measured as per the Time and 
Events Schedule.
In addition, body  mass index (BMI) will be calculated and neck circumference measured as part 
of the information required for the STOP -Bang questionnaire.
Nasal Examinations
Nasal examinations (including the upper respiratory  tract/throat) will be conducted by  a qualified 
healthcare practitioner. The objective of the examination at screening isto rule out any subjects 
with anatomical or medical conditions that may  impede dr ug delivery  or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary /blood vessel disruption ,and epistaxis ,
and will be graded as follows: Abs ent, mild, moderate, or severe. 
Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire. The nasal symptom questionnaire was 
developed by the sponsor to assess nasal tolerability  following intranasal administration of study  
drug. The questionnaire asks about nasal s ymptoms, which are rated by  the subject as none, mild, 
moderate, or severe, based on how he or she feels at the time of the assessment.
C-SSRS
The C -SSRS will be performed to assess potential suicidal ideation and behavi or. 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in the National Institute of Mental Health Treatment of Adolescent Suicide 
Attempters Study  to assess severit y and track suicidal events through any treatment.69It is a 
clinical interview providing a summary  of both suicidal ideation and behavior that can be 
administered during any  evaluation or risk assessment to identify  the level and ty pe of suicidality  
present. The C -SSRS can also be used during treatment to monitor for clinical worsening.
Two versions of the C-SSRS will be used in this study , the Baseline/Screening version, and the 
Since Last Visit version. The Baseline/Screening version of the C-SSRS will be used in the 
screening/prospective observational phase. In this version, suicidal ideation will be assessed at 
2time points (“lifetime” and “in the past 6 months” )and suicidal behavio r will be assessed at 
2time points (“lifetime” and “in the past year”).All subsequent C-SSRS assessments in this 
study  will use the Since Last Visit version, which will assess suicidal ideation and behavior since 
the subject’s last visit.
CADSS
The CADSS is an instrument for the measurement of present- state dissociative symptoms ,4and 
will be administered to assess treatment -emergent dissociative sy mptoms.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 111The CADSS consists of 23 subjective items, divided into 3 components: Depersonalization 
(Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia 
(Items 14, 15, and22). Participant’s responses are coded on a 5-point scale (0=notat all through 
to 4=extremely ). CADSS has excellent inter -rater reliability  and internal consistency . 
BPRS+
Four items of the BPRS will be administered to assess potential treatment -emergen t psychotic 
symptoms. 
The BPRS is an 18-item rating scale that is used to assess a range of psychotic and affective 
symptoms ,rated from both observation of the subject and the subject's own report.64It reportedl y 
provides a rapid and efficient evaluation of treatment response in clinic drug studies and in 
clinical settings.73
Only  the 4-item positive symptom subscale BPRS+ ( ie, suspiciousness, hallucinations, unusual 
thought content, and conceptual disorganization) will be used in this study . It is highl y sensitive 
to change, and excellent inter-rater reliability  can be achieved with training and a standard 
interview procedure. 
MOAA/S
The MOAA/S will be used to measure treatment -emergent sedation ,with correlation to levels of 
sedation defined b y the American Societ y of Anesthesiol ogists (ASA) continuum.
The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA 
continuum for general anesthesia )to 5=readil y responds to name spoken in normal tone (awake; 
corresponds to ASA continuum for minimal sedation).
On each intranasal dosing day, the MOAA/S will be performed every  15 minutes from predose
to t=+1.5 hours postdose.
If the score is 3 at any time during the 1.5 hour postdose interval, the MOAA/S will be 
performed every  5 minutes until a score of 4 is rea ched (at which point a frequency  of every 
15 minutes can be resumed until t=+1.5 hours post dose). 
If a subject does not have a score of at least 5 at t=+1.5 hours postdose, they  should continue 
to be monitored. For subjects with a score of 4, the assessm ent should be repeated every 
15minutes. And for subjects with a score of 3, the assessment should be repeated every 
5minutes until the score returns to 5 or the subject is referred for appropriate medical care, 
if clinically  indicated.
CGADR
The CGA DRwill be used to measure the subject’s current clinical status and is the clinician’s 
assessment of the readiness to be discharged from the study  site.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 112The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status ( eg, sedation, blood pressure , and other adverse 
events )?”
On each intranasal dosing day, the CGADR will be performed at 1 hour and 1.5 hours postdose; 
if the response is not “Yes” at 1.5 hours postdose, the assessme nt will be repeated every 
15minutes until a “Yes” response is achieved or until the subject is referred for appropriate 
medical care ,if clinically indicated .A subject should not be discharged prior to the 1.5 hour time 
point.
On all intranasal treatment session days, subjects must remain at the clinical site until study 
procedures have been completed and the subject is read y for discharge.
PWC -20
The PWC -20 will be administered to assess potential withdrawal symptoms following cessation 
of intranasal esketamine treatment. An assessment will be performed on Day 25 to establish a 
baseline prior to discontinuation of intranasal esketamine treatment. In order to better assess 
potential withdrawal symptoms from the intranasal medicat ion it is recommended that the oral 
antidepressant medication be continued for at least the first 2 weeks of the follow up phase 
unless determine d as not clinically  appropriate.
The PWC -20 is a 20-item simple and accurate method to assess potential development of 
discontinuation symptoms after stopping of study drug. The PWC -20 is a reliable and sensitive 
instrument for the assessment of discontinuation symptoms.71Discontinuation symptoms occur 
early and disappear rather swiftl y, depending upon speed of taper, daily medication dose, and 
drug elimination half- life.
BPIC- SS
The BPIC-SS is a subject -reported outcome measure that was developed to identify an 
appropriate bladder pain syndrome/interstitial cystitis population for clinical studies evaluating
new treatments for bladder pain s yndrome .40
The BPIC-SS will be used to monitor subjects for potential symptoms of cystitis, bladder pain, 
and interstitial cy stitis. 
The BPIC-SS includes 8 questions with a recall period of the past 7 days, and addresses key 
symptoms identified by subjects with BPS including symptom concepts of pain and/or pressure 
of the bladder andurinary  frequency .Subjects respond to items using a 5-point scale (0=never , 
1=rarely, 2=sometimes, 3=most of the time, 4=alway sfor frequency -based questions ,and 0=not 
at all , 1=a little, 2=somewhat, 3=moderately, and 4=a great deal for items related to bother 
associated with symptoms ). Question 8 records the worst bladder pain in the last 7 days using a 
0-10 numerical rating scale. A total score is calculated by adding up the numbers beside the 
response options chosen by  the subject . The range of scores for the scale is 0 to 38 .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 113A total score of 19 or more has demonstrated good sensitivity /specificity  and is considered a 
relevant cut -off to distinguish those with significant bladder s ymptoms or cy stitis .40
If any items are missing, a total score cannot be calculated.
If a subject has a score greater than 18 on the BPIC-SS scale and urinaly sis and microscop y 
indicate no evidence of urinary  tract infection, then the subject will be referred to a specialist for 
further evaluation. If asubject is determined to have a dia gnosis of ulcerative cystitis, the subject
must be discontinued from the study  and followed up with appropriate medical care. As such, in 
addition to urinaly sis, a urine culture should also be obtained if the BPIC-SS score on applicable 
study  day is greate r than 18.
Cognition Testing: Computerized Cognitive Battery and HVLT -R
The computerized cognitive battery  provides assessment of multiple cognitive domains,
including attention, visual learning and memory , and executive function. The tests use 
culture -neutral stimuli, enabling use in multilingual/multicultural settings. The computerized 
battery  includes :
Simple and choice reaction time tests; scored for speed of respon se (mean of the 
log10-transformed reaction times for correct responses)
Visual episodic memory ; visual recall test scored using arcsine transformation of the 
proportion of correct responses
Working memory  (n back); scored for speed of correct respon se (mean of the 
log10-transformed reaction times for correct responses)
Executive function; maze/sequencing test ,scored for total number of errors
All measures have been validated against traditional neuropsy chological tests and are sensitive to 
the effects of various drugs on cognitive performance ,including alcohol and benzodiazepines.
Completing the cognitive battery requires approximately  25 minutes.
The HVLT -R, a measure of verbal learning and memory , is a 12-item word list recall test.
Administration includes 3 learning trials, a delay ed recall (20-minute) trial, and a 24-word 
recog nition list (including 12 target and 12foil words ).3The test administrator reads instructions 
and word lists aloud, and records word srecalled /recognized by the subject. Scores include 
learning, delay ed recall , and recognition. The HVLT -R is a well-validated and widely used 
measure of verbal episodic memory. 
The tests will be administered in the following order: HVLT -R, computerized cognitive test
battery , and HVLT -R D elayed.
All subjects will complete a practice session for the computerized cognitive battery  during the 
screening/prospective observational phase. There is no practice session for the HVLT -R.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 114UPSIT and Smell Threshold Test
To assess any potential treatment -emergent effects on the sense of smell, olfactory  function will 
be qualitatively  and quantitatively  assessed using validated standardized olfactory  tests prior to 
and at specified time points during the study . The 2tests to be admi nistered are: 
The UPSI T assesses a subject ’s ability  to identify  odors. This standardized test, the most 
widely  used olfactory test in the world, is derived from basic psychological test 
measurement theory  and focuses on the comparative ability  of subject s to identify  odorants 
at the suprathreshold level. The UPSI T consists of 4envelope -sized booklets, each 
containing 10“scratch and sniff” odorants embedded in 10-to 50-µm polymer 
microcapsules positioned on brown strips at the bottom of the pages of thebooklets. The 
internal consistency  and test-retest reliability  coefficients of this instrument are >0.90.17,18,19
Numerous studies have shown this and related tests to be sensitive to subtle changes in smell 
function associated with multiple etiologies, including those due to viruses, head trauma, 
and a number of neurodegenerative diseases.
The Smell Threshold Test will assess the smell threshold using a forced -choice single 
staircase threshold procedure. This test quantifies a detection threshold for the rose-like 
smelling odorant pheny l ethyl alcohol (PEA). This odorant is used because it has little 
propensity  to stimulate the trigeminal nerve within the nose. This test is sensitive to 
olfactory  deficits from a wide range of disorders. 
These tests will be administered bilaterally  (ie, both nostrils at the same time). Testing will occur 
during the screening /prospecti ve observational phase to establish a subject’s baseline sensitivity . 
The degree of change from this baseline will be determined subsequently  over time. The percent 
change from baseline will serve as the dependent measure for each subject for each test. 
If the subject has significant nasal congestion on the day of ascheduled UPSI T and/or Smell 
Threshold Test, the site should consider postponing the smell test assessment(s) to the next 
scheduled clinic visit.
9.8. Other Evaluations
MINI
Subjects will undergo MINI (a brief , structured diagnostic interview )to confirm the diagnosis of 
MDD and to determine if there are other psychiatric conditions present. It has an administration 
time of approximately  15 minutes .
MGH -ATRQ
The MGH -ATRQ is used to determine treatmen t resistance in MDD .15
The MGH -ATRQ evaluates the adequacy  of duration and dosage of all antidepressant 
medications used for the current major depressive episode . In addition, the MGH -ATRQ asse sses 
the degree of improvement on a scale from 0% (not improved at all) to 100% (completely 
improved). The MGH -ATRQ will be completed by the clinician in collaboration with the 
subject.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 115STOP -Bang Questionnaire
The STOP -Bang Questionnaire is a concise, easy-to-use, validated, and sensitive screening tool 
for obstructive sleep apnea (OSA). This questionnaire has 8 items which address key risk factors 
for obstructive sleep apnea: snoring, tiredness, observed breathing interruption during sleep, high 
blood pressure, body mass index, age, neck size, and gender. The STOP -Bang questions do not 
specify  a  recall period. Subjects will answer yes or no to questions about snoring, tiredness, 
observed breathing interruption, and high blood pressure (these are the “STOP” items in the 
STOP -BANG acron ym); this takes approximately  1 minute.6
Study  site staff will answer yes or no to questions about body  mass index (more than 35 kg/m²?), 
age (older than 50 years?), neck circumference (larger than 17 inches [43 cm] in men, or larger 
than 16 inches [41 cm] in women?), and gender (male?).
The total STOP -BANG score is calculated by summing the number of positive responses, 
yielding a score range of 0 to 8. A score of 5 on the STOP -Bang indicates a moderate to severe 
risk for Obstructive Sleep Apnea (apnea h ypopnea index of >30) .6
Site Indep endent Qualification Assessment
Independent psychiatrists/psy chologists will perform the Site Independent Qualification 
Assessment in the screening/prospective observational phase for all subjects to confirm diagnosis 
of depression and eligibility  for the stud y.85
Further information regarding this assessment will be provided to sites in a separate document.
IDS-C30
The 30-item IDS-C30is designed to assess the severit y of depressive symptoms.74The IDS 
assesses all the criteri on symptom domains designated by the DSM -5to diagnose a major 
depressive episode. These assessments can be used to screen for depression, although they have 
been used predominantly as measures of symptom severit y. The 7- day period prior to assessment 
is the usual time frame for assessing symptom severit y. The psychometric properties of the 
IDS-C30have been established in various study  samples.86
Massachusetts General Hospital Female Reproductive Lifecycle and Hormones 
Questionnaire ( MGH -Female RLHQ): Module I and Menstrual Cycle Tracking
The MGH -Female RLHQ Module I (childbearing potential, menopausal status, and menstrual 
cycle) is a brief questionnaire aimed at standardizing the minimal collection of relevant 
information about reproductive hormones and status. Itwill be completed by a clinician. This 
information may facilitate exploratory  analyses of the impact of endogenous and exogenous 
reproductive hormones on the course of treatment of MDD and potentially  inform care of women 
with MDD in the future.33
Menstrual cycle tracking (start date of last menstrual period) will be documented at the study  
visits specified i n the Time and Events Schedule for women with a menstrual cy cle.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 116PAQ
Subjects’ adherence to their oral antidepressant treatment regimen during the 
screening/prospective observational phase will be assessed using the PAQ. It is a brief, 2-item 
subject -report outcome measure that was developed at the University  of Texas Southwestern 
Medical Center to assess how often the subject has taken, and whether heor she has made any 
changes tohis/her antidepressant treatment regimen in the last 2 weeks . The total score is based 
on the response selected to Question 1, and is interpreted as 0-1=adherent and 2or 
more=nonadherent.
9.9. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, United States 
Pharmacopeia (USP) (or equivalent) and charged with a volume equal to the dead space volume 
of the lock.
Refer to the Time and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the double -blind induction phase of the study  if 
he or she has completed the MADRS assessment at the end of the 4 -week double -blind induction
phase (ie,Day 28 MADRS) .
Subjects who prematurely discontinue study  treatment for any reason before completion of the 
double -blind induction phase will not be considered to have completed the double -blind 
induction phase of the study .
Subjects who enter the follow -up phase will be consider ed to have completed thisphase of the 
study  if he or she has completed the MADRS asse ssment atWeek 24 of the follow -up phase .
10.2. Withdrawal from the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 117Withdrawal of consent (Note: See “Withdraw of Consent” section below; this should only 
be selected as a reason for withdrawal if the subject does not agree to any further study  
assessments or procedures. If the subject is agreeable to participating in the Early 
Withdrawal visit and the follow -up phase, another reason for withdrawal should be 
selected.)
Violation of protocol procedures (determined on a case- by-case basis)
Blind is broken (double -blind induction phase)
Lack of efficacy
The investigator or sponsor believes (eg, that for safety or tolerability  reasons such as an 
adverse event) it is in the best interest of the subject to discontinue the study .See also 
guidance on blood p ressure monitoring on intranasal dosing day s (Section 6.2.1 ).
At any time point after baseline (Day  1, predose) , the subject has a :
-QTcF change from baseline ≥ 60 msec and QTcF > 480 msec, or 
-QTcF > 500 msec.
Subject becomes pregnant
Study  is terminated by  sponsor for futility
Death
If the subject withdraws from the study  before the end of the double -blind induction phase, an 
Early Withdrawal visit is to be performed .
If a subject is lost to follow -up, every reasonable effort must be made by  the study  site personnel
to contact the subject and determine the reason for discontinuation/withdrawal. This should 
include at least 3 telephone calls, certified letters, email requests, etc. To ensure access to follow -
up subjects, the study  sites should attempt to obtain both primary  and secondary  telephone 
contact numbers (eg, home, work, and mobile phone numbers), as well as other contact 
information (eg, email addresses) from subjects before randomization. In addition, the study  site 
should emphasize the importance of follow -up information to the subject before randomization . 
The measures taken to follow up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Subjects who withdraw will not be 
replaced.
Withdrawal of Consent
Every  effort will be made in the study  to ensure withdrawal of consent is not selected as a reason 
for discontinuation when in fact the subject withdre w for an identifiable reason (eg, due to an 
adver se event or lack of efficacy ).
Subjects who wish to withdraw from the study  should be asked if they are agreeable to continue 
to an early withdrawal visit (if withdrawing from the double -blind induction phase) and the 
follow up phase, or to be contacted tocollect follow -up information. Subjects who are not 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 118agreeable to follow -up contact will be withdrawn from the study  as “withdrawal of consent .”
Subjects who no longer wish to take study  drug but agree to provide follow -up information will 
be withdrawn from the double -blind induction phase with the reason noted as “Other” and will 
specify  the reason wh y.
For a subject who “withdraw sconsent ”,it is recommended that the subject withdraw consent in 
writing; if the subject refuses or is physicall y unavailable, the study  site should document and 
sign the reason for the subject’s failure to withdraw consent in writing and maintain it with the 
subje cts source records.
The investigator will be responsible for making all required notifications to the Institutional 
Review Board (I RB) or Independent Ethics Committee (IEC).
10.3. Withdrawal from the Use of Sample s in Future Research
The subject may withdraw consent for use of sample sfor research (refer toSection 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for research are presented in the main ICF.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor orunder the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
At the end of the double -blind induction phase the database will be locked for the analy sis and 
reporting of this phase. The subject treatment assignment will be revealed only to sponsor’s 
study  staff. The investigators and the site personnel will be blinded to the treatment assignment 
until all subjects have completed study  participation through the follow -up phase.
11.1. Subject Information
The primary  efficacy  and safet y analysis sets are defined below.
Full Analysis Set: All randomized subjects who receive at least 1dose of intranasal study 
medication and 1 dose of oral antidepressant in the double -blind induction phase .
Safety Analysis Set: All randomized subjects who receive at least 1dose of intranasal study  
medication or 1 dose of oral antidepressant in the double -blind induction pha se.
11.2. Sample Size Determination
Themaximum sample size planned for this study  was calculated assuming a treatment difference 
for the double -blind induction phase of 6.5 points in MADRS total score between any dose of 
esketamine and the active comparator, a standard deviation of 12, a 1-sided significance level of 
0.0125 ,and a drop-out rate of 25%.A maximum of about 116 subjects will need to be 
randomized to each treatment group to achieve 90% power for comparison of each esketamine 
dose plus oral antidepressant arm with oral antidepressant plus intranasal placebo arm (active 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 119comparator) using a fixed design with no interim analy sis.The treatment difference and standard 
deviation used in this calculation were based onresults of Panel A of the ESKETI NTRD2003 
study  and onclinical judgment.
As detailed below, an interim analysis is planned to re-estimate sample size or to stop the study  
due to futility .
11.3. Interim A nalysis for Sample Size Re -estimation or Stopping for Futility
One unblinded interim analy sis will be performed 4weeks after randomizing 120subjects in the 
study  (approximately  40subjects per treatment arm). It is projected that at that time 
approximately  90subjects in the full analy sis setwould have completed the double -blind 
induction phase of the study (approximately  30 subjects per treatment group) . The dropout rate 
will be monitored to ensure a sufficient number of subjects areincluded in the interim analy sis. 
As the assumptions of the expected treatment difference and variability may or may not be 
upheld, the purpose of the interim anal ysis is to either re- estimate sample size or to stop the study 
due to futility . The sample size may be adjusted to achieve the desired power while maintaining 
control of the overall Type I error. The maximum sample size planned for this study  is 116 per 
treatment group. If the study  is not stopped for futility , sample size re-estimation will be 
conducted for both doses of esketamine, ie, the analy sis does not allow for sto pping a dose based 
on the results of the interim analy sis.
A rigorous interim statistical analy sis plan (SAP) and charter will be developed detailing the 
algorithm for a sample size re-estimation based on the interim data and how the analy sis will be 
executed. An IDMC will perform the interim analy sis and will make recommendations for any 
sample size adjustment based on the rules defined in the interim SAP. Any changes to sample 
size will be communicated IDMC (or the statistician from the Statistical Suppor t Group) to the 
IWRS vendor to ensure that the appropriate number of subjects is enrolled in the study . None of 
the esketamine team members or staff members at the investigational sites conducting the 
clinical study will be informed of the results of the interim anal ysis and any  adjustments that will 
be made to the sample size; however, the clinical supplies group will be informed of the decision 
made at interim anal ysis so that only  the required amount of study  medication will be packaged .
Procedures willbe in place to ensure that the results of the interim analy sis do not influence the 
conduct of the stud y, investigators, or subjects.
11.4. Efficacy  Analyses
Efficacy  analyses will be performed on the fullanalysis set, which will include all randomized 
subject swho receive at least 1 dose of intranasal study  drugand 1 dose of oral antidepressant 
medication in the double -blind induction phase.
With the exception of European Union (EU) dossier, theprimary  efficacy  variable, change from 
baseline in MADRS total score at Week 4 in the double -blind induction phase , will be analyzed 
using MMRM. The model will include baseline MADRS total score as a covariate, and 
treatment, country , class of antidepressant (SNRIor SSRI), day, and day-by-treatment 
interaction as fixed effects, and a random subject effect. Comparison of each esketamine plus 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 120oral antidepressant arm versus oral antidepressant plus intranasal placebo will be performed 
using the appropriate contrast.
For the EU dossier, the primary  efficacy  analysis will be based on an analysis of covariance 
(ANCOVA) model using last observation carried forward (LOCF) data. The model will include 
factors for treatment, country , and class of oral antidepressant (SNRIorSSRI) and baseline 
MADRS total score as a covariate. Comparison of each esketamine plus oral antidepressant arm 
versus intranasal placebo plus oral antidepressant will be performed using the appropriate 
contrast .
For the analy sis of the first key secondary  efficacy endpoints, the proportion of subjects showing 
onset of clinical response by Day 2  that is maintained for the duration of the double -blind 
induction phase in the esketamine plus oral antidepressant arm will be compared with the oral 
antidepressant plus intranasal placebo arm using a Cochran- Mantel -Haenszel chi-square test 
adjusting for country  and class of antidepressant (SNRIor SSRI).Clinical response is defined as 
50% improvement in MADRS total score by Day 2 (ie, the day after taking the first dose of 
double -blind intranasal medication) that continues through the end of the double -blind phase
with one excursion allowed. Subjects who discontinue the study  prior to end of the double -blind
induction phase will not be considered to have maintained clinical response.
The second and third key secondary  efficacy  endpoints, change from baseline in SDS total score 
at Week 4 and change from baseline in PHQ -9 total score at Week 4(subject to regul atory  
acceptance of PHQ -9) in the double -blind induction phase , will be analy zed using the same 
models described above for the MADRS total score. Responses to questions H1 to H3 from the 
SDS will be summarized separately.
To strongl y control Type I error across the primary  and the 3 key secondary  efficacy  endpoints 
(change in MADRS total score , onset of clinical response, and change in SDS, change in PHQ -9 
total score), and across the 2 esketamine dose-placebo comparisons, a truncated fixed sequence 
paralle l gatekeeping test procedure20,21  w ill be applied between families of hypotheses 
corresponding to the endpoints, and between the two dose-placebo comparisons within each 
family  (where, 84 mg esketamine dose group will be tested first and 56 mg esketamine dose 
group will be tested only if 84 mg is shown to be significant). The 2 dose-placebo comparisons 
corresponding to each efficacy  endpoint are considered as a family  of hypotheses.  Further 
details of this approach will be provided in the SAP. The following is a high level summary  of 
the approach:
Testing will start with the primary  endpoint, and will proceed to oth er endpoints along the 
sequence only if at least 1 esketamine dose-placebo comparison is significant at a pre-specified 
level of significance.
The 84 mg dose comparison will be tested at a 1-sided α= 0.025 for MADRS total score. If this 
dose is significantly  different from placebo, then the 56 mg dose of esketamine will be tested 
against placebo at a 1 -sided α1=0.02125. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 121If both dose-placebo comparisons are significant for the MADRS total score, then testing will 
proceed to onset of clinical response. The84 mg dose comparison will be tested at a 1-sided α= 
0.025. If this dose is significantly  different from placebo, then the 56 mg dose of esketamine will 
be tested against placebo at a 1-sided α1=0.02125. However, if only the 84 mg dose is 
significant for the MADRS total score then testing will proceed to onset of clinical response at a 
1-sided α2=0.00375, where the 84 mg dose will be compared to placebo. The 56 mg dose will 
not be tested for an y of the remaining endpoints.
Similarly , if both-dose compari sons are significant for onset of clinical response, then testing 
will proceed to SDS at a 1-sided α= 0.025 for the 84 mg dose and at a 1-sided α1=0.02125 for 
the 56 mg dose in a fixed sequence. However, if only the 84 mg dose is significant for onset of 
clinical response then testing will proceed to SDS at a 1- sided α2=0.00375, where only  the 84 mg 
dose will be compared to placebo. The 56 mg dose will not be tested for the remaining  
endpoints.
Finally , if both-dose comparisons are significant for SDS, then testing will proceed to PHQ -9 at 
1-sided α= 0.025 for the 84 mg dose and at a 1-sided α1=0.02125 for the 56 mg dose in a fixed 
sequence. However, if only the 84 mg dose is significant for SDS then testing will proceed to 
PHQ -9 at 1- sided α 2=0.00375, whe re onl y the 84 mg dose will be compared to placebo.
Response and remission rates wil l be summarized at each visit.
Change from baseline in GAD-7 total scores and ranks of change from baseline in CGI-S scores 
at the end of the double -blind induction phase will be analy zed based on LOCF data using an 
ANCOVA model, with country  and class of antidepressant (SNRI or SSRI) as factors, and the 
respective baseline score (unranked score in the case of CGI- S) as the covariate. 
Dimension scores of EQ-5D- 5L data, health status index, and the overall health status score will 
be summarized over time.
Additionally , scores of all efficacy endpoints will be summariz ed for all visits in the 
double -blind induction phase . Summaries will be provided to show consistency  of effect among 
relevant subgroups (eg, antidepressant class S NRI and S SRI).
11.5. Pharmacokinetic Analyses
Plasma esketamine (and noresketamine , if warranted) concentrations will be listed for all 
subjects. The plasma concentration -time data of esketamine (and noresketamine , if warranted)
will be analyzed using population PKmodeling. Data may be combined with those of other 
select ed studies to support a relevant structural model. Typical population values of basic PK
parameters will be estimated together with the inter-individual variability . Effects of subject 
demographics, laboratory parameter values, and other covariates on the PKof esketamine will be 
explored. The results of the population PKanalyses may  be reported separately .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 12211.6. Pharmacokinetic/Pharmacody namic A nalyses
The relationship between MADRS total score (and possibly  selected adverse events as additional 
PDparameters) ,and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
graphical analysis, suitable models will be applied to describe the exposure -effect relationships. 
The results of the PK/PDanalysesmay be reported separately .
11.7. Biomarker and P harmacogenomic Analyses
Baseline biomarker values and changes from baseline biomarker values to the time points 
specified in the Time and Events Schedule will be summarized. Exploratory  analyses may 
include comparison of biomarker measures between the treatment groups and correlation with 
baseline and change from baseline biomarker values in the efficacy and other measures. 
Additional exploratory  analyses may also include relationship of baseline and change from 
baseline in biomarker measures to clinical response, maintenance/stabilization of response, 
relapse, and non -response.
Pharmacogenomic analyses may include candidate gene analy ses or genome -wide association 
analyses in relation to treatment response, maintenance/stabilization of response, relapse, 
non-response , and MDD/TRD. Expression analy ses may include testing of known messenger 
RNA/mi croRNA (mRNA/miRNA) transcripts or transcriptome -wide analy sis in relationship to 
antidepressant treatment response and MDD/TRD.
Details of the analy sis plan and summ ary of results from both biomarker and pharmacogenomics 
analyses will be reported separately .
11.8. Medical Resource Utilization Analyses 
Medical resource utilization data will be descriptively  summarized.
11.9. Safety  Analyses
Safety  data will be analy zed for the double -blind induction phase using the safety  analysis set. 
The safet y data from the follow -up phase will be summarized separatel y.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the MedDRA . All reported adverse events with onset during the double -blind induction 
phase (ie, TEAEs, and adverse events that have worsened since baseline) will be included in the 
analysis. For each adverse event, the percentage of subjects who experience at least 1occurrence 
of the given event will be summarized by treatment group. Adverse events occurring during the 
follow -up phase will be summarized separatel y.
TEAEs of special interest will be examined separatel y (please refer to Section 3.2.6 ).AEs of 
special interest will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adver se event will be summarized separatel y.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 123Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data.Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and at each scheduled time point in each phase of the study .Changes from baseline results will 
be presented. Frequency tabulations of the abnormalities will be provided . Listing sof subjects 
with laboratory  results outside the reference ranges andmarkedl y abnormal results will also be 
provided.
ECG
The effects on cardiovascular variables will be evaluated by means of descriptive statistics and 
frequency  tabulati ons. These tables will include observed values and change from baseline 
values.
Electrocardiogram data will be summarized by ECG parameter. Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and QTc interval using the following correction methods: QT corrected accor ding to Bazett's 
formula (QTcB) and QTcF .2,39,77
Descriptive statistics of QTc intervals and changes from double -blind baseline will be 
summarized at each scheduled time point. The percentage of subjects with QTc interval 
>450 msec , >480 msec , or >500 msec will be summarized, as will the percentage of subjects 
with QTc interval increases from baseline <30 msec, 30 -60 msec, or >60 msec .
All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T -wave morphology  or the occurrence of U -waves).
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory  rate, pulse oximetry , and blood 
pressure (s ystolic and diastolic) ( supine) values and changes from baseline will be summarized at 
each scheduled time point. The percentage of subjects with values beyond clinically  important 
limits will be summarized.
Nasal Exam ination
Changes in findings from the baseline nasal examinatio n (including the upper respiratory  
tract/throat) will be listed by treatment group. Examinations will provide ratings (absent ,mild, 
moderate, or severe) that are based on a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary /blood vessel disruption and epistaxis. A 
shift table for changes from double -blind baseline in rating sfor each examination will be 
presented b y treatment group.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 124Nasal Symptom Questionnaire
Scoring from the nasal symptom questionnaire will be summarized descriptivel y for each 
scheduled time point by treatment group.
C-SSRS 
Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by treatment 
group in incidence and shift tables. Separate endpoints for suicidal ideation and suicidal behavior 
will be defined and summarized descriptively  by treatment group. Missing scores will not be 
imputed. 
CADSS, BPRS+, and MOAA/S
Descriptive statistics of each score and changes from predose will be summarized at each
scheduled time point.
Clinical Global Assessment of Discharge Readiness , PWC-20, BP IC-SS, UPSIT, and Smell 
Threshold Test
Descriptive statistics of each score and changes and/or percent changes from baseline will be 
summarized at each scheduled time point.
Cognition Testing
Descriptive statistics of the cognitive domain scores and changes from baseline will be 
summarized at each scheduled time point.
11.10. Independen t Data Monitoring Committee
An IDMC will be established to monitor data on an ongoing basis to ensure the continuing safet y 
of the subjects enrolled in this study . In addition, the committee will review 1interim analy sis 
for a sample size re-estimation. The committee will meet every  6months to review safety  data 
and will meet once to review efficacy  data after the interim analysis has been completed. After 
the reviews, the IDMC will make recommendations regarding the continuation of the study  or,in 
the case of the interim analy sis for efficacy ,to either stop the study  due to futility  or to adjust the 
sample size to achieve the desired power while maintaining control of the overall Type I error. 
The details will be provided in a separate IDMC cha rter.
The IDMC will consist of at least onemedical expert in the relevant therapeutic area and at least 
one statistician. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
12. ADVERSE EVENT REPORT ING
Timely , accurate, a nd complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 12512.1. Definitions
12.1.1. Adverse E vent Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causa l relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product , whether or not 
related to that medicinal (investigational or non-investigational) product (definition per 
International Conference on Harmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Huma n Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life-threat ening (for example, the subject was at risk of death at the time of the event. 
“Life threatening” d oes not refer to an event that hy pothetically  might have caused death if it 
were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent v ia a medicinal product
Is medicall y important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threateni ng or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 126be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. Foresketamine, the expectedness of an adverse 
event will be determined by whether or not it is listed in the Reference Safet y Information 
Section of the Investigator's Brochure .
For duloxetine, escitalopram, sertraline, and venlafaxine XR, the expectedness of an adverse 
event will be determined by whether or not it is listed in the SmPC or US prescribing 
information .22,23,27,28,79,80,87,88
Adverse Event Associated With the Use of the Drug
An adverse event is considere d associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by the definitions listed in Section 12.1.2 .
12.1.2. Attribut ion Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests th at a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the c ausal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely , eg,concomitant 
drug(s), concomitan t disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 12712.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity .
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure (which may include contact for follow -up of safety ), with the exception 
of pregnancy  which will be reported up to 6 weeks after the last dose of study  medication 
(females) or 90 da ys after the last dose of study  medication (partners of male participants) . 
Serious adverse events, including those spontaneously  reported to the investigator, must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 128
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 129Attachment 4.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due toa common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory  infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study  therap y. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). The 
investigator (or sponsor where required) must report SUSARs to the appropriate Independent 
Ethics Committee/I nstitutional Review Board (IEC/IRB) that approved the protocol ,unless 
otherwise required and documented by the IEC/IRB . A SUSAR will be reported to regulatory 
authorities unblended. Participating investigators and IEC/IRB will receive a blinded SUSAR 
summary , unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contac t person b ystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 130All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event, except hospitalizations for the following:
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospit alization was planned has not worsened ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospitalization is to be reported as a new serious adverse event.
For convenience the investig ator may choose to hospitalize the subject at times during the 
treatment period.
The cause of death of a subject in a study , whether or not the event is expected or associated with 
the study  drug , is considered a serious adverse event.
12.3.3. Pregnancy
All initia l reports of pregnancy  must be reported to the sponsor by the study -site personnel
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillb irth, congenital 
anomal ies, ectopic pregnancy ) are considered serious adverse events and must be reported using 
the Serious Adverse Event Form. Any subject who becomes pregnant during the study  must be 
promptly  withdrawn from the study  and discontinue furt her study treatment.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study  will be reported by the study -site personnel within 24 hours of 
their knowledge of the event using the appropriate pregnancy  notification form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 13112.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product quality  complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrit y. A PQC may 
have an impact on the safet y and efficacy  of the product. Timely , accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of subjects, 
investigators, and the sponsor, and are mandated by regulatory  agencies worldwide. Thesponsor 
has established procedures in conformit y with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Proce dures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor.
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
Intranasal Study Drug
Esketamine will be supplied as a clear, colorless intranasal solution of esketamine hydrochloride
(16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine base) in a nasal spray  
pump . The solution will consist of 161.4 mg/mL  esketamine hydrochloride (equivalent to 
140mg of esketamine base) formulated in 0.12 mg/mL ethylenediaminetetraacetic acid (EDTA) 
and 1.5 mg/mL citric acid at a pH of 4.5 in water for injection. It is provided in a nasal spray 
pump, which delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) per 100L
spray . Each individual nasal s pray pump (device) contains a total of 28 mg (ie, 2 spray s). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 132The placebo solution will be supplied as a clear, colorless intranasal solution of water for 
injection ,with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001mg/ mL) added to simulate the taste of the intranasal solution with active drug. The placebo 
solution will be provided in matching nasal spray  pump devices. Benzalkonium chloride is added 
as a preservative at a concentration of 0.3 mg/mL. Each individual nasal spray  pump (device) 
contains 2 sprays.
Esketamine and placebo will be manufactured and provided under the responsibility  of the 
sponsor. Please refer to the Investigator's Brochure for a list of excipients.42
Oral Antidepressant Medications
Duloxetine
Duloxetine 30 mg will be obtained from commercial stock and provided under the responsibility  of 
the sponsor. Please refer to the package insert/SmPC for the physical description and a list of 
excipients.22,23
Escitalopram
Escitalopram 10mg will be obtained from commercial stock and provided under the 
responsibility  of the sponsor. Please refer to the package insert/SmPC for the physical description 
and a list of excipients .27,28
Sertraline
Sertraline 50 mg and 25 mg (as applicable) will be obtained from commercial stock and provided 
under the responsibility  of the sponsor. Please refer to the package insert/SmPC for the physical 
description and a list of excipients .79,80
Venlafaxine XR
Venlafaxine 75 mg and 37.5 mg (as applicable) will be obtained from commercial stock and 
provided under the responsibility  of the sponsor. Please refer to the package insert/SmPC for the 
physical description and a list of excipients .87,88
14.2. Packaging
Intranasal Study Drug
Study  drug (ie, intranasal esketamine and placebo solution) will be supplied by the sponsor in a 
bi-dose nasal spray  device. The devices will contain 200 µL. Each device delivers 16.14 mg 
esketamine hydrochloride (14mg esketamine base) or 0.1µg of denatonium benzoate per 100µL
spray .
Each nasal spray  device will be individuall y packaged in a blister tray and subsequentl y put into a 
carton box. Each carton box constitutes a non-child -resistant subject kit, labeled with a unique 
medication kit number.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 133Device for Practicing Intranasal Study Drug Administration
The demonstration intranasal device will also be supplied by the sponsor and will contain placebo 
solution. Subjects will practice spray ing into the air and will not spray  intranasally .
Oral Antidepressant Medication
Oral antidepressant tablets or capsules will remain in their commercial packaging.
If blisters are supplied, each blister will be packaged into a child -resistant dose pack to constitute 
a subjec t kit, labeled with a unique medicat ion kit number. These will be labeled according to 
applicable regulatory  requirements.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory  requirements.
14.4. Preparation, Handling, and Storage
Study  drug will be stored at the study site in a secure area with restricted access until dispensed to 
the subjects. 
All study  drug must be stored at controlled temperatures as indicated on the product -specific 
labeling.
Please refer to the pharmacy  manual/study  site investigational product manual and instructions for 
use documents for additional guidance on study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .
The dispensing of study drug to the subject, and the return of study  drug from the subject (if 
applicable), must be documented on the drug accountabilit y form. Subjects must be instructed to 
return all orig inal containers, whether empt y or containing study  drug.
The study  drug administered to the subject must be documented on the drug accountabilit y form. 
All study  drug will be stored and disposed of according to the sponsor's instructions. Study-site 
person nelmust not combine contents of the study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and must 
be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug,and study  drug returned by the subject, must be 
available for verification by the sponsor's study  site monitor during on-site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study drug for destruction, will be 
documented on theinvestigational product destruction form . When the study  site is an authorized 
destruction unit and study drug supplies are destroyed on -site, this must also be documented on the
investigational product de struction form.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 134Potentiall y hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediatel y in a safe manner and therefore will not be 
retained for drug accountabilit y purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member of 
the study -site personnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. 
Whenever a subject brings his or her study  drug to the study  site for pill count (ie,compliance 
check) , this is not seen as a return of supplies. 
Study  drug may not be relabeled or reassigned for use by othersubjects. The investigator agrees 
neither to dispense the study  drug from, nor store it at, any site other than the study  sites agreed 
upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Practice intranasal devices 
Investigator's Brochure for esketamine
Local prescribing information for oral antidepressant options in double -blind induction 
phase
Investigational Product (IP) Binder, including the IP Procedures Manual
Laboratory  manual and materials
Clinician -administered and subject -reported outcome assessments:
Paper versions, as applicable
Electronic devices and associated materials
IWRS Manual
ECG equipment and associated materials (e g, manual )
Instructions for Use documents (subject and healthcare provider versions) for intranasal 
study  medication
Rater qualifications/requirements for select clinician -administered assessments
Computerized cognitive battery  and HVLT -R, and all associated equipment and materi als
Device to measure respiratory  rate
Procedural documents for Site -Independent Qualification Assessment
Procedural documents for independent, remote rater interviews
Guidance on recommen ded order of study  procedures
MGH -ATRQ Guidance document
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 135SmPCs of th e active comparators: Duloxetine, escitalopram, sertraline, and venlafaxine XR
Subject diary
16. ETHICA L ASPECTS
16.1. Study -specific Design Considerations
Clinical Study in Treatment-resistant Major Depression
Major depressive disorder is a common, severe, chronic ,and often life-threatening illness. It is 
now the leading cause of disability  worldwide. There is a clear need to develop novel and 
improved therapeutics for treatment -resistant depression.
Studies with esketamine have shown robust antidepressant effects in several clinical studies and 
it has been well tolerated in these clinical studies.
Selection of Subjects
The primary  aim of the study  is to evaluate the efficacy  of intranasal esketamine plus an oral 
antidepressant for the treatment of TRD. Thus, the study  cannot be completed in health y 
subjects. 
Potential subjects will be fully informed of the risks and requirements of the study  and, during 
the study , subjects will be given any new information that may affect their decision to continue 
participation.
For eligibility , subjects must have had non-response to at least 1 prior antidepressant treatment 
and be currentl y taking an antidepressant treatment at the start of the screening/prospective 
observational phase that will be continued as prospective treatment in the screening/prospective 
observational phase . Only  subjects with non-response to their current antidepressant treatment 
after 4weeks of prospectivel y observe dtreatment (for a total duration of antidepressant 
treatment of at least 6 weeks by the end of the screening/prospective observational phase ),will 
be eligible to proceed to the double -blind induction phase, when all subject swill receive a new 
oral antidepressant in addition to intranasal esketamine or placebo. Subjects will receive 4 weeks 
of treatment in the double -blind phase and at the end of this phase, those who are responders and 
willing to do so may participate in the maintenance study  (ESKETINTRD3003). Subjects who 
are not responders or who otherwise choose not to enter the ESKETINTRD3003 study  will enter
the 24 week follow -up phase
All subjects will be provided with an additional 4week suppl y of the oral antidepress ant 
medication and appropriate follow -up care will be arranged.
They  will be told that their consent to participate in the study  is voluntary  and may  be withdrawn 
at any time with no reason given and without penalty  or loss of benefits to which they would 
otherwise be entitled. Only  subjects who are fully  able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 136Justification for Using Placebo
Intranasal placebo is being used as a double -blind for intranasal esketamine to maintain study  
blinding . All subjects will also receive anewly initiated oral antidepressant during the induction 
phase. Subjects will not be on placebo alone. Assessment of the potential efficacy  of a new 
compound for the treatment of treatment -resistant major depression requires adequate and 
well-controlled clinical studies. This superiority  study  will compare intranasal esketamine plus a 
newly -initiated oral antidepressant to switching to an oral antidepr essant as an active comparator.
Recent analyses have shown response to placebo varies considerabl y,from 10% to 55%. 
Therefore, there is a concern that randomized, controlled studies that rely on comparison with 
standard antidepressant treatment s alone will generate unreliable results with limited assay  
sensitivity . However, some have considered it unethical to do placebo -controlled studies in major 
depression due to the potential risk of irreversible harm.72In a  m eta-analy sis of drug studies 
conducted in MDD , it was reported that adult subjects did not have higher rates of suicide 
behaviors or attempts in the placebo group compared with those receivin g an active 
antidepressant.47These studies show edannual suicide rates of 0.8% on the investigational drug, 
0.7% on the active comparator, and 0.4 % on placebo. Thus, t he risk of irreversible harm was not 
higher in the placebo arm compared with the active control arms. 
Some subjects may  decide to not participate in a placebo -controlled study  due to the potential for 
increased distress and d ysfunctio n from prolonged depression. 
Therefore, the use of anactive -controlled study  allows for assessment of efficacy  of a new 
compound to allow for scientifically  meaningful results. 
Moreover, the duration of the double -blind induction phase is relativel y short (4week duration). 
Subjects will visit the study  site at least twice a week during the double -blind induction phase,
and their symptoms will be carefully  monitored during each study  visit. Safety  evaluations will 
include evaluation of suicidal ideation/ behavior at each clinic visit. At any  point in the study ,the 
subject may withdraw consent or be removed from the study  by the investigator if there are any 
clinical concerns.
Intranasal esketamine may not be available for subjects after the study . However, following 
completion of the double -blind induction phase, those subjects not continuing into the 
ESKETINTRD3003 study can be treated according to standard of care. 
Precautions to Ensure Subject Safety in the Study 
Subjects may participate in the study  only if they have adequate capacity  to give consent and 
after fully  understanding the potential risks and giving an informed consent. Determination of 
capacity  will be made by the study  investigator. Subjects may discontinue the study at any time. 
The probability  of receiving placebo and the concept of random assignment will be explained to 
the subject. The duration of the study  is short, minimizing the time on intranasal placebo (which 
is being administered with a newly -initiated oral antidepressant) . Potential disadvantages and 
adverse events of participating in the study  and alternative treatment options will be discussed. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 137For subjects who do not meet predefined response criteria during the study , clinical care will be 
arranged bet ween the study  investigator and their phy sician.
Compensation for any procedure will be fair per local standards and approved by the 
participating sites IRB in order to not offer an y undue incentive to participate in the study .
Subjects will be carefully monitored during the study  and subjects who are unable to tolerate 
study  drug during the double -blind induction phase will be discontinued from the study . If the 
investigator judges it to be necessary  to immediately  stop study  drug, he or she has the option to 
do so.Specific guidance is provided regarding blood pressure monitoring on intranasal dosing 
days (Section 6.2.1 ).
Only  subjects who had non-response to their current oral antidepressant treatment, where a 
clinician would consider changing it in the future due to lack of response, will be enrolled.
Only  qualified and trained investigators will participate in the study .
The total blood volume to be collected is considered to be within the normal range allowed for 
thissubject population over this time frame. The approximate blood volume to be collected is 
123.5mL,which will be less than a Red Cross blood donation.
16.2. Regul atory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice (GCP) is an international ethical and scientific qualit y standard for 
designing, conducting, recording, and reporting studies that involve the participation of human 
subjects. Compliance with this standard provid es public assurance that the rights, safety , and 
well-being of study  subjects are protected, consistent with the principles that originated in the 
Declaration of Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
(IEC/IRB)
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/IRB 
with current and complete copies of the following documents (as required by  local regulations) :
Final protocol and, if applicable, a mendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Sponsor -approved training and informational materials
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 138Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Informa tion regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after theIEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purel y administrative, with no consequences for 
subjects, data or study  conduct), the ICF, applicable recruiting materials, and subject compensation 
programs, and the sponsor has received a copy  of this approval. This approval letter must be dated 
and must clearl y identify  the IEC/ IRB and the documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/IRB for review and approval before implementation of the 
change(s). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 139At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required . 
The reapproval should be documented in writing (excluding the ones that are purel y 
administrative, with no consequences for subjects, data, or study  conduct).
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB about 
the study  completion.
16.2.3. Informed Consent
Each subjec tmust give written consent according to local requirements after the nature of the study 
has been fully explained. The ICF(s) must be signed before performance of any study-related 
activit y. The ICF(s) that is/areused must be approved by both the sponsor and by the reviewing 
IEC/IRB and be in a language that the subject can read and understand. The informed consent  
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH 
and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably  anticipated benefits, 
and potential hazards of the study , and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw consent 
to participate at any time. They  will be informed that choosing to not participate will not affect the 
care the subject will receive for the treatment of his or her disease. Subjects will be told that 
alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finall y, they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records may 
be accessed by health authorities and authorized sponsor personnel without violating the 
confidentialit y of the subject, to the extent permitted by the applicable law(s) or regulat ions. By 
signing the ICFthe subject is authorizing such access, and agrees to allow his or her study 
physician to re-contact the subject for the purpose of obtaining consent for additional safety 
evaluations, if needed.
The subject will be given sufficien t time to read the ICF and the opportunit y to ask questions. After 
this explanation and before entry  into the study , consent should be appropriatel y recorded by 
means of the subject's personally  dated signature. After having obtained the consent, a copy ofthe 
ICFmust be given to the subject.
Where local regulations require, a separate ICF may be used for the required DNA component of 
the study .
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study  will be limited 
to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y and 
compliance with applicable data privacy  protection laws and regulations . Appropriate technical 
and organizational measures to protect the personal data against unauthorized disclosures or 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 140access, accidental or unlawful destruction, or accidental loss or alteration must be put in place.  
Sponsor personnel whose responsibilities require access to personal data agree to keep the identit y 
of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access t o his or her original medical 
records (source data/documents) for study -related monitoring, audit, IEC/I RB review, and 
regulatory  inspection. This consent also addresses the transfer of the data to other entities and to 
other countries.
The subject has theright to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps will 
be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  PK, PD, biomarker, DNA ,and RNA research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory 
research data will not be returned to subjects or investigators, unless required by lawor local 
regulations. Privacy  and confidentialit y of data generated in the future on stored samples will be 
protected by  the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may  be stored for up to 15 years (oraccording to local regulations) 
for additional research. Samples will only be used to understand esketamine, oral antidepressants, 
to understand depression , to understand differential drug responders, and to develop tests/assay s 
related to esketamine , oral antidepressants, and depression. The research may begin at any time 
during the study  or the post -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer toSection 10.3, Withdrawal from the use of research samples
(Withdrawal f rom t he Use of Samples in Future Research) .
16.2.6. Country Selection
This study  will only  be conducted in those countries where the intent is to launch or otherwise help 
ensure access to the developed product, unless explicitly  addressed as a specific ethical 
consider ation in Section 16.1, Study -specific Design Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment by 
the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by the 
investigator. Protocol amendments must not be implemented witho ut prior IEC/IRB approval, or 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 141when the relevant competent authorit y has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the subjects, in which case the amendment must be 
promptl y submitted to the IEC/IRB and relevant competent authority . Documentation of 
amendment approval by the investigator and IEC/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IRB (and IEC where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other phy sician in attendance will contact the appropriate sponsor representative 
(see Contact Information page(s) provide d separately ). Except in emergency  situations, this contact 
should be made before implementing any  departure from the protocol. In all cases, contact with the 
sponsor must be made as soon as possible to discuss the situation and agree on an appropriate 
course of action. The data recorded in the eCRF and source documents will reflect any departure 
from the protocol, and the source documents will describe this departure and the circumstances 
requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notificat ion
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities in 
each respective country , if applicable. A study  may not be initiated until all local regulatory  
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study.
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 157 2), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 142Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial a greement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all sub- investigators
Documentation of sub -investigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by  the 
investigator in the study  file. To ensure subject confidentialit y, no copy will be made. All reports 
and communications relating to the study  will identify  subjects by  subject identification and date of 
birth. In cases where the subject is not randomized into the study , the date seen and date of birth 
will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibilit y for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation s consistent in the type and level of detail with that 
commonl y recorded at the study  site as a basis for standard medical care must be available for the 
following :subject identification, eligibilit y, and study  identification; study  discussion and date of 
signed informed consent; dates of visits; results of safety and efficacy  parameters as required by 
the protocol; record of all adverse events and follow -up of adverse events; concomitant 
medication; drug receipt/dispensing/return records; study  drug administration information; and
date of study  completion and reason for early  discontinuation of study  drug or withdrawal from the 
study , if applicable. 
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring guidelines 
(or other equivalent document).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 143The minimum source documentation requirements for Section 4.1(Inclusion Criteria )and 
Section 4.2(Exclusion Criteria ) that specify  a need for documented medical history  are as follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Antidepressant treatment in the current episode of depression
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. All CRF entries, corrections, 
and alterations must be made by the investigator or authorized study -site personnel. The 
investigator must verify  that all data entries in the CR F are accurate and correct.
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure manner 
to the sponsor within the timeframe agreed upon between the sponsor and the study  site. The 
electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source document s. All data relating to the study  
must be recorded in eCRFs prepared by the sponsor. Data must be entered into eCRFs in English. 
Study site personnel must complete the eCRF as soon as possible after a subject visit, and the 
forms should be a vailable for review at the next scheduled monitoring visit.
The investigator must verify that all data entries in the eCRFs are accurate and correct.
All eCRF entries, corrections, and alterations must be made by the investigator or other authorized 
study -site personnel. If necessary , queries will be generated in the eDC tool. The investigator or 
study -site personnel must adjust the eCRF (if applicable) and complete the query .
If corrections to a n eCRF are needed after the initial entry  into the eCRF, this can be done in either 
of the following ways:
Investigator and study site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  the eDC tool) .
Sponsor or sponsor delegate can generate a query  for resolution by the investigator and 
study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 144study -sitepersonnel before the study , periodic monitoring visits by  the sponsor, and uploading data 
transfers from external service providers into the sponsor's data base. Written instructions will be 
provided fo r collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .
The sponsor will review eCRFs for accuracy  and completeness during on -site moni toring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study  database they will be verified for 
accuracy  and consistency  with the data sou rces.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by the applicable regulatory  requirement(s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least 2years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period if 
required by the applicable regulatory  requirements or by an agreement with the sponsor. It is the 
respon sibilit y of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibilit y of keeping the study  records , custody must be transferred to a person who will accept 
the responsibilit y. The sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the investigator relocate or dispose of any  study  documents 
before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory  authorit y to review any 
documentation relating to this study , the investigator /institution must permit access to such reports.
17.8. Monit oring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospital or clinic records (source 
documents) ; a sample will be reviewed . The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the eCRF are known to 
the sponsor and study -site personnel and are accessible for verification by the sponsor study -site 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 145contact. If electronic records are maintained at the study site, the meth od of verification must be 
discussed with the study -site personnel. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel . 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
availab le, the source documentation will be accessible, and a suitable environment will be provided 
for review of study -related documents. The monitor will meet with the investigator on a regular 
basis during the study  to provide feedback on the study  conduct.
Inaddition to on-site monitoring visits, the monitor may contact thesite by telephone for an 
update on study  progress. It is expected that study-site personnel will be available to provide an 
update on the progress of the study  at the site .
17.9. Study Completio n/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject participating 
in the study . The final data from the study site will be sent to the sponsor (or designee) after 
completion of the final subject assessment at that study  site, in the time frame specified in the 
Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor . Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study supplies have been collected 
and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of astudy site by the sponsor or investigator may include but are not 
limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
Study  is termina ted b y sponsor due to futility
17.10. On-site A udits
Representatives of the sponsor's clinical qualit y assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 146with regulatory guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible for 
being present and available for consultation during routinel y scheduled study -site audit visits 
conducted by  the sponsor or its designees. 
Similar auditing procedures may  also be conducted by  agents of any regulatory  body , either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify the sponsor if he or shehas
been contacted by  a regulatory  agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esketamine or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previousl y published, and any  data, including pharmacogenomic or exploratory  biomarker research 
data, generated as a result of this study , are considered confidential and remain the sole pro perty of 
the sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study , and will not use it for other purposes without the 
sponsor's prior written consent.
The investigator understand s that the information developed in the study  will be used by the 
sponsor in connection with the continued development of esketamine, and thus may  be disclosed as 
required to other clinical investigators or regulatory  agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all 
data obtained in the study.
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all study  sites that participated in the study and will represent 
uploaded data transfer redfrom external service providers into the sponsor's database . Recruitment 
performance or specific expertise related to the nature and the key assessment paramete rs of the 
study  will be used to determine a coordinating investigator. Results of pharmacogenomic or 
exploratory  biomarker analyses performed after the Clinical Study  Report has been issued will be 
reported in a separate report and will not require a revis ion of the Clinical Study  Report. Study 
subject identifiers will not be used in publication of results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publicatio n by the investigator as provided for below) shall be the propert y of the 
sponsor as author and owner of copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study , a copy  of the manuscript must be provided to the sponsor for review at 
least 60 days before submission for publication or presentation. Expedited reviews will be arranged 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 147for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the 
investigator will withhold such publication for up to an additional 60days to allow for filing of a 
patent application. In the event that issues arise regarding scientific integrit y or regulator y 
compliance, the sponsor will review these issues with the investigator. The sponsor will not 
mandate modifications to scientific content and does not have the right to suppress information. 
For multicenter study  designs and sub-study  approaches, secondar y results generall y should not be 
published before the primary  endpoints of a study  have been published. Similarl y, investigators 
will recognize the integrity  of a multicenter study by not submitting for publication data derived 
from the individual study  site until the combined results from the completed study  have been 
submitted for publication, within 12months of the availabilit y of the final data (tables, listings, 
graphs), or the sponsor confirms there will be no multicenter study  publication. Authorsh ip of 
publications resulting from this study  will be based on the guidelines on authorship, such as those 
described in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which 
state that the named authors must have made a significan t contribution to the design of the study  or 
analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required by  law.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 148REFERENCES
1. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated -dose intravenous ketamine for 
treatment -resistant depression. Biol Psychiatry. 2010;67(2):139 -145.
2. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -380.
3. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test -Revised: normative data 
and analysis of inter -form and test -retest reliability. Clin. Neuropsychologist. 1998;12:43 -55.
4. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician -Administered Dissociative States Scale (CADSS). J T rauma Stress. 
1998;11(1):125 -136.
5. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI-581) in normal human subjects. Clin Res. 1970;18:597.
6. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea. Anesthesiology. 2008;108:812 -821.
7. Clinical Study Report ESKETINTRD1001. An open -label Phase 1 study to evaluate the pharmacokinetics of 
intranasal esketamine administered w ith and without a nasal guide on the intranasal device. Document No. 
EDMS -ERI-73676925 (21 Aug 2014).
8. Clinical Study Report ESKETINTRD1002. An open -label, single -dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy Japanese and Caucasian subjects. 
Document No. EDMS -ERI-74234860 (21 Aug 2014).
9. Clinical Study Report ESKETINTRD1003. An open -label, single -dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healt hy elderly and adult subjects. Document 
No. EDMS -ERI-81854053 ( 30 Dec 2014 ).
10. Clinical Study Report ESKETIVTRD2001. A double -blind, double -randomization, placebo -controlled study of 
the efficacy of intravenous esketamine in adult subjects w ith treatment -resistant depression. Document No. 
EDMS -ERI-63623355 (01 May 2014 ).
11. Clinical Study Report KETIVTRD2002. A double -blind, randomized, placebo -controlled, parallel group, dose 
frequency study of ketamine in subjects w ith treatment -resistan t depression. Document No. 
EDMS -ERI-63976766 (5 Sep 2014).
12. Critchlow DG. A case of ketamine dependence with discontinuation sympto ms. Addiction. 
2006;101(8):1212 -1213.
13. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
thenight of drug use and 3 days later. Addiction. 2000;95(4):575 -590.
14. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long -term maintenance with intramuscular ketamine for 
treatment -resistant bipolar II depression. Am J Psychiatry. 2012 Aug;169(8):868 -9.
15. Desseill es M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, 
Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant 
treatment response questionnaire. J Clin Psychiatry. 2011;72( 8):1152 -1154.
16. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment -
resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 Feb 3.
17. Doty RL. Office procedures for quantitative assess ment of olfactory function. Am J Rhinol. 
2007 Jul-Aug;21(4):460 -73. Review.
18. Doty RL, Newhouse MG, Azzalina JD. Internal consistency and short -term test-retest reliability of the 
University of Pennsylvania Identification Smell Test. Chem Senses 10:297 –300, 1985.
19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a 
standardized microencapsulated test of olfactory function. Physiol Behav. 1984 Mar;32(3):489 -502.
20. Dmitrienko A, Tamhane AC, Wiens BL. General multis tage gatekeeping procedures. Biom J. 2008 
Oct;50(5):667 -77.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 14921. Dmitrienko A, Tamhane AC. Mixtures of multiple testing procedures for gatekeeping applications in clinical 
trials. Stat Med. 2011 Jun 15; 30(13):1473 -1488.
22. Duloxetine (Cymbalta®): US Prescribing Information. Lilly USA, LLC, Indi anapolis, Indiana, USA; Dec 2014. 
http://pi.lilly.com/us/cymb alta-pi.pdf (accessed 9 Feb 2015).
23. Duloxetine (Cymbalta®): Summary of Product Characteristics. Eli Lilly Nederland, Houten, The Netherlands;
Aug 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Information/human/000572/WC500036781.pdf (accessed 6 Mar 2015).
24. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 
Oct 5;338(6 103):68 -72.
25. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a 
non-competitive NMDA receptor antagonist in the rat cortex and spinal cor d. Eur J Pharmacol. 
1997;333:99 -104.
26. Endou M, Hattori Y, Nakaya H, Gotoh Y, Kanno M. Electrophysiologic mechanisms responsible for inotropic 
responses to ketamine in guinea pig and rat myocardium. Anesthesiology. 1992;76:409 -418.
27. Escitalopram (Cipralex®): US Prescribing Information. Lundbeck Canada I nc., Quebec, Canada; 12 Nov 2014. 
http://www.lundbeck.com/upload/ca/en/files/pdf/product_pi/Cipralex_November_2013/C ipralex.pdf (accessed 
9 Feb 2015).
28. Escitalopram: Summary of Product Characteristics. Actavis Group PTC ehf., Iceland; Jul 2014. 
http://www.medicines.org.uk/emc/medi cine/28956 (accessed 6 Mar 2015).
29. EuroQol Group. About EQ -5D. http://www.euroqol.org/ab out-eq-5d.html (accessed 18 Jun 2014).
30. EuroQol Group. EQ -5D-5L User Guide: basic information on how to use the EQ -5D-5L instr ument. Version 
2.0; Oct 2013. 
http://www.e uroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ -5D-
5L_v2.0_Oct ober_2013.pdf (accessed 6 Aug 2014).
31. Fava M. Diagnosis and definition of treatment -resistant depression. Biol Psychiatry. 2003 Apr 
15;53(8):64 9-659. Review .
32. Fond G, L oundou A, Rabu C et al. Ketamine administration in depressive disorders: a systematic review and 
meta -analysis. Psychopharmacology (Berl). 2014:231(18):3663 -3676.
33. Freeman MP, Walker R, Laughren TP, Miller KK, Fava M. Female reproductive life cycle and horm ones: 
Methodology to improve clinical trials. J Clin Psychiatry. 2013:74(10):1018 -1021.
34. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselecti ve analytical method. Br J 
Anaesth. 1993;70:666 -671.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, 
Education, and Welfare; 1976.
36. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and u se in ambulatory anesthesia. 
Anesth Prog. 1992;39(3):61 -68.
37. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:625 -629.
38. Hijazi Y, Boulieu R. Contribu tion of CYP3A4, CYP2B6, and CYP2C9 isoforms to N -demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853 -858.
39. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
40. Humphrey L, Arbuckle R, Moldw in R, et al. The Bladder Pain/Interstitial Cystitis Symptom Score: 
development, validation, and identification of a cut score. Eur Urology. 2012;61:271 -279.
41. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994 May;151(5):779.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 15042. Investigator’s Brochure, JNJ -54135419 -AAC (eske tamine hydrochloride) . Document ID: 
EDMS -ERI-49489196.
43. Jansen KL. Ketamine --can chronic use impair memory? Int J Addict. 1990 Feb;25(2):133 -9.
44. Ketalar 10 mg/mL solution for injection/infusion : Summary of Product Characteristics; Aug 2014. Pfizer 
Healthcare Ireland, Dublin, Ireland. 
http://www.medicines.ie/medicine/5913/SPC/Ketalar+10mg+ml+Injection +Infusion/ (accessed 25 Feb 2015).
45. Ketamine HCl Injection : US Prescribing Information ; Mar 2012 . JHP Pharmaceuticals, LLC. Rochester, 
Minnesota, USA. http://www.drugs.com/pro/ketalar.html (accessed 25 Feb2015).
46. Ketanest -S [Summary of Product Characteristics]. Ankeveen, Netherlands: Eurocept BV; 2011.
47. Khan A, Warner HA, Brown WA, Symptom reduction and suicide risk in patients treated with placebo in 
antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 
2000 Apr;57(4):311 -317.
48. Khin, NA. Update on FDA Exploratory Analyses of Aggregated Efficacy Data from Depression Trials. Slide 
presentation at NCDEU; May 28 -31, 2013; Hollyw ood, Florida.
49. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with 
the Sheeh an Disability Scale. Int J Psychiatry Med. 1997;27(2):93 -105.
50. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44(1):31 -34.
51. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta -analysi s of 
randomized, double- blind, placebo -controlled trials of ketamine in the rapid treatment of major depressive 
episodes. Psychol Med. 2015 Mar;45(4):693 -704.
52. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clini cal 
practice. Curr Opin Neurobiol. 2015 Feb;30C:139 -143.
53. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:382 -389.
54. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuro psychoph armacology. 
1994;(4)283 -284.
55. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 
1999 Jul-Aug;40(4):356 -9.
56. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188 :408-424.
57. Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review . Addiction. 2012 
Jan;107(1):27 -38.
58. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self -administration upon 
neurocognitive function and psychological wellbeing: a 1 -year longitudinal study. Addiction. 2010 
Jan;105(1):121 -33.
59. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008 Jun 1;95(3):219 -29.
60. Murrough JW. Ketamine as a novel antidepressant: from synapse to beha vior. Clin Pharmacol Ther. 
2012 Feb;91(2):303 -9.
61. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005 Dec;162(12):2352 -9.
62. Opler LA, Opler MG, Arnsten AF. Ameliorating treatment -refractory depression with intranasal ketamine: 
potential NMDA receptor actions in the pain circuitry representing mental anguish. CNS Spectr. 2015 Jan 
26:1-11.
63. Ostad Haji E, Tadic A, Wagner S, et al. Early improvement and serum concentrations of citalopram to predict 
antidepressant drug response of patients with major depression. Pharmacopsychiatry. 2013 Nov;46(7):261 -6.
64. Overall JE; Gorham D R. The Brief Psych iatric Rating Scale. Psychol Rep. 1962;10:799 -812.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 15165. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002 Jun;30(3):382 -4.
66. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010 Aug;23(4):455 -60.
67. Pharm acokinetic Report KET -PK-007. A randomized, open label, single center, single -dose, cross -over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI -150 (intranasal ketamine) 
in healthy adult volunteers. Javelin Pharmaceuticals, Inc. Docum ent No. EDMS -ERI-44757121 (31 Oct 2008).
68. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary 
electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942 -7948.
69. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C -CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysi s of 
antidepressants. Am J Psychiatry. 2007;164:1035 -1043.
70. Protocol ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of intranasal 
esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment -resistant depression 
(SYNAPSE). Document ID No. EDMS -ERI-71950055 (28 Apr 2014).
71. Rickels K, Garcia -Espana F, Mandos L, Case GW. Physician Withdrawal Checklist (PWC -20). J Clin 
Psychopharmacol. 2008;28(4):447 –451.
72. Rothman KJ, Michels KB. The continuing unethical use of placebo controls . N Engl J Med. 
1994;331(6):394 -398.
73. Rugani F, Bacciardi S, Rovai L, et al. Symptomatological Features of patients with and without ecstasy use 
during their first psychotic episode. Int. J. Environ. Res. Public Health. 2012;9(7):2283 -2292.
74. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology 
(IDS): Psychometric properties. Psychol Med. 1996;26(3):477 -486.
75. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcom es in depressed out patients 
requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905 -17.
76. Safety Report (Interim) ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of 
intranasal esketamine in an adaptive treat ment protocol to assess safety and efficacy in treatment -resistant 
depression (SYNAPSE). Document ID No. EDMS -ERI-97270375 ( 6 Feb 2015 ).
77. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797 -801.
78. Saveanu R, Etkin A, Duchemin AM, et al. The International Study to Predict Optimized Treatment in 
Depression (iSPOT -D): Outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015 
Feb;61:1 -12.
79. Sertraline (Zoloft®): US Prescribing Information. Pfizer, Inc., New  York, New York, USA; Aug 2014. 
http://labeling.pfizer.com/ShowLabeling. aspx?id=517 (accessed 9 Feb 2015).
80. Sertraline: Summary of Product Characteristics. Sandoz Limited, Surrey, United Kingdom; Sep 2012. 
http://www.medicines.org.uk/emc/medicine/28749/SPC (accessed 6 Mar 2015).
81. Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 
1996 Jun;11 Suppl 3:89 -95. Review.
82. Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. 
Drug Alcohol Depend. 2011 Apr 1;114(2 -3):185 -93.
83. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the 
GAD -7. Arch Intern Med. 2006;166(10):1092 -1097.
84. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self -report version of PRIME -MD: the PHQ 
primary care study. JAMA. 1999; 282:1737 -1744.
85. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relev ance for drug development. CNS 
Neurosci Ther. 2008;14(1):2 -9.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 15286. Trivedi MH, Rush AJ, Ibrahim MH, et al. The Inventory of Depressive Symptomatology, Clinician Rating 
(IDS -C) and Self -Report (IDS -SR), and the Quick Inventory of Depressive Symptomatology, Clini cian Rating 
(QIDS -C) and Self -Report (QIDS -SR) in public sector patients with mood disorders: a psychometric 
evaluation. Psychol Med. 2004;34(1):73 -82.
87. Venlafaxine Extended -release: US Prescribing Information. Pfizer, Inc., New  York, New York, USA; 
Aug 2014. http://labeling.pfizer.com/ShowLabeling .aspx?id=612 (accessed 9 Feb 2015).
88. Venlafaxine: Summary of Product Characteristics. Actavis Group PTC ehf, Iceland; May 2012. 
http://www.medicines.org.uk/emc/medicine/24329 (accessed 6 Mar 2015).
89. Vesierra (5 mg/mL solution for injection/infusion): Summary of Product Characteristics, Jun 2014. Pfizer 
Limited, Kent, United Kingdom http://www.drugs.com/uk/vesierra -5-mg-ml-solution -for-injection -leaflet.html 
(accessed 25 Feb 2015).
90. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases 
and injuries 1990 -2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 
15;380(9859):2163 -96.
91. Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A 
System atic Review and Meta -analysis. JAMA Psychiatry. 2015 Feb 11.
92. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of keta mine in man. Anaesthesist. 
1975 Jun;24(6):260 -3.
93. Woolf TF, Adams JD. Biotransformation of ketamine, (Z) -6-hydroxyketamine, and (E) -6-hydroxyketamine by 
rat, rabbit, and human liver microsomal preparations. Xenobiotica. 1987;17:839 -847.
94. World Health Organization. Depression (fact sheet). Oct 2012. 
http://www. who.int/mediacentre/factsheets/fs369/en/ (accessed 5 Feb 2015).
95. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N demethylation of ketamine in human 
liver micros omes. Drug Metab Dispos. 2001;29:887 -890.
96. Yang P. Recent Advances in Design and Methodology in Psychiatric Clinical Trials. Slide presentation at Joint 
Statistical Meetings; Aug 3-8, 2013; Montréal, QC Canada.
97. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N -methyl-D-aspartate antagonist in 
treatment -resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856 -64.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 153Attachment 1:Prohibited Concomitant Medications w ith Intranasal Study Medication
(Esk etamine or Placebo )
This list of medications is not all-inclusive ; if necessary, please contact the medical monitor for any 
questions regarding a medication(s).
Please refer to the local prescribing information of the subject’s oral antidepressant treatmen t for 
information regarding prohibited concomitant medications. 
Except where specifically noted, the prohibited medications listed in the following table are prohibited 
from 1 week (or 5 half-lives, whichever is longer) prior to the first dose of intranas al study medication 
until after the last dose of intranasal study medication. Note: If amedication is part of the antidepressant 
treatment regimen being taken at the time of signing the ICF (ie, start of screening/ prospective 
observational phase), it must be continued unchanged until the end of Week 4 of the 
screening /prospective observational phase , therefore this requirement is not applicable. In such cases the 
investigator may choose to taper the relevant medication during the up to 3-week taper period based on 
their clinical judgment.
Note in the following table : N, Prohibited ; Y, Permitted, with restrictions (please refer to the column
label ed “Comments” for additional guidance ).
Drug ClassEpisodic 
Use ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Amantadine N N PD interaction
Anorexiants 
(eg, phenter mine , 
phendimetrazine )N N Safety
Anticholinesterase 
inhibitorsN N Subject 
population is 
excluded
Anticonvulsants N N Subjects with seizures are excluded.
Use as adjunctive treatment for major 
depressive disorder ( MDD) is 
prohibited. 
-Note: Anticonvulsants used for 
indications other than seizures may be 
allow ed (eg valproate for migraine; 
pregabalin )Safety and PD 
interaction
Antidepressants 
(other than the specific 
antidepressant started in 
the induction phase of the 
study)N N-Only 1 of the 4 predefined oral 
antidepressant treatment options are 
permitted
-If a sub ject is taking a monoamine 
oxidase inhibitor (MAOI) during the 
screening/prospective observational 
phase, there must be a minimum 
washout interval of 2 weeks prior to 
the first dose of intranasal study 
medication.
-Even if used for other indications (eg, 
trazodone for sleep ), the use of any 
medication listed on the ATRQ is not 
permitted during the treatment phase.Safety and PD 
interaction
Antipsychotics N N PD interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 154Drug ClassEpisodic 
Use ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Benzodiazepines (at 
dosages equal to or less 
than the equivalent of 
6mg/day lorazepam) and 
non-benzodiazepine 
sleeping medication 
(including: zolpidem, 
zaleplon, eszop iclone, and 
ramelteon)Y Y P rohibited w ithin 12 hours prior to the 
start of each intranasal treatment session 
or cognition testingSafety and PD 
interaction
Benztropine Y N Prohibited if use is continuous and 
prohibited w ithin 12 hours prior to the 
start of cognition testingSafety and PD 
interaction. 
Chloral hydrate, 
melatonin, valerianN N Safety and PD 
interaction
Clonidine N N Safety and PD 
interaction
Corticosteriods ( system ic) Y N Inhaled, intranasal, topical, and 
ophthalmic steroids are not prohibited.
Intermittent IM/IV corticosteroids are 
permitted (chronic use prohibited)PD interaction
Cough/cold 
preparations/nasal 
solutions containing 
vasoconstrictors, 
decongestantsY Y Intranasally -administered decongestants 
(vasoconstrictors) should not be used 
from 1 hour prior to each intranasal 
study medication administration.
Pseudoephedrine -containing oral 
products should not be used within 
12hours prior to an intranasal treatment 
session.Safety and PD 
interaction
CYP3A4 inducers -Potent N N Subjects may not take a known potent 
inducer of hepatic CYP3A activity 
within 2 weeks of the first 
administration of intranasal st udy 
medication until at least 24 hours after 
the last intranasal dose of study 
medication.
Examples (not all -inclusive): Efavirenz, 
nevirapine, barbiturates, carbamazepine, 
glucocorticoids, modafinil, 
oxcarbazepine, phenobarbital, 
phenytoin, rifabutin, rifampin, and St. 
John's wortPK
Dextromethorphan N N PD interaction
Diphenhydramine Y N Prohibited w ithin 12 hours prior to the 
start of each intranasal treatment sessionSafety
Ketanserin N N Safety
Lithium N N PD interaction
Mem antine N N PD interaction
Methyldopa N N Safety and PD 
Interaction
Metyrosine N N Safety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 155Drug ClassEpisodic 
Use ( as 
needed )Continuous 
Use CommentsReason for 
Prohibition
Non-vitamin K antagonist 
oral anticoagulation agents 
(eg, dabigatran, 
rivaroxaban, apixabanN N Safety
Opioids N N PD interaction
Psychostimulants 
(eg, amphetamines , 
methylphenidate, and 
modafanil , arm odafinl )N Y Prescribed psychostimulants taken for 
indications other than MDD can be 
continued but must not be taken within 
12 hours prior to the intranasal 
treatment session or for 2 hours after the 
intrana sal treatment session.Cardiovascular 
safety
ADHD medications (e.g., 
atom oxetine, guanfacine)N Y Can be continued but must not be taken 
within 12 hours prior to the intranasal 
treatment session or for 2 hours after the 
intranasal treatment session. .Safety
Reserpine N N PD interaction
Scopolamine N N PD interaction
St. John’s Wort N N PD interaction 
and PK
Thyroid hormone 
supplement for treatment 
of thyroid condition only 
(not for depression)N Y Safety
Thyroxine/ 
triiodothyronine (T3), 
thyroid h ormone 
prescribed for depressionN N PD interaction
Warfarin N N Primary 
condition 
where used is 
excluded
Abbreviations: N, Prohibited; PD, pharmacodynamics; PK, pharmacokinetics; Y, Permitted, w ith restrictions (please 
refer to the column labeled “Comments” for additional guidance).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 156Attachment 2:New York Heart A ssociation Classification of Cardiac Disease
New York Heart Association Classification of Cardiac Disease
Category Description
Functional Capacity
Class I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
Class II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are com fortable 
at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the angi nal syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort is increased.
Objective Assessment
A No objective evidence of cardiovascular disease.
B Objective evidence of minimal cardiovascular disease.
C Objective evidence of moderately severe cardiovascular disease.
D Objective evidence of severe cardiovascular disease.
Source: Criteria Committee of the New York Heart Association. Functional capacity and objective assessment. In: 
Dolgin M, ed. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, 
MA: Little, Brow n & Co; 1994, 253 -255.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 157Attachment 3:Oral A ntidepressant Titration Schedule for Double -Blind Induction Phase
The titration schedule for the 4 oral antidepressants to be used in the current study is provided below. 
Adjustments to the titration schedule may be required in other countries in order to conform to local 
prescribing information.
Global titration schedule:
Oral Antide pressant 
(Active Com parator)Titration Schedule
Week 1
(Starting Day 1)Week 2
(Starting Day 8)Week 3
(Starting Day 15)Week 4
(Starting Day 22)
Duloxetine 60 mga60 mg 60 mg 60 mg
Escitalopram 10 mg 20 mg 20 mg 20 mg
Sertraline 50 mg 100 mg 150 mg 200 mg
Venlafaxine XR 75 mg 150 mg 225 mg 225 mg
aSubjects should be initiated with 60 mg/day. Subjects that have in the past shown increased sensitivity towards 
serotonin reuptake inhibitors (SSRI) /norepinephrine reuptake inhibitors (SNRI) can ,at the discretion of the treating 
physician ,be started on a30mgdose and up -titrated into the therapeutic range of 60 mg by the start of Week2.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 158Attachment 4:Anticipated Events
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen. For 
the purposes of this study the following events will be considered anticipated events.22,23,27,28,42,79,80,87 ,88
For esketamine and major depressive disorder (MDD) (including treatment -resistant depression [TRD]; 
based on DSM -5):
 Suicidal thinking, ideation, and behavior
 Sleep changes, difficulty sleeping, reduced sleep, abnormal sleep, abnormal sleep, tiredness, fatigue, 
and reduced energy
 Difficulty in sexual desire, performance or satisfaction
 Reduced appetite and weight changes (loss or increase)
 Activation or hypomania/ mania
 Excessive happiness
 Irritabi lity, anger, and impulsive behav ior
 Agitation, feeling anxious/anxiety, tension, panic attacks, and phobia
For esketamine, regarding events related to concomitant therapy with oral antidepressants (from the 
product’s reference safety information/US prescribing information):
 Duloxetine
 Most commonly observed adverse reactions from pooled studies of all indications (incidence of 
at least 5% and at least twice the incidence in placebo subjects) were nausea, dry mouth, 
somnolence, fatigue, constipation, decreased appetite, and hyperhidrosis (sweating). Duloxetine 
treatment worsens glycemic control in some subjects with diabetes.
 Increased the risk compared to placebo of suicidal thinking and behavior; serotonin syndrome; 
hepatotoxicity; hepatic failure; orthostatic hypotension, syncope; abno rmal bleeding; severe 
skin reactions, including erythema multiforme and Stevens -Johnson Syndrome (SJS); activation 
of mania or hypomania; hyponatremia.
 Venlafaxine XR
 According to the US prescribing information, adverse events in short -term studies occurri ng in 
at least 5% of subjects receiving venlafaxine XR and at a rate twice the incidence in placebo 
subjects : abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and 
sweating. Sustained hypertension is noted within Warnings and Precautions section.
 Increased the risk compared to placebo of suicidal thinking and behavior , treatment -emergent 
insomnia and nervousness , activation of mania/hypomania , hyponatremia , mydriasis, abnormal 
bleeding , sustained hypertension , and serotonin syndrome.
 Escitalopram
 Most commonly observed adverse reactions (incidence of approximately 5% or greater and 
approximately twice the incidence in placebo subjects ) were insomnia, ejaculation disorder 
(primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.
 Increased the risk compared to placebo of suicidal thinking and behavior, serotonin syndrome, 
activation of mania/hypomania, hyponatremia and abn ormal bleeding
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 159 Sertraline
 Most common treatment -emergent AEs associated with sertraline (incidence of at least 5% for 
sertraline or at least twice the incidence in placebo subjects) were ejaculation failure, dry mouth, 
increased sweating, somnolence, tremo r, dizziness, fatigue, pain, malaise, abdominal pain, 
anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, agitation, insomnia, and 
decreased libido, and serotonin syndrome. 
 Increased the risk compared to placebo of suicidal thinking and beha vior, activation/mania; 
bleeding events related to SSRI use (have ranged from ecchymosi s, hematomas, epistaxis, and 
petechiae to life-threatening hemorrhages), hyponatremia (appears to be the result of the 
syndrome of inappropriate antidiuretic hormone secretion [SIADH]); serotonin syndrome
Reporting of Anticipated Events
These events will be captured on the eCRF and in the database, and will be reported to the sponsor as 
described in Section 12.3.1 , All Adverse Events. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited reporting as individual single cases to Health 
Authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be establ ished to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated even t is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine) Clinical Protocol ESKETINTRD3001 Amendment 2
Status: Approved , Date: 31 May 2016 160INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]